https://app.readthrough.bio/stories/university-of-washington-trial-testing-rylaze-in-adult-all-is-suspended-06aa5d2026-09-30monthly0.7 https://app.readthrough.bio/stories/biomarin-and-ascendis-sign-settlement-and-license-agreement-over-cnp-08621f2026-09-30monthly0.7 https://app.readthrough.bio/stories/unicycive-resubmits-nda-for-oxylanthanum-carbonate-after-june-2026-crl-08d34e2026-09-29monthly0.7 https://app.readthrough.bio/stories/bright-minds-biosciences-to-join-fpwr-symposium-and-pws-family-08fe652026-10-01monthly0.7 https://app.readthrough.bio/stories/sagimet-biosciences-prices-107-5-million-stock-offering-0951a32026-10-01monthly0.7 https://app.readthrough.bio/stories/oculis-board-member-lionel-carnot-resigns-after-nearly-a-decade-0971622026-09-30monthly0.7 https://app.readthrough.bio/stories/indaptus-extends-outside-date-for-24-million-private-placement-to-0c9bfb2026-09-30monthly0.7 https://app.readthrough.bio/stories/nanoviricides-extends-employment-terms-for-president-diwan-and-cfo-vyas-0e94db2026-09-29monthly0.7 https://app.readthrough.bio/stories/kyntra-bio-adds-andrew-singer-to-board-maykin-ho-departs-after-eight-0f42652026-10-01monthly0.7 https://app.readthrough.bio/stories/larimar-therapeutics-names-john-b-harlow-jr-president-and-coo-117f392026-09-29monthly0.7 https://app.readthrough.bio/stories/evommune-reports-phase-2a-data-for-evo301-in-atopic-dermatitis-at-eadv-13183a2026-10-01monthly0.7 https://app.readthrough.bio/stories/celularity-appoints-viome-founder-naveen-jain-to-board-of-directors-1c6ce82026-09-29monthly0.7 https://app.readthrough.bio/stories/immix-biopharma-prices-125-million-stock-offering-after-nexicart-2-23e3662026-09-29monthly0.7 https://app.readthrough.bio/stories/silexion-doses-first-patient-in-phase-2-3-trial-of-sil204-for-292dad2026-09-30monthly0.7 https://app.readthrough.bio/stories/agomab-reports-positive-ole-data-for-ontunisertib-in-crohn-s-bowel-2d107b2026-10-01monthly0.7 https://app.readthrough.bio/stories/tiziana-life-sciences-seeks-fda-orphan-drug-status-for-foralumab-in-msa-3767882026-09-30monthly0.7 https://app.readthrough.bio/stories/satellos-completes-enrollment-in-basecamp-phase-2-trial-of-forazapadin-3e6b8b2026-09-30monthly0.7 https://app.readthrough.bio/stories/vetmab-biosciences-files-form-d-for-equity-offering-worth-nearly-12-4293622026-09-29monthly0.7 https://app.readthrough.bio/stories/lifecore-biomedical-to-be-acquired-by-webster-equity-partners-50c69d2026-09-29monthly0.7 https://app.readthrough.bio/stories/heron-therapeutics-signs-multi-product-license-deal-with-long-grove-571ad62026-09-29monthly0.7 https://app.readthrough.bio/stories/phase-1b-indibulin-capecitabine-trial-ended-early-after-no-dose-5a0cc82026-10-01monthly0.7 https://app.readthrough.bio/stories/q32-bio-reports-part-b-data-for-bempikibart-in-alopecia-areata-at-eadv-5b44872026-09-30monthly0.7 https://app.readthrough.bio/stories/invivyd-reports-vyd2311-topline-safety-edge-over-mrna-covid-vaccine-in-5bdc712026-09-29monthly0.7 https://app.readthrough.bio/stories/cadrenal-therapeutics-shareholders-back-share-plan-increase-warrant-5f17db2026-09-29monthly0.7 https://app.readthrough.bio/stories/vir-biotechnology-names-aziz-sawaf-as-new-cfo-effective-october-5-2026-60c45d2026-10-01monthly0.7 https://app.readthrough.bio/stories/celcuity-launches-revtorpyk-for-hr-her2-advanced-breast-cancer-6568bd2026-09-30monthly0.7 https://app.readthrough.bio/stories/atossa-plans-stapled-cvr-tied-to-rare-pediatric-disease-review-voucher-66d07b2026-09-29monthly0.7 https://app.readthrough.bio/stories/dyne-reports-new-one-year-data-from-achieve-trial-of-z-basivarsen-in-dm1-6b12442026-09-29monthly0.7 https://app.readthrough.bio/stories/aeon-gets-fda-type-2b-feedback-on-abp-450-biosimilar-pathway-for-botox-7e801f2026-09-30monthly0.7 https://app.readthrough.bio/stories/conexeu-sciences-files-form-d-for-30-875-equity-offering-7f01b92026-09-29monthly0.7 https://app.readthrough.bio/stories/beyondspring-gets-fda-fast-track-for-plinabulin-sells-china-unit-stake-7f2c342026-09-29monthly0.7 https://app.readthrough.bio/stories/redhill-reports-h1-2026-results-after-rebyota-clenpiq-deal-and-talicia-7ffcc82026-09-30monthly0.7 https://app.readthrough.bio/stories/pyxis-oncology-launches-stock-offering-to-fund-micvo-s-phase-3-trial-81b4d32026-09-29monthly0.7 https://app.readthrough.bio/stories/kardigan-names-kristin-reinke-to-board-giordano-departs-854c302026-09-30monthly0.7 https://app.readthrough.bio/stories/altimmune-names-richard-menziuso-as-principal-accounting-officer-87ee332026-09-29monthly0.7 https://app.readthrough.bio/stories/alaunos-therapeutics-trial-of-darinaparsin-in-blood-cancers-ended-early-8dc08e2026-10-01monthly0.7 https://app.readthrough.bio/stories/hutchmed-astrazeneca-file-us-nda-for-orpathys-plus-tagrisso-in-met-8de3552026-09-29monthly0.7 https://app.readthrough.bio/stories/uniqure-reports-48-month-amt-130-data-for-huntington-s-disease-gene-8f531a2026-09-29monthly0.7 https://app.readthrough.bio/stories/standard-biotools-switches-mass-cytometry-buyer-to-gmt-venture-unit-91d1102026-09-30monthly0.7 https://app.readthrough.bio/stories/gt-biopharma-files-form-d-for-offering-of-up-to-38-96-million-9500862026-09-29monthly0.7 https://app.readthrough.bio/stories/connect-biopharma-reports-positive-phase-2-topline-data-for-9625e42026-09-30monthly0.7 https://app.readthrough.bio/stories/beyondspring-files-11-9-million-at-the-market-offering-with-citizens-9666d32026-09-29monthly0.7 https://app.readthrough.bio/stories/monte-rosa-reports-phase-1-data-for-mrt-8102-in-cardiovascular-risk-9e112b2026-10-01monthly0.7 https://app.readthrough.bio/stories/fda-approves-camzyos-for-children-with-obstructive-hypertrophic-9f37bf2026-09-30monthly0.7 https://app.readthrough.bio/stories/iovance-lifts-2026-revenue-guidance-to-410-420-million-a4ab312026-09-29monthly0.7 https://app.readthrough.bio/stories/alaunos-therapeutics-trial-of-darinaparsin-in-liver-cancer-ends-after-a83a0a2026-10-01monthly0.7 https://app.readthrough.bio/stories/lexeo-to-acquire-mantle-adding-four-fa-pipeline-programs-a977a02026-09-27monthly0.7 https://app.readthrough.bio/stories/tscan-therapeutics-sets-separation-terms-for-outgoing-cfo-and-cmo-ab402a2026-09-30monthly0.7 https://app.readthrough.bio/stories/biocardia-submits-revised-fda-pre-submission-for-helix-catheter-ac41b92026-10-01monthly0.7 https://app.readthrough.bio/stories/tectonic-reports-phase-1a-safety-data-for-tx2100-in-hht-program-ac48392026-09-29monthly0.7 https://app.readthrough.bio/stories/lantern-pharma-prices-4-million-offering-of-stock-and-pre-funded-ac53a12026-09-30monthly0.7 https://app.readthrough.bio/stories/biostem-technologies-raises-3-million-in-at-the-market-private-placement-af85922026-09-30monthly0.7 https://app.readthrough.bio/stories/ema-validates-polypid-s-marketing-application-for-d-plex100-b073c62026-10-01monthly0.7 https://app.readthrough.bio/stories/pyxis-oncology-terminates-150-million-at-the-market-stock-offering-b090992026-09-29monthly0.7 https://app.readthrough.bio/stories/bioaffinity-and-avmedical-bring-cypath-lung-test-to-va-conference-b4ac012026-09-30monthly0.7 https://app.readthrough.bio/stories/eupraxia-reports-52-week-data-from-highest-dose-cohort-of-ep-104gi-in-b523702026-09-30monthly0.7 https://app.readthrough.bio/stories/alaunos-therapeutics-trial-of-palifosfamide-plus-doxorubicin-in-sarcoma-b5d36d2026-10-01monthly0.7 https://app.readthrough.bio/stories/apimeds-names-eric-sherb-as-cfo-after-erick-frim-resigns-b9942a2026-10-01monthly0.7 https://app.readthrough.bio/stories/imunon-exchanges-part-of-promissory-note-for-new-series-b-preferred-c1ca7c2026-09-29monthly0.7 https://app.readthrough.bio/stories/evotec-s-chief-scientific-officer-cord-dohrmann-to-step-down-september-c1e3862026-09-29monthly0.7 https://app.readthrough.bio/stories/adlai-nortye-names-christopher-liu-head-of-investor-and-public-relations-c2cc542026-09-30monthly0.7 https://app.readthrough.bio/stories/brainsway-posts-5-0-million-net-profit-for-h1-2026-expands-mental-c6d9a52026-09-29monthly0.7 https://app.readthrough.bio/stories/azitra-clears-safety-review-moves-atr-04-trial-to-cohort-2-c9cda32026-10-01monthly0.7 https://app.readthrough.bio/stories/halozyme-adds-james-daly-to-board-of-directors-ca0eaf2026-09-30monthly0.7 https://app.readthrough.bio/stories/alzamend-neuro-discloses-mgh-lithium-imaging-data-but-8-k-and-exhibit-cbc9712026-09-29monthly0.7 https://app.readthrough.bio/stories/scilex-expands-vivasor-credit-line-to-30-million-ccfc072026-09-29monthly0.7 https://app.readthrough.bio/stories/regeneron-grants-long-term-psus-to-co-founders-forms-new-subsidiary-d373702026-09-30monthly0.7 https://app.readthrough.bio/stories/mirati-s-sapphire-trial-in-nsclc-terminated-results-posted-on-d4e54d2026-10-01monthly0.7 https://app.readthrough.bio/stories/bnb-plus-corp-amends-registration-rights-agreement-with-majority-holders-d663bd2026-10-01monthly0.7 https://app.readthrough.bio/stories/lifeward-taps-interim-ceo-hexter-to-also-serve-as-interim-finance-chief-db75522026-10-01monthly0.7 https://app.readthrough.bio/stories/fda-panel-to-meet-october-1-on-southern-hemisphere-flu-vaccine-strains-e086922026-09-29monthly0.7 https://app.readthrough.bio/stories/moderna-creates-coo-role-brings-back-juan-andres-as-jerh-collins-retires-e4fa5b2026-09-30monthly0.7 https://app.readthrough.bio/stories/aquestive-therapeutics-adds-rich-daly-to-board-of-directors-e60dc12026-09-29monthly0.7 https://app.readthrough.bio/stories/calcimedica-files-for-up-to-25-million-at-the-market-stock-offering-e986f92026-09-30monthly0.7 https://app.readthrough.bio/stories/lakefront-biotherapeutics-reports-seven-weekly-buyback-tranches-from-eb71ce2026-09-29monthly0.7 https://app.readthrough.bio/stories/lantern-pharma-closes-4-million-registered-direct-offering-eccc2f2026-09-30monthly0.7 https://app.readthrough.bio/stories/foghorn-and-lilly-halt-fhd-909-program-company-cuts-40-of-workforce-f044352026-10-01monthly0.7 https://app.readthrough.bio/stories/oncolytics-reports-faster-enrollment-in-reo-033-colorectal-cancer-study-f63ea22026-09-28monthly0.7 https://app.readthrough.bio/stories/rafael-holdings-phase-3-npc-trial-misses-primary-endpoint-subgroup-hits-f76b592026-09-30monthly0.7 https://app.readthrough.bio/stories/nomad-power-solutions-raises-6-0-million-via-secured-note-with-lixte-as-f9d9132026-09-30monthly0.7 https://app.readthrough.bio/stories/silexion-strikes-warrant-inducement-deal-to-raise-about-0-84-million-fdc9d02026-09-29monthly0.7 https://app.readthrough.bio/stories/celularity-raises-11-01-million-through-convertible-notes-settles-with-06e4cb2026-09-28monthly0.7 https://app.readthrough.bio/stories/nanobiotix-reports-first-half-2026-update-on-jnj-1900-nbtxr3-programs-08b54e2026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-efficacy-supplement-for-genentech-s-gazyva-0edbb42026-09-30monthly0.7 https://app.readthrough.bio/stories/iqvia-inc-completes-2-billion-senior-notes-offering-due-2034-103e5a2026-09-28monthly0.7 https://app.readthrough.bio/stories/ionis-and-roche-report-positive-phase-3-interim-data-for-sefaxersen-in-160ffd2026-09-25monthly0.7 https://app.readthrough.bio/stories/biotricity-director-jainal-bhuiyan-resigns-from-board-and-compensation-184ed52026-09-28monthly0.7 https://app.readthrough.bio/stories/volitionrx-issues-shares-to-lind-to-satisfy-note-conversions-1ffa102026-09-28monthly0.7 https://app.readthrough.bio/stories/navigator-medicines-files-form-d-for-40-million-offering-215ac12026-09-28monthly0.7 https://app.readthrough.bio/stories/neurocrine-names-eiry-roberts-chief-medical-officer-replacing-sanjay-24c7312026-09-28monthly0.7 https://app.readthrough.bio/stories/scisparc-s-neurothera-expands-us-patent-filings-on-psychedelic-pea-2bfecc2026-09-28monthly0.7 https://app.readthrough.bio/stories/cullinan-therapeutics-outlines-fourth-quarter-2026-data-plans-across-2db5f72026-09-28monthly0.7 https://app.readthrough.bio/stories/scynexis-gets-barda-award-worth-up-to-214-million-for-antifungal-scy-247-2f4e3f2026-09-28monthly0.7 https://app.readthrough.bio/stories/telix-gets-fda-fast-track-for-bipass-pre-biopsy-prostate-imaging-program-332c9a2026-09-30monthly0.7 https://app.readthrough.bio/stories/transcode-reports-updated-phase-1a-data-for-ttx-mc138-in-advanced-solid-3c5c772026-09-28monthly0.7 https://app.readthrough.bio/stories/ib-acquisition-corp-amends-gnq-insilico-deal-terms-discloses-50m-equity-3f24962026-09-28monthly0.7 https://app.readthrough.bio/stories/hcw-biologics-prices-1-5-million-private-placement-with-existing-431f192026-09-28monthly0.7 https://app.readthrough.bio/stories/creative-medical-technology-raises-biodefense-stake-to-80-via-stock-47f92b2026-09-27monthly0.7 https://app.readthrough.bio/stories/azitra-files-3-5-million-at-the-market-stock-offering-with-a-g-p-48f7622026-09-28monthly0.7 https://app.readthrough.bio/stories/c4-therapeutics-presents-cemsidomide-biomarker-data-at-ims-annual-4bb35e2026-09-26monthly0.7 https://app.readthrough.bio/stories/jaguar-health-issues-481-584-shares-to-streeterville-to-cut-note-balance-5148d72026-09-28monthly0.7 https://app.readthrough.bio/stories/kyverna-reports-one-year-data-for-miv-cel-in-stiff-person-syndrome-and-514b542026-09-28monthly0.7 https://app.readthrough.bio/stories/dbv-technologies-submits-bla-to-fda-for-viaskin-peanut-patch-in-53c0552026-09-30monthly0.7 https://app.readthrough.bio/stories/adicet-bio-reports-positive-lupus-data-for-prula-cel-plans-pivotal-54c6fb2026-09-28monthly0.7 https://app.readthrough.bio/stories/glucotrack-amends-multiple-warrants-and-notes-removing-floor-price-559a152026-09-28monthly0.7 https://app.readthrough.bio/stories/adarx-pharmaceuticals-closes-ipo-and-abbvie-private-placement-59a39f2026-09-28monthly0.7 https://app.readthrough.bio/stories/hemab-therapeutics-adds-keli-walbert-to-board-and-audit-committee-5a04d52026-09-28monthly0.7 https://app.readthrough.bio/stories/stoke-therapeutics-adds-alexander-cumbo-to-board-after-kaye-resignation-5ac9282026-09-28monthly0.7 https://app.readthrough.bio/stories/ligand-agrees-to-fund-avencell-s-car-t-pipeline-for-up-to-47-million-5db6df2026-09-28monthly0.7 https://app.readthrough.bio/stories/kodiak-s-zenkuda-and-tabirafusp-ted-hit-primary-endpoints-in-phase-3-6234bc2026-09-28monthly0.7 https://app.readthrough.bio/stories/adarx-prices-ipo-at-17-per-share-abbvie-to-buy-stake-65a0da2026-09-28monthly0.7 https://app.readthrough.bio/stories/legend-biotech-shareholders-back-directors-auditor-and-share-plan-6a1eb82026-09-28monthly0.7 https://app.readthrough.bio/stories/rezolute-updates-on-ersodetug-trials-fda-review-fiscal-2026-results-6be6962026-09-28monthly0.7 https://app.readthrough.bio/stories/black-hawk-acquisition-and-vesicor-sign-financing-deals-with-meteora-7292062026-09-28monthly0.7 https://app.readthrough.bio/stories/viking-prices-225m-convertible-notes-and-275m-stock-sale-reports-vk2735-8c726e2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-efficacy-supplement-for-eli-lilly-s-olumiant-baricitinib-8cb4362026-09-30monthly0.7 https://app.readthrough.bio/stories/glucotrack-prices-3-million-public-offering-of-stock-and-pre-funded-8e651c2026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-supplement-35-for-eisai-s-lenvima-90c82f2026-09-30monthly0.7 https://app.readthrough.bio/stories/inventiva-completes-last-patient-visit-in-nativ3-phase-iii-trial-for-964d722026-09-28monthly0.7 https://app.readthrough.bio/stories/senti-biosciences-board-member-brenda-cooperstone-resigns-effective-9baf2c2026-09-28monthly0.7 https://app.readthrough.bio/stories/keros-doses-first-patient-in-phase-2-trial-of-rinvatercept-for-duchenne-a0cd3a2026-09-28monthly0.7 https://app.readthrough.bio/stories/gain-therapeutics-cfo-to-resign-ceo-to-serve-as-interim-finance-chief-a6a8b92026-09-28monthly0.7 https://app.readthrough.bio/stories/phio-pharmaceuticals-holds-2026-annual-meeting-expands-incentive-plan-aa21822026-09-28monthly0.7 https://app.readthrough.bio/stories/acadia-s-remlifanserin-narrowly-misses-primary-endpoint-in-phase-2-aa29062026-09-28monthly0.7 https://app.readthrough.bio/stories/tuhura-draws-two-more-tranches-on-parkview-credit-line-each-for-650-000-ae7e472026-09-28monthly0.7 https://app.readthrough.bio/stories/im-cannabis-director-einat-zakariya-resigns-from-board-b5315e2026-09-28monthly0.7 https://app.readthrough.bio/stories/unbuzzd-wellness-names-michael-zapolin-as-ceo-ahead-of-planned-stock-bd47aa2026-09-28monthly0.7 https://app.readthrough.bio/stories/cdt-equity-sets-1-for-25-reverse-stock-split-effective-september-28-c7078c2026-09-26monthly0.7 https://app.readthrough.bio/stories/humacyte-adds-scott-coward-and-paul-kuznik-to-board-of-directors-cba8ee2026-09-28monthly0.7 https://app.readthrough.bio/stories/tempest-therapeutics-adds-board-member-new-cfo-and-related-party-r-d-d003d92026-09-28monthly0.7 https://app.readthrough.bio/stories/jaguar-health-exchanges-shares-to-reduce-streeterville-notes-fully-d029732026-09-27monthly0.7 https://app.readthrough.bio/stories/azitra-sets-up-3-5-million-at-the-market-stock-sale-facility-with-a-g-p-d141042026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-clears-two-welireg-supplements-for-merck-s-belzutifan-both-approved-d24c0f2026-09-30monthly0.7 https://app.readthrough.bio/stories/satellos-gets-fda-clearance-for-forazapadin-ind-in-fshd-da78832026-09-28monthly0.7 https://app.readthrough.bio/stories/fate-therapeutics-gets-15-million-cirm-grant-for-lupus-nephritis-car-t-de33df2026-09-28monthly0.7 https://app.readthrough.bio/stories/medicinova-amends-la-jolla-office-lease-extending-term-to-april-2030-dfdf952026-09-28monthly0.7 https://app.readthrough.bio/stories/hutchmed-sets-esmo-2026-presentations-for-two-phase-iii-savolitinib-e1b6402026-09-27monthly0.7 https://app.readthrough.bio/stories/neonc-to-hold-fda-meeting-on-neo212-for-glioma-program-e4ce3a2026-09-28monthly0.7 https://app.readthrough.bio/stories/autoivf-discloses-1-5-million-private-securities-offering-in-sec-form-d-eab0472026-09-28monthly0.7 https://app.readthrough.bio/stories/regenxbio-upenn-settle-patent-suit-with-sarepta-over-elevidys-f664d02026-09-28monthly0.7 https://app.readthrough.bio/stories/genmab-grants-employees-restricted-stock-units-and-warrants-fcff242026-09-28monthly0.7 https://app.readthrough.bio/stories/jasper-therapeutics-cfo-herb-cross-to-resign-interim-officers-named-fec0e12026-09-28monthly0.7 https://app.readthrough.bio/stories/lakewood-amedex-registers-extra-4-5-million-shares-tied-to-series-c-04a84d2026-09-27monthly0.7 https://app.readthrough.bio/stories/meiragtx-adds-alan-m-sebulsky-former-adage-capital-manager-to-board-05ed2e2026-09-27monthly0.7 https://app.readthrough.bio/stories/electra-therapeutics-prices-350-million-ipo-sets-nasdaq-listing-under-075b192026-09-27monthly0.7 https://app.readthrough.bio/stories/enlivex-terminates-rain-token-financing-deal-with-rain-foundation-075d012026-09-28monthly0.7 https://app.readthrough.bio/stories/helus-pharma-ceo-to-join-td-cowen-neuropsychiatry-summit-fireside-chat-0a083c2026-09-28monthly0.7 https://app.readthrough.bio/stories/alkermes-reports-positive-phase-1b-data-for-adhd-drug-alks-7290-0a94472026-09-28monthly0.7 https://app.readthrough.bio/stories/zymeworks-theravance-merger-cvr-agreement-details-milestone-and-royalty-0f334f2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-lifts-clinical-hold-on-filana-s-simufilam-clearing-path-for-tsc-0f8a4d2026-09-28monthly0.7 https://app.readthrough.bio/stories/longeveron-s-elpis-ii-trial-misses-primary-endpoint-in-hlhs-study-11bc5d2026-09-25monthly0.7 https://app.readthrough.bio/stories/typewriter-therapeutics-discloses-56-3-million-equity-offering-in-form-146f9a2026-09-28monthly0.7 https://app.readthrough.bio/stories/insight-molecular-diagnostics-amends-chronix-merger-royalty-terms-again-153e682026-09-28monthly0.7 https://app.readthrough.bio/stories/biostem-technologies-registers-40-million-stock-facility-files-related-1570362026-09-28monthly0.7 https://app.readthrough.bio/stories/cypherpunk-technologies-names-amanda-fabiano-to-board-of-directors-1800062026-09-28monthly0.7 https://app.readthrough.bio/stories/gt-biopharma-expands-preferred-stock-offering-to-7-75-million-with-new-1876442026-09-28monthly0.7 https://app.readthrough.bio/stories/jazz-pharmaceuticals-reprices-and-extends-term-loan-b-facility-1c87b42026-09-27monthly0.7 https://app.readthrough.bio/stories/recursion-pharmaceuticals-amends-tempus-ai-data-pact-and-licenses-rna-208fe72026-09-28monthly0.7 https://app.readthrough.bio/stories/adial-holds-2026-annual-meeting-adjourns-vote-on-four-proposals-pending-2235462026-09-28monthly0.7 https://app.readthrough.bio/stories/sol-gel-completes-patient-follow-up-in-gorlin-syndrome-phase-3-trial-233d4c2026-09-28monthly0.7 https://app.readthrough.bio/stories/cdt-equity-issues-2-126-250-convertible-note-to-j-j-astor-co-246f7c2026-09-28monthly0.7 https://app.readthrough.bio/stories/chmp-backs-two-astrazeneca-drugs-klygefa-in-gmg-enhertu-in-early-breast-29f1352026-09-27monthly0.7 https://app.readthrough.bio/stories/halozyme-completes-1-5-billion-convertible-notes-offering-due-2033-30fbaf2026-09-28monthly0.7 https://app.readthrough.bio/stories/change-agents-corporation-corrects-warrant-share-count-in-amended-sec-30fcb02026-09-28monthly0.7 https://app.readthrough.bio/stories/anteris-aus-operations-amends-supply-agreement-with-harvey-industries-3170942026-09-28monthly0.7 https://app.readthrough.bio/stories/decoy-therapeutics-closes-3-85-million-warrant-inducement-transaction-32f1742026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-new-efficacy-supplement-for-eli-lilly-s-verzenio-3557e82026-09-25monthly0.7 https://app.readthrough.bio/stories/biomea-fusion-files-preliminary-prospectus-for-stock-and-pre-funded-3bfd482026-09-27monthly0.7 https://app.readthrough.bio/stories/astrazeneca-s-trixeo-approved-in-eu-for-asthma-maintenance-treatment-4057af2026-09-25monthly0.7 https://app.readthrough.bio/stories/aytu-reports-first-full-launch-quarter-for-exxua-fiscal-2026-results-4515372026-09-28monthly0.7 https://app.readthrough.bio/stories/mesoblast-gets-fda-nod-for-new-potency-assay-to-release-ryoncil-batches-498a552026-09-28monthly0.7 https://app.readthrough.bio/stories/therapeutic-neuromodulation-systems-files-form-d-for-5-million-equity-4b44fd2026-09-28monthly0.7 https://app.readthrough.bio/stories/onemednet-stockholders-back-equity-plan-increase-and-possible-reverse-4c486f2026-09-28monthly0.7 https://app.readthrough.bio/stories/zymeworks-closes-acquisition-of-theravance-biopharma-4c912f2026-09-27monthly0.7 https://app.readthrough.bio/stories/lexaria-bioscience-reports-form-d-covering-warrant-exercise-proceeds-5130922026-09-28monthly0.7 https://app.readthrough.bio/stories/cue-biopharma-reports-positive-phase-2-results-for-cue-221-in-chronic-59bf692026-09-27monthly0.7 https://app.readthrough.bio/stories/rocket-one-agrees-to-acquire-tracer-drone-technologies-5a46e72026-09-28monthly0.7 https://app.readthrough.bio/stories/proqr-names-chris-hart-as-chief-data-and-ai-officer-adds-thomas-wolf-to-5ec9b92026-09-27monthly0.7 https://app.readthrough.bio/stories/glucotrack-director-resigns-citing-conflict-of-interest-ceo-details-lt-605c0f2026-09-28monthly0.7 https://app.readthrough.bio/stories/black-hawk-discloses-missed-trust-deposits-amid-pending-vesicor-merger-64bb7a2026-09-27monthly0.7 https://app.readthrough.bio/stories/celldex-says-barzolvolimab-hit-all-primary-and-secondary-goals-in-two-666b322026-09-28monthly0.7 https://app.readthrough.bio/stories/telix-pharmaceuticals-to-merge-with-itm-isotope-technologies-munich-in-6c44ff2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-supplemental-application-for-eli-lilly-s-inluriyo-6d375e2026-09-25monthly0.7 https://app.readthrough.bio/stories/calidi-biotherapeutics-closes-1-2-million-registered-direct-stock-7332aa2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-tells-compass-therapeutics-to-run-survival-trial-before-bla-for-774d2c2026-09-28monthly0.7 https://app.readthrough.bio/stories/quidelortho-amends-credit-agreement-resets-financial-covenants-through-7a92f82026-09-28monthly0.7 https://app.readthrough.bio/stories/corcept-names-justin-gunn-to-succeed-retiring-endocrinology-president-7e79aa2026-09-27monthly0.7 https://app.readthrough.bio/stories/biostem-technologies-enters-40-million-committed-equity-facility-with-7f278f2026-09-28monthly0.7 https://app.readthrough.bio/stories/optimi-health-finishes-psilocybin-batch-for-canadian-mdd-trial-and-867f0e2026-09-28monthly0.7 https://app.readthrough.bio/stories/vogenx-appoints-ken-toombs-to-board-of-directors-90c0362026-09-28monthly0.7 https://app.readthrough.bio/stories/adagene-gets-nmpa-clearance-for-her2xcd3-bispecific-adg138-932fec2026-09-28monthly0.7 https://app.readthrough.bio/stories/fennec-reports-phase-2-pedmark-data-from-japan-met-primary-endpoint-at-98247f2026-09-28monthly0.7 https://app.readthrough.bio/stories/scynexis-names-steven-k-burke-to-board-as-adpkd-program-advances-99d01c2026-09-27monthly0.7 https://app.readthrough.bio/stories/quoin-gets-fda-fast-track-for-qrx003-in-peeling-skin-syndrome-9ba75e2026-09-28monthly0.7 https://app.readthrough.bio/stories/vicora-inc-reports-form-d-for-2-5-million-private-offering-9ff5702026-09-28monthly0.7 https://app.readthrough.bio/stories/vistagen-reports-preliminary-open-label-data-from-palisade-4-extension-a230ce2026-09-28monthly0.7 https://app.readthrough.bio/stories/cardiol-hits-maveric-enrollment-goal-early-expands-trial-to-150-patients-a289192026-09-27monthly0.7 https://app.readthrough.bio/stories/valion-bio-names-dean-zikria-interim-ceo-shifts-board-leadership-a42c192026-09-27monthly0.7 https://app.readthrough.bio/stories/vitruvias-therapeutics-recalls-thyroid-tablets-as-class-i-fda-says-a615142026-09-29monthly0.7 https://app.readthrough.bio/stories/halozyme-prices-upsized-1-3-billion-convertible-notes-offering-due-2033-a9c7e22026-09-27monthly0.7 https://app.readthrough.bio/stories/travere-therapeutics-names-bradley-campbell-ceo-as-eric-dube-exits-adf46b2026-09-27monthly0.7 https://app.readthrough.bio/stories/neonc-ceo-buys-more-stock-after-positive-neo100-phase-2a-data-b32bf72026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-eli-lilly-s-onswik-a-new-insulin-efsitora-alfa-gobe-b520042026-09-30monthly0.7 https://app.readthrough.bio/stories/abivax-reports-h1-2026-results-cash-runway-into-q4-2029-leadership-b77c012026-09-27monthly0.7 https://app.readthrough.bio/stories/viking-reports-positive-maintenance-data-for-obesity-drug-vk2735-b969d02026-09-28monthly0.7 https://app.readthrough.bio/stories/decoy-therapeutics-closes-3-85-million-warrant-inducement-transaction-bd5ed82026-09-28monthly0.7 https://app.readthrough.bio/stories/pds-biotech-publishes-versatile-002-phase-2-results-for-pds0101-in-jama-c27cb42026-09-28monthly0.7 https://app.readthrough.bio/stories/fibrobiologics-cso-buys-0-5-million-in-stock-in-private-placement-c4fced2026-09-28monthly0.7 https://app.readthrough.bio/stories/nasus-pharma-files-to-sell-up-to-8-5-million-in-shares-via-atm-offering-c652a12026-09-28monthly0.7 https://app.readthrough.bio/stories/ligand-pays-23-million-for-royalty-rights-on-santen-s-myopia-drug-c6645f2026-09-28monthly0.7 https://app.readthrough.bio/stories/evommune-to-present-phase-2a-evo301-atopic-dermatitis-data-at-eadv-2026-c9a0a72026-09-28monthly0.7 https://app.readthrough.bio/stories/ac-immune-reports-positive-week-100-safety-and-immunogenicity-data-for-ca857b2026-09-28monthly0.7 https://app.readthrough.bio/stories/tiziana-completes-last-patient-visit-in-phase-2a-inform-ms-foralumab-cc2b472026-09-28monthly0.7 https://app.readthrough.bio/stories/sarepta-settles-patent-litigation-with-regenxbio-upenn-catalent-over-d0ec222026-09-28monthly0.7 https://app.readthrough.bio/stories/ptc-therapeutics-closes-acquisition-of-sangamo-s-st-920-fabry-gene-d70ac92026-09-27monthly0.7 https://app.readthrough.bio/stories/bio-techne-shareholders-approve-merck-kgaa-acquisition-d81ef52026-09-27monthly0.7 https://app.readthrough.bio/stories/sovargen-doses-first-patient-in-paxalisib-epilepsy-trial-triggers-2m-e572852026-09-27monthly0.7 https://app.readthrough.bio/stories/optimi-health-to-launch-phase-2-trial-of-psilocybin-therapy-for-major-ef6e802026-09-26monthly0.7 https://app.readthrough.bio/stories/immuron-presents-pipeline-and-financial-update-at-coffee-microcaps-f08ca02026-09-27monthly0.7 https://app.readthrough.bio/stories/alaunos-closes-registered-direct-offering-gross-proceeds-about-1-12-f255a92026-09-28monthly0.7 https://app.readthrough.bio/stories/blossomhill-reports-q2-2026-results-fda-fast-track-for-lung-cancer-drug-faaef52026-09-28monthly0.7 https://app.readthrough.bio/stories/pds-biotech-closes-first-tranche-of-pipe-adds-soon-shiong-to-board-0666232026-09-27monthly0.7 https://app.readthrough.bio/stories/astrazeneca-s-serena-4-trial-misses-main-goal-for-etcamah-in-first-line-0682b82026-09-25monthly0.7 https://app.readthrough.bio/stories/emergent-biosolutions-cuts-full-year-2026-revenue-and-ebitda-guidance-0709ec2026-09-28monthly0.7 https://app.readthrough.bio/stories/alkermes-adds-anne-c-whitaker-to-board-of-directors-0bc9d62026-09-27monthly0.7 https://app.readthrough.bio/stories/connect-biopharma-reports-phase-2-asthma-data-for-rademikibart-0d54392026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-telix-s-pixclara-for-glioma-imaging-0eff862026-09-28monthly0.7 https://app.readthrough.bio/stories/fibrobiologics-raises-0-5-million-from-cso-hamid-khoja-in-private-1090442026-09-28monthly0.7 https://app.readthrough.bio/stories/indivior-and-reckitt-benckiser-move-up-end-date-of-suboxone-subutex-1a3bc62026-09-28monthly0.7 https://app.readthrough.bio/stories/adial-pharmaceuticals-amends-pipe-and-note-exchange-agreements-ahead-of-1a7de72026-09-28monthly0.7 https://app.readthrough.bio/stories/shuttle-pharmaceuticals-converts-preferred-shares-issues-warrants-after-1e95932026-09-28monthly0.7 https://app.readthrough.bio/stories/contineum-s-moonlight-1-phase-2-trial-fails-to-hit-primary-endpoint-in-2081702026-09-27monthly0.7 https://app.readthrough.bio/stories/louisiana-biotech-therapeutic-neuromodulation-systems-files-form-d-for-21d3012026-09-28monthly0.7 https://app.readthrough.bio/stories/tempo-therapeutics-discloses-14-million-raised-in-debt-offering-2475052026-09-28monthly0.7 https://app.readthrough.bio/stories/benitec-reports-fiscal-2026-results-updates-bb-301-trial-progress-and-33bcb12026-09-28monthly0.7 https://app.readthrough.bio/stories/oncobiomix-files-form-d-for-2-5-million-offering-3c68dc2026-09-28monthly0.7 https://app.readthrough.bio/stories/faeth-therapeutics-expands-board-adds-co-founder-karen-vousden-4273d82026-09-27monthly0.7 https://app.readthrough.bio/stories/agomab-reports-positive-phase-1-data-for-inhaled-ipf-drug-agmb-447-42ecb82026-09-28monthly0.7 https://app.readthrough.bio/stories/jaguar-health-to-complete-1-for-15-reverse-stock-split-on-september-17-44274c2026-09-28monthly0.7 https://app.readthrough.bio/stories/moonwalk-biosciences-discloses-70-2-million-equity-offering-in-sec-form-45a1cb2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-supplement-for-nuvation-s-ibtrozi-nda219713-45e7ab2026-09-27monthly0.7 https://app.readthrough.bio/stories/teva-subsidiaries-price-3-2-billion-and-1-5-billion-in-new-senior-notes-501efb2026-09-28monthly0.7 https://app.readthrough.bio/stories/lisata-acquires-marea-therapeutics-raises-225-million-in-private-51e2252026-09-27monthly0.7 https://app.readthrough.bio/stories/mindwalk-reports-21-revenue-growth-gross-margin-expands-to-58-6-in-554a712026-09-28monthly0.7 https://app.readthrough.bio/stories/sanofi-and-cheplapharm-announce-mature-medicines-partnership-5bc15d2026-09-25monthly0.7 https://app.readthrough.bio/stories/myriad-genetics-names-vishal-sikri-as-evp-of-commercial-effective-5d36db2026-09-28monthly0.7 https://app.readthrough.bio/stories/quince-therapeutics-sells-italian-unit-and-a-t-drug-technology-to-ayma-5e61cf2026-09-28monthly0.7 https://app.readthrough.bio/stories/anteris-technologies-grants-contingent-options-and-psus-to-executives-64a3e62026-09-28monthly0.7 https://app.readthrough.bio/stories/indivior-declares-8-13-per-share-special-dividend-tied-to-supernus-6f19312026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-supplemental-efficacy-application-for-astrazeneca-s-truqap-70e2be2026-09-25monthly0.7 https://app.readthrough.bio/stories/surgibox-inc-discloses-486-000-raised-in-regulation-d-offering-74e6552026-09-28monthly0.7 https://app.readthrough.bio/stories/aim-immunotech-converts-two-streeterville-notes-into-stock-via-exchange-7547392026-09-27monthly0.7 https://app.readthrough.bio/stories/inmune-bio-adds-two-directors-with-rare-disease-and-business-7690082026-09-27monthly0.7 https://app.readthrough.bio/stories/aethlon-medical-amends-executive-employment-agreements-ahead-of-change-77f2ca2026-09-28monthly0.7 https://app.readthrough.bio/stories/summit-reports-updated-harmoni-overall-survival-data-at-wclc-2026-77fdfd2026-09-28monthly0.7 https://app.readthrough.bio/stories/impact-biomedical-says-zoar-limited-filed-form-f-4-for-merger-with-7f976d2026-09-28monthly0.7 https://app.readthrough.bio/stories/volitionrx-issues-shares-to-lind-on-convertible-note-conversions-84a3f42026-09-28monthly0.7 https://app.readthrough.bio/stories/blossomhill-reports-45-response-rate-for-bh-30643-in-egfr-c797s-lung-90e9d12026-09-28monthly0.7 https://app.readthrough.bio/stories/aethlon-medical-to-merge-with-north-immunology-in-reverse-merger-91cb402026-09-28monthly0.7 https://app.readthrough.bio/stories/lb-pharmaceuticals-names-susan-kozauer-as-chief-medical-officer-93b0b12026-09-27monthly0.7 https://app.readthrough.bio/stories/repligen-board-member-karen-dawes-to-retire-after-over-20-years-98d3652026-09-28monthly0.7 https://app.readthrough.bio/stories/jaguar-health-exchanges-debt-and-preferred-stock-for-common-stock-9e304c2026-09-28monthly0.7 https://app.readthrough.bio/stories/xenetic-biosciences-and-santersus-agree-to-all-stock-combination-a18f592026-09-28monthly0.7 https://app.readthrough.bio/stories/yarrow-bioscience-prices-161-8m-stock-offering-expected-to-close-sept-14-a6da022026-09-28monthly0.7 https://app.readthrough.bio/stories/avalyn-pharma-adds-robert-meyer-m-d-to-board-of-directors-a86cba2026-09-27monthly0.7 https://app.readthrough.bio/stories/vera-s-trutakna-hits-all-endpoints-in-origin-3-final-analysis-for-iga-aa45692026-09-27monthly0.7 https://app.readthrough.bio/stories/tevogen-grants-performance-based-restricted-stock-to-ceo-and-cfo-tied-ad49352026-09-28monthly0.7 https://app.readthrough.bio/stories/aligos-therapeutics-extends-south-san-francisco-headquarters-lease-to-b4613d2026-09-28monthly0.7 https://app.readthrough.bio/stories/clene-prices-4-million-registered-direct-offering-with-insider-b610af2026-09-28monthly0.7 https://app.readthrough.bio/stories/gsk-to-acquire-trispecific-t-cell-engager-for-multiple-myeloma-from-b678d22026-09-27monthly0.7 https://app.readthrough.bio/stories/gossamer-bio-adds-greg-ciongoli-to-board-and-audit-committee-bdeec02026-09-28monthly0.7 https://app.readthrough.bio/stories/tuhura-biosciences-adopts-inducement-equity-plan-adds-detail-in-amended-bfc0902026-09-28monthly0.7 https://app.readthrough.bio/stories/ernexa-therapeutics-appoints-robert-j-spiegel-to-board-of-directors-c24c122026-09-28monthly0.7 https://app.readthrough.bio/stories/clene-sells-4-million-in-stock-directly-to-insiders-and-existing-holders-c6fd2b2026-09-28monthly0.7 https://app.readthrough.bio/stories/aquestive-resubmits-fda-application-for-anaphylm-epinephrine-film-cd9a8b2026-09-28monthly0.7 https://app.readthrough.bio/stories/sionna-to-advance-sion-451-plus-sion-2222-into-phase-2a-after-precision-ce1b492026-09-28monthly0.7 https://app.readthrough.bio/stories/jazz-pharmaceuticals-completes-acquisition-of-actio-biosciences-cfe3a62026-09-27monthly0.7 https://app.readthrough.bio/stories/calidi-biotherapeutics-prices-1-2-million-stock-offering-at-1-17-per-d220162026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-supplement-6-for-pharming-s-joenja-tablets-d6c09e2026-09-28monthly0.7 https://app.readthrough.bio/stories/tempest-secures-option-to-license-senlang-s-cd7-lentiviral-in-vivo-car-d951e02026-09-28monthly0.7 https://app.readthrough.bio/stories/rocket-pharmaceuticals-says-fda-aligns-on-danon-disease-pivotal-trial-db574b2026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-two-tagrisso-supplements-for-astrazeneca-dfb1f52026-09-25monthly0.7 https://app.readthrough.bio/stories/geovax-files-s-1-for-resale-of-11-4-million-warrant-shares-tied-to-e3ba732026-09-27monthly0.7 https://app.readthrough.bio/stories/glucotrack-stockholders-approve-nasdaq-required-share-issuances-at-e806a22026-09-28monthly0.7 https://app.readthrough.bio/stories/innate-pharma-reports-h1-2026-net-loss-of-19-6-million-amid-cash-decline-e8d8a42026-09-27monthly0.7 https://app.readthrough.bio/stories/innate-pharma-and-sobi-close-lacutamab-partnership-triggering-75m-e8d9f62026-09-27monthly0.7 https://app.readthrough.bio/stories/legend-biotech-names-ingrid-zhang-ceo-effective-september-15-2026-ea0ad52026-09-27monthly0.7 https://app.readthrough.bio/stories/tyra-biosciences-prices-400-million-stock-offering-fd87952026-09-28monthly0.7 https://app.readthrough.bio/stories/korsana-biosciences-completes-cyclerion-merger-closes-380-million-13ef6d2026-09-27monthly0.7 https://app.readthrough.bio/stories/veru-advances-oral-sabizabulin-toward-phase-2-in-daraxonrasib-resistant-19f0f62026-09-26monthly0.7 https://app.readthrough.bio/stories/scynexis-names-sanjay-subramanian-as-cfo-replacing-retiring-ivor-macleod-1d98512026-09-28monthly0.7 https://app.readthrough.bio/stories/engene-reports-q3-2026-results-keeps-4q-bla-related-timelines-for-20224c2026-09-28monthly0.7 https://app.readthrough.bio/stories/roivant-reports-positive-phase-2-phocus-results-for-mosliciguat-in-ph-2036012026-09-26monthly0.7 https://app.readthrough.bio/stories/virax-biolabs-caps-at-the-market-share-sales-at-about-2-07-million-2073092026-09-28monthly0.7 https://app.readthrough.bio/stories/mirum-names-rob-myers-as-cmo-succeeding-joanne-quan-20fa9d2026-09-28monthly0.7 https://app.readthrough.bio/stories/quoin-pharmaceuticals-reports-50-million-private-placement-in-form-d-25156e2026-09-28monthly0.7 https://app.readthrough.bio/stories/veraxa-biotech-names-raju-willener-as-new-cfo-2c0a9b2026-09-28monthly0.7 https://app.readthrough.bio/stories/cybin-s-helus-pharma-to-join-three-investor-conferences-in-new-york-in-2c59322026-09-28monthly0.7 https://app.readthrough.bio/stories/rallybio-cfo-jonathan-lieber-shifts-to-part-time-role-ahead-of-avenzo-2d7f9a2026-09-28monthly0.7 https://app.readthrough.bio/stories/biolinerx-files-form-d-for-3-75-million-warrant-related-offering-2deb1d2026-09-28monthly0.7 https://app.readthrough.bio/stories/cervomed-to-present-nfvppa-biomarker-data-in-late-breaking-session-at-36ef072026-09-26monthly0.7 https://app.readthrough.bio/stories/turn-therapeutics-names-redfield-chief-scientific-officer-sets-stifel-37c0a72026-09-28monthly0.7 https://app.readthrough.bio/stories/lyell-completes-lyl273-manufacturing-transfer-pushes-back-phase-1-2-3a8f4e2026-09-26monthly0.7 https://app.readthrough.bio/stories/pharvaris-reports-positive-phase-3-chapter-3-results-for-deucrictibant-3d79902026-09-26monthly0.7 https://app.readthrough.bio/stories/fda-accepts-intellia-s-bla-for-lonvo-z-in-hereditary-angioedema-grants-3ee69f2026-09-25monthly0.7 https://app.readthrough.bio/stories/kura-oncology-names-jennifer-fulk-as-chief-financial-officer-49eecc2026-09-27monthly0.7 https://app.readthrough.bio/stories/whitehawk-therapeutics-adds-vijay-iyengar-to-board-of-directors-521e302026-09-26monthly0.7 https://app.readthrough.bio/stories/tarsus-closes-acquisition-of-alkeus-gains-stargardt-disease-drug-53dcd92026-09-26monthly0.7 https://app.readthrough.bio/stories/prelude-therapeutics-gets-fda-clearance-for-kat6a-degrader-ind-57981a2026-09-26monthly0.7 https://app.readthrough.bio/stories/radiopharm-reports-positive-phase-1-imaging-data-for-rad301-in-5e9a992026-09-27monthly0.7 https://app.readthrough.bio/stories/kiora-pharmaceuticals-names-keith-lane-as-evp-of-clinical-development-6c79a22026-09-28monthly0.7 https://app.readthrough.bio/stories/biolinerx-and-hemispherian-to-present-glix1-data-at-eano-2026-734ff32026-09-26monthly0.7 https://app.readthrough.bio/stories/os-therapies-stockholders-back-director-slate-pay-plan-changes-at-2026-757c3f2026-09-28monthly0.7 https://app.readthrough.bio/stories/aspire-lakewood-holdings-authorizes-10-million-stock-buyback-completes-79bb3c2026-09-26monthly0.7 https://app.readthrough.bio/stories/qiagen-names-jonathan-pratt-as-next-ceo-effective-september-1-2026-7a56422026-09-28monthly0.7 https://app.readthrough.bio/stories/trinity-biotech-s-trinovium-unit-signs-cooling-deal-with-red-team-7ae24f2026-09-28monthly0.7 https://app.readthrough.bio/stories/maplight-therapeutics-registers-13-2-million-shares-for-resale-after-7e4a562026-09-28monthly0.7 https://app.readthrough.bio/stories/proqr-doses-first-participant-in-phase-1-trial-of-ax-0811-7e7c8f2026-09-26monthly0.7 https://app.readthrough.bio/stories/inhibrx-reports-phase-2-hnscc-data-showing-inbrx-106-combo-nearly-80b7a62026-09-26monthly0.7 https://app.readthrough.bio/stories/century-therapeutics-adds-joseph-truitt-to-board-of-directors-82499f2026-09-27monthly0.7 https://app.readthrough.bio/stories/biocardia-to-present-cardiamp-and-helix-updates-at-h-c-wainwright-8352a22026-09-25monthly0.7 https://app.readthrough.bio/stories/united-therapeutics-enters-477-6-million-accelerated-share-repurchase-84ed7a2026-09-25monthly0.7 https://app.readthrough.bio/stories/pharvaris-reports-positive-chapter-3-phase-3-data-for-deucrictibant-xr-851b7d2026-09-26monthly0.7 https://app.readthrough.bio/stories/evotec-s-just-biologics-unit-starts-phase-1-trial-of-antibody-cocktail-877c0f2026-09-26monthly0.7 https://app.readthrough.bio/stories/hcw-biologics-signs-exclusive-distribution-deal-with-akron-biotech-for-8b17bc2026-09-27monthly0.7 https://app.readthrough.bio/stories/amylyx-signs-two-manufacturing-deals-to-secure-avexitide-drug-substance-8cdffd2026-09-27monthly0.7 https://app.readthrough.bio/stories/pyxis-oncology-names-thomas-civik-permanent-ceo-and-chairman-9152a82026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-astrazeneca-s-etcamah-for-hr-positive-breast-cancer-928e092026-09-25monthly0.7 https://app.readthrough.bio/stories/spyre-reports-positive-phase-2-spy003-data-completing-proof-of-concept-92e3162026-09-26monthly0.7 https://app.readthrough.bio/stories/cdt-equity-registers-resale-of-16-8-million-shares-tied-to-notes-and-94de0d2026-09-27monthly0.7 https://app.readthrough.bio/stories/clearmind-gets-yale-irb-clearance-to-expand-cmnd-100-trial-recruitment-978ea92026-09-26monthly0.7 https://app.readthrough.bio/stories/indaptus-therapeutics-raises-24-million-in-private-placement-revamps-97b0182026-09-27monthly0.7 https://app.readthrough.bio/stories/braveheart-bio-starts-phase-3-ohcm-trial-reports-q2-2026-results-992ba02026-09-27monthly0.7 https://app.readthrough.bio/stories/evommune-s-evo756-fails-phase-2b-atopic-dermatitis-trial-shifts-focus-9b7fb32026-09-26monthly0.7 https://app.readthrough.bio/stories/candel-therapeutics-adds-martine-zimmermann-to-board-ahead-of-planned-9bdae92026-09-27monthly0.7 https://app.readthrough.bio/stories/apnimed-s-osa-drug-nda-accepted-by-fda-pdufa-date-set-for-february-2027-a46c052026-09-28monthly0.7 https://app.readthrough.bio/stories/disc-medicine-reports-early-phase-2-data-for-disc-3405-in-polycythemia-a552a12026-09-26monthly0.7 https://app.readthrough.bio/stories/champions-oncology-posts-8-8-revenue-growth-and-wider-margins-in-fiscal-a8f9d62026-09-28monthly0.7 https://app.readthrough.bio/stories/pyxis-oncology-reports-updated-phase-1-data-for-micvo-in-head-and-neck-aa4bf02026-09-26monthly0.7 https://app.readthrough.bio/stories/opus-genetics-reports-cohort-1-data-for-opgx-best1-aligns-with-fda-on-aa90432026-09-26monthly0.7 https://app.readthrough.bio/stories/cocrystal-pharma-completes-dosing-in-norovirus-challenge-study-of-cdi-ab22be2026-09-26monthly0.7 https://app.readthrough.bio/stories/okyo-pharma-to-present-at-two-european-ophthalmology-industry-events-in-ac54c92026-09-26monthly0.7 https://app.readthrough.bio/stories/iqvia-subsidiary-to-sell-2-billion-in-senior-notes-due-2034-afc6132026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-grants-second-rare-pediatric-disease-designation-to-quoin-s-qrx003-b3e49e2026-09-27monthly0.7 https://app.readthrough.bio/stories/kala-bio-signs-exclusive-us-distribution-deal-with-virotek-for-eye-b4551a2026-09-27monthly0.7 https://app.readthrough.bio/stories/incannex-reports-first-dosing-in-ihl-42x-phase-2-study-new-patent-70-c23b152026-09-26monthly0.7 https://app.readthrough.bio/stories/xeris-details-phase-3-plan-for-weekly-hypothyroidism-therapy-xp-8121-c3aed82026-09-28monthly0.7 https://app.readthrough.bio/stories/anteris-names-brent-moen-as-new-cfo-shifts-mcdonnell-to-australia-role-cda0842026-09-28monthly0.7 https://app.readthrough.bio/stories/clearmind-medicine-agrees-to-acquire-51-stake-in-israeli-wireless-ev-d2fa242026-09-26monthly0.7 https://app.readthrough.bio/stories/belite-bio-files-japan-nda-for-tinlarebant-in-stargardt-disease-type-1-d7eeda2026-09-27monthly0.7 https://app.readthrough.bio/stories/novabridge-names-martin-dewhurst-as-independent-director-d8d5272026-09-28monthly0.7 https://app.readthrough.bio/stories/novartis-starts-phase-2-trial-of-monte-rosa-s-mrt-6160-in-sj-gren-s-db685d2026-09-26monthly0.7 https://app.readthrough.bio/stories/x4-pharmaceuticals-gets-fda-agreement-to-cut-4ward-trial-size-to-126-e01f652026-09-26monthly0.7 https://app.readthrough.bio/stories/xortx-starts-clinical-and-commercial-manufacturing-for-gout-drug-xorlo-e3533a2026-09-26monthly0.7 https://app.readthrough.bio/stories/can-fite-biopharma-discloses-8-3-million-warrant-offering-in-sec-form-d-e569b12026-09-28monthly0.7 https://app.readthrough.bio/stories/neonc-prices-15-million-registered-direct-offering-of-stock-and-warrants-e57c442026-09-28monthly0.7 https://app.readthrough.bio/stories/teva-prices-multi-tranche-notes-offering-to-fund-redemption-of-five-e5a5e82026-09-28monthly0.7 https://app.readthrough.bio/stories/japan-clears-prefilled-syringe-version-of-gsk-s-shingrix-e941a52026-09-26monthly0.7 https://app.readthrough.bio/stories/lexaria-raises-about-5-9-million-through-warrant-exercise-inducement-e9ed052026-09-28monthly0.7 https://app.readthrough.bio/stories/structure-therapeutics-reports-new-data-on-oral-amylin-and-glp-1-ea15dc2026-09-26monthly0.7 https://app.readthrough.bio/stories/adagene-reports-two-collaboration-milestones-with-third-arc-bio-and-ec6e482026-09-26monthly0.7 https://app.readthrough.bio/stories/acurx-files-s-1-to-register-1-5-million-more-shares-for-lincoln-park-f664f12026-09-28monthly0.7 https://app.readthrough.bio/stories/scinai-ends-pc111-arrangements-shifts-focus-to-nanoab-and-cdmo-business-fe43662026-09-27monthly0.7 https://app.readthrough.bio/stories/passage-bio-and-remix-amend-merger-deal-into-two-step-structure-058e5c2026-09-27monthly0.7 https://app.readthrough.bio/stories/scribe-therapeutics-starts-phase-1-trial-of-pcsk9-silencer-stx-1150-0913512026-09-27monthly0.7 https://app.readthrough.bio/stories/aclarity-genomics-files-form-d-for-4-625-000-equity-offering-0e8d7e2026-09-28monthly0.7 https://app.readthrough.bio/stories/medicinova-terminates-standby-equity-purchase-agreement-with-yorkville-14abfa2026-09-27monthly0.7 https://app.readthrough.bio/stories/latigo-reports-q2-2026-results-nejm-publication-for-onzotrigine-and-16227c2026-09-28monthly0.7 https://app.readthrough.bio/stories/adicet-bio-finishes-final-patient-visits-in-lupus-car-t-study-plans-1c9c932026-09-26monthly0.7 https://app.readthrough.bio/stories/moderna-completes-3-billion-convertible-notes-offering-upsized-from-30de7b2026-09-28monthly0.7 https://app.readthrough.bio/stories/telix-finishes-enrollment-in-phase-3-bipass-trial-aligns-with-fda-on-35cbf22026-09-26monthly0.7 https://app.readthrough.bio/stories/fda-accepts-bla-for-alvotech-s-avt80-a-subcutaneous-entyvio-biosimilar-39eb822026-09-27monthly0.7 https://app.readthrough.bio/stories/abbvie-closes-10-9-billion-acquisition-of-apogee-therapeutics-402eb42026-09-25monthly0.7 https://app.readthrough.bio/stories/gossamer-bio-files-form-d-for-150-million-offering-of-rights-to-acquire-40780b2026-09-28monthly0.7 https://app.readthrough.bio/stories/valion-bio-names-lisa-wolf-president-and-coo-adds-two-directors-424fd92026-09-28monthly0.7 https://app.readthrough.bio/stories/cdt-equity-names-james-bligh-ceo-andrew-regan-resigns-42631c2026-09-28monthly0.7 https://app.readthrough.bio/stories/can-fite-sees-longer-survival-in-blinded-phase-iii-liver-cancer-study-46e1c12026-09-26monthly0.7 https://app.readthrough.bio/stories/upstream-bio-sets-phase-3-plans-for-verekitug-in-asthma-and-crswnp-4847422026-09-26monthly0.7 https://app.readthrough.bio/stories/revolution-medicines-to-lease-four-redwood-city-buildings-for-new-hq-49a9322026-09-27monthly0.7 https://app.readthrough.bio/stories/china-s-nmpa-approves-milestone-s-etripamil-nasal-spray-for-psvt-51c2392026-09-26monthly0.7 https://app.readthrough.bio/stories/jupiter-neurosciences-files-form-d-for-774-787-private-offering-54b32b2026-09-28monthly0.7 https://app.readthrough.bio/stories/bioaffinity-technologies-to-present-at-h-c-wainwright-investment-553aa12026-09-28monthly0.7 https://app.readthrough.bio/stories/jazz-pharmaceuticals-closes-1-25-billion-exchangeable-notes-offering-55ef1f2026-09-27monthly0.7 https://app.readthrough.bio/stories/tuhura-biosciences-draws-1-5-million-more-from-parkview-credit-line-565a452026-09-28monthly0.7 https://app.readthrough.bio/stories/novartis-s-pelacarsen-fails-cardiovascular-outcomes-trial-in-phase-3-57bd682026-09-25monthly0.7 https://app.readthrough.bio/stories/indaptus-therapeutics-board-member-tim-ruan-resigns-effective-5b0d1c2026-09-28monthly0.7 https://app.readthrough.bio/stories/attovia-reports-atto-1310-pruritus-proof-of-concept-plans-phase-2-for-5b308e2026-09-28monthly0.7 https://app.readthrough.bio/stories/indaptus-corrects-dilution-math-in-100m-at-the-market-offering-600eee2026-09-27monthly0.7 https://app.readthrough.bio/stories/senti-biosciences-closes-2-million-note-sale-to-nsg-secures-celadon-601bfb2026-09-27monthly0.7 https://app.readthrough.bio/stories/biomarin-and-ascendis-settle-global-patent-dispute-over-yuviwel-61cb8d2026-09-27monthly0.7 https://app.readthrough.bio/stories/eu-clears-enhertu-plus-pertuzumab-as-first-line-her2-positive-6385ef2026-09-27monthly0.7 https://app.readthrough.bio/stories/alumis-lumus-trial-misses-main-goals-in-lupus-but-subgroup-shows-benefit-66984f2026-09-26monthly0.7 https://app.readthrough.bio/stories/cogent-biosciences-signs-commercial-supply-deal-with-hovione-for-6747542026-09-27monthly0.7 https://app.readthrough.bio/stories/vertex-names-jonathan-poole-as-next-cfo-effective-january-2027-6c08952026-09-27monthly0.7 https://app.readthrough.bio/stories/cadrenal-reports-fda-alignment-on-phase-3-design-for-hit-drug-cad-1005-6dd8042026-09-26monthly0.7 https://app.readthrough.bio/stories/adarx-pharmaceuticals-files-s-1-for-nasdaq-ipo-under-ticker-adrx-6f3f5c2026-09-25monthly0.7 https://app.readthrough.bio/stories/intellia-secures-up-to-400-million-credit-facility-from-orbimed-6fee4d2026-09-25monthly0.7 https://app.readthrough.bio/stories/redhill-acquires-rebyota-and-clenpiq-rights-from-ferring-for-12-million-72502a2026-09-26monthly0.7 https://app.readthrough.bio/stories/ispecimen-agrees-to-buy-ai-assets-from-foldlab-for-4-5-million-793fbf2026-09-27monthly0.7 https://app.readthrough.bio/stories/invivyd-names-chairman-marc-elia-as-ceo-adds-board-member-ahead-of-7e0f272026-09-28monthly0.7 https://app.readthrough.bio/stories/uniqure-files-bla-and-uk-maa-for-huntington-s-gene-therapy-amt-130-7e81d52026-09-26monthly0.7 https://app.readthrough.bio/stories/inventiva-reports-last-patient-visit-completed-in-nativ3-phase-3-7f0d212026-09-26monthly0.7 https://app.readthrough.bio/stories/harrow-s-pollard-steps-down-as-chief-accounting-officer-boll-adds-the-8098c32026-09-28monthly0.7 https://app.readthrough.bio/stories/lb-pharmaceuticals-names-joseph-miller-as-chief-financial-officer-8121a32026-09-28monthly0.7 https://app.readthrough.bio/stories/parabilis-medicines-chief-medical-officer-to-depart-in-september-840a022026-09-28monthly0.7 https://app.readthrough.bio/stories/pluri-prices-1-50-registered-offering-plans-concurrent-private-85bc8d2026-09-28monthly0.7 https://app.readthrough.bio/stories/hutchmed-licenses-kras-egfr-conjugate-hmpl-a830-to-gsk-deal-worth-up-to-8675cf2026-09-27monthly0.7 https://app.readthrough.bio/stories/pds-biotechnology-amends-promissory-note-with-ya-ii-pn-8686932026-09-27monthly0.7 https://app.readthrough.bio/stories/clearmind-starts-phase-iia-dosing-in-alcohol-use-disorder-trial-six-89edce2026-09-26monthly0.7 https://app.readthrough.bio/stories/pmv-pharma-reports-46-orr-in-ovarian-cancer-cohort-of-rezatapopt-trial-918e2e2026-09-26monthly0.7 https://app.readthrough.bio/stories/pmgc-s-northstrive-and-yuva-biosciences-expand-ai-drug-discovery-pact-934c752026-09-27monthly0.7 https://app.readthrough.bio/stories/vertex-completes-10-0-billion-acquisition-of-crinetics-pharmaceuticals-972fb22026-09-27monthly0.7 https://app.readthrough.bio/stories/pmv-pharma-prices-50-8-million-offering-to-fund-rezatapopt-push-9b08072026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-grants-accelerated-approval-to-astrazeneca-s-etcamah-for-breast-a10d692026-09-25monthly0.7 https://app.readthrough.bio/stories/fda-approves-ionis-s-zanvastro-for-alexander-disease-a51a952026-09-25monthly0.7 https://app.readthrough.bio/stories/vaxcyte-names-new-chief-medical-and-legal-officers-moves-up-opus-1-data-a535e62026-09-26monthly0.7 https://app.readthrough.bio/stories/shuttle-pharmaceuticals-amends-united-dogecoin-merger-milestone-terms-bbdb652026-09-27monthly0.7 https://app.readthrough.bio/stories/climb-bio-reports-phase-1-data-for-anti-april-antibody-clym116-in-iga-bc525b2026-09-26monthly0.7 https://app.readthrough.bio/stories/allogene-therapeutics-cfo-geoffrey-parker-to-retire-in-november-2026-bd57be2026-09-28monthly0.7 https://app.readthrough.bio/stories/medicus-pharma-subsidiary-signs-co-development-deal-with-pfizer-for-c17e052026-09-27monthly0.7 https://app.readthrough.bio/stories/jaguar-health-cuts-atm-offering-size-after-triggering-form-s-3-share-c4e3792026-09-28monthly0.7 https://app.readthrough.bio/stories/tscan-cuts-75-of-staff-pauses-alloha-2-to-focus-on-in-vivo-solid-tumor-d14c232026-09-26monthly0.7 https://app.readthrough.bio/stories/fda-approves-zanvastro-first-drug-for-alexander-disease-d8b2c02026-09-25monthly0.7 https://app.readthrough.bio/stories/volitionrx-gets-waiver-from-lind-on-atm-sales-exceeding-annual-cap-dedc7b2026-09-27monthly0.7 https://app.readthrough.bio/stories/aptevo-files-prospectus-for-resale-of-over-6-4-million-warrant-shares-df61442026-09-28monthly0.7 https://app.readthrough.bio/stories/bnb-plus-corp-board-turns-over-adds-three-directors-tied-to-globalstake-dfc6852026-09-28monthly0.7 https://app.readthrough.bio/stories/polaryx-therapeutics-names-will-charlton-chief-medical-officer-ahead-of-e12d862026-09-28monthly0.7 https://app.readthrough.bio/stories/agen-genomics-files-form-d-for-offering-of-up-to-1-5-million-e27b972026-09-28monthly0.7 https://app.readthrough.bio/stories/nextcure-exits-remaining-beltsville-lab-space-early-pays-0-8-million-fee-e4e9e62026-09-27monthly0.7 https://app.readthrough.bio/stories/cdt-equity-amends-sarborg-purchase-pact-issues-and-repays-convertible-ecbf902026-09-27monthly0.7 https://app.readthrough.bio/stories/cybin-discloses-form-d-for-stock-option-grant-tied-to-11-78-strike-price-f37c3f2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-grants-fast-track-designation-to-liquidia-s-yutrepia-for-ssc-fbf7e02026-09-27monthly0.7 https://app.readthrough.bio/stories/mira-pharmaceuticals-reports-positive-toxicology-results-for-mira-55-fccb7e2026-09-26monthly0.7 https://app.readthrough.bio/stories/volitionrx-issues-shares-to-lind-global-under-convertible-note-fd62dd2026-09-28monthly0.7 https://app.readthrough.bio/stories/biolinerx-closes-3-75-million-offering-adds-warrant-coverage-from-01a6b12026-09-28monthly0.7 https://app.readthrough.bio/stories/hutchmed-wins-nmpa-approval-for-atled-in-fgfr2-altered-bile-duct-cancer-06201f2026-09-26monthly0.7 https://app.readthrough.bio/stories/vyome-holdings-names-jerry-leonard-as-cfo-effective-september-1-2026-0689e22026-09-28monthly0.7 https://app.readthrough.bio/stories/oragenics-gets-nyse-american-deficiency-notice-updates-trial-and-fda-06a7842026-09-26monthly0.7 https://app.readthrough.bio/stories/glucotrack-files-financials-for-merged-lokahi-therapeutics-flags-going-0cf3342026-09-28monthly0.7 https://app.readthrough.bio/stories/outlook-therapeutics-names-kevin-lundquist-as-new-cfo-0f9e292026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-updated-pfizer-biontech-covid-19-vaccine-targeting-xfg-1253f32026-09-26monthly0.7 https://app.readthrough.bio/stories/mesoblast-reports-fy2026-revenue-of-120-3-million-driven-by-ryoncil-12b1a62026-09-26monthly0.7 https://app.readthrough.bio/stories/quoin-prices-50-million-private-placement-reports-positive-netherton-1b228c2026-09-28monthly0.7 https://app.readthrough.bio/stories/aptevo-therapeutics-discloses-3-47-million-private-placement-registers-1c706c2026-09-28monthly0.7 https://app.readthrough.bio/stories/boundless-bio-and-serapha-bio-amend-merger-agreement-terms-1cd8ee2026-09-27monthly0.7 https://app.readthrough.bio/stories/phibro-reports-record-fiscal-2026-sales-plans-chicago-heights-plant-22bb5d2026-09-28monthly0.7 https://app.readthrough.bio/stories/adaptin-bio-files-s-1-to-register-resale-of-382-400-shares-from-private-23f8502026-09-27monthly0.7 https://app.readthrough.bio/stories/tevogen-holders-reelect-two-directors-back-kpmg-and-charter-changes-at-246ba92026-09-28monthly0.7 https://app.readthrough.bio/stories/ubivac-files-form-d-for-equity-offering-discloses-80-000-raised-so-far-27e8842026-09-28monthly0.7 https://app.readthrough.bio/stories/pds-biotechnology-cuts-workforce-by-about-36-focuses-on-pds0301-2914512026-09-26monthly0.7 https://app.readthrough.bio/stories/tezspire-meets-primary-endpoints-in-phase-iii-eoe-trial-crossing-2c240c2026-09-25monthly0.7 https://app.readthrough.bio/stories/incannex-doses-first-patient-in-phase-2-dreamzz-trial-of-ihl-42x-2e44c32026-09-27monthly0.7 https://app.readthrough.bio/stories/quince-therapeutics-discloses-departure-of-president-charles-ryan-2f116b2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-ziihera-in-two-regimens-for-first-line-her2-2f7f1a2026-09-26monthly0.7 https://app.readthrough.bio/stories/regenxbio-adds-greg-ciongoli-to-board-two-directors-depart-3610142026-09-27monthly0.7 https://app.readthrough.bio/stories/spero-therapeutics-sets-up-new-100m-atm-offering-ends-cantor-sales-pact-38e3b22026-09-27monthly0.7 https://app.readthrough.bio/stories/jupiter-neurosciences-executives-forgive-875-315-in-accrued-pay-3cab112026-09-27monthly0.7 https://app.readthrough.bio/stories/kyntra-bio-cuts-royalty-financing-cap-to-65-million-after-upfront-4079052026-09-28monthly0.7 https://app.readthrough.bio/stories/lifeward-ceo-mark-grant-departs-josh-hexter-named-interim-chief-441b6c2026-09-28monthly0.7 https://app.readthrough.bio/stories/turn-therapeutics-discloses-1-65-million-equity-raise-in-form-d-filing-4807472026-09-28monthly0.7 https://app.readthrough.bio/stories/platform-therapeutics-files-form-d-for-4-million-equity-offering-4c49f02026-09-28monthly0.7 https://app.readthrough.bio/stories/dare-bioscience-files-resale-registration-for-shares-tied-to-august-4c9c6d2026-09-28monthly0.7 https://app.readthrough.bio/stories/pluri-inc-announces-2-98-million-registered-direct-offering-4d9a412026-09-27monthly0.7 https://app.readthrough.bio/stories/electra-therapeutics-files-for-ipo-to-fund-lead-antibody-in-blood-53aad02026-09-27monthly0.7 https://app.readthrough.bio/stories/radiopharm-advances-three-programs-across-rad202-rad101-and-betabart-5666c42026-09-26monthly0.7 https://app.readthrough.bio/stories/cytokinetics-reports-positive-acacia-hcm-results-for-aficamten-in-non-5683bf2026-09-25monthly0.7 https://app.readthrough.bio/stories/adial-pharmaceuticals-grants-inducement-stock-option-to-new-employee-5bd1b22026-09-28monthly0.7 https://app.readthrough.bio/stories/biomerica-completes-2-23-million-private-placement-of-common-stock-6b17cc2026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-efficacy-supplement-for-lilly-s-zepbound-tirzepatide-6d0bdf2026-09-25monthly0.7 https://app.readthrough.bio/stories/fluidform-bio-reports-form-d-offering-with-1-7-million-raised-so-far-7186712026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-roivant-s-lisraya-for-dermatomyositis-launch-begins-7503432026-09-26monthly0.7 https://app.readthrough.bio/stories/coherus-oncology-files-to-sell-up-to-50-million-in-stock-through-7543a32026-09-28monthly0.7 https://app.readthrough.bio/stories/ibio-reports-fiscal-2026-results-cites-progress-across-obesity-antibody-77f7242026-09-28monthly0.7 https://app.readthrough.bio/stories/biohaven-licenses-kv7-epilepsy-platform-to-sk-biopharmaceuticals-7b32a82026-09-27monthly0.7 https://app.readthrough.bio/stories/alterity-therapeutics-discloses-governance-practices-in-august-2026-80cc552026-09-26monthly0.7 https://app.readthrough.bio/stories/alto-neuroscience-elevates-cfo-nicholas-smith-to-president-role-813ba42026-09-28monthly0.7 https://app.readthrough.bio/stories/ispecimen-names-shahin-behroyan-as-ceo-replacing-katharyn-field-82f56d2026-09-28monthly0.7 https://app.readthrough.bio/stories/biontech-ends-phase-2-trial-of-autogene-cevumeran-in-colorectal-cancer-8d04322026-09-26monthly0.7 https://app.readthrough.bio/stories/jasper-therapeutics-receives-nasdaq-notice-over-stockholders-equity-8e58082026-09-27monthly0.7 https://app.readthrough.bio/stories/beone-medicines-files-star-market-interim-report-discloses-r-d-spend-by-92827d2026-09-27monthly0.7 https://app.readthrough.bio/stories/rocket-pharmaceuticals-adopts-new-severance-program-signs-executive-92de152026-09-28monthly0.7 https://app.readthrough.bio/stories/geovax-completes-warrant-inducement-collects-about-3-6-million-969bbb2026-09-27monthly0.7 https://app.readthrough.bio/stories/sunshine-biopharma-director-andrew-keller-to-leave-board-at-next-annual-9c6d3a2026-09-28monthly0.7 https://app.readthrough.bio/stories/telix-pharmaceuticals-names-david-gill-as-board-chair-9ccec22026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-grants-orphan-drug-status-to-lakefront-s-gamgertamig-for-pemphigus-9fab022026-09-27monthly0.7 https://app.readthrough.bio/stories/kazia-prices-40-million-offering-tied-to-paxalisib-breast-cancer-data-a120d92026-09-27monthly0.7 https://app.readthrough.bio/stories/addex-raises-2-8-million-via-atm-offering-extends-cash-runway-to-q4-2027-a694612026-09-28monthly0.7 https://app.readthrough.bio/stories/ptc-therapeutics-agrees-to-acquire-sangamo-s-fabry-disease-gene-therapy-a82dd42026-09-27monthly0.7 https://app.readthrough.bio/stories/summit-s-partner-akeso-reports-positive-phase-iii-data-for-ivonescimab-ac96062026-09-26monthly0.7 https://app.readthrough.bio/stories/inventiva-names-chris-benecchi-as-chief-operating-officer-b0955d2026-09-27monthly0.7 https://app.readthrough.bio/stories/lifevantage-reports-fourth-quarter-and-fiscal-2026-revenue-decline-b3cff52026-09-28monthly0.7 https://app.readthrough.bio/stories/sunshine-biopharma-files-s-1-for-shares-tied-to-series-b-warrants-c12a472026-09-28monthly0.7 https://app.readthrough.bio/stories/vyome-holdings-reports-q2-2026-results-advances-vt-1953-malodor-program-c1ed262026-09-28monthly0.7 https://app.readthrough.bio/stories/argenx-completes-acquisition-of-forte-biosciences-c4eb452026-09-26monthly0.7 https://app.readthrough.bio/stories/spyre-reports-mixed-phase-2-results-for-spy072-in-rheumatoid-arthritis-c643582026-09-26monthly0.7 https://app.readthrough.bio/stories/oruka-therapeutics-files-500-million-at-the-market-stock-offering-with-c7d5252026-09-28monthly0.7 https://app.readthrough.bio/stories/black-hawk-acquisition-corp-secures-up-to-300-000-convertible-note-from-cccef92026-09-27monthly0.7 https://app.readthrough.bio/stories/abvc-completes-partial-spinoff-of-biokey-cayman-subsidiary-ce7f1c2026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-two-efficacy-supplements-for-eli-lilly-s-mounjaro-da22232026-09-25monthly0.7 https://app.readthrough.bio/stories/adaptin-bio-opens-phase-1-trial-of-aptn-101-in-glioblastoma-with-duke-dd1ed82026-09-28monthly0.7 https://app.readthrough.bio/stories/mbx-biosciences-doses-first-patient-in-phase-3-trial-of-canvuparatide-e084f72026-09-26monthly0.7 https://app.readthrough.bio/stories/obsidian-therapeutics-files-s-1-for-resale-of-29-16-million-shares-post-e41b7e2026-09-27monthly0.7 https://app.readthrough.bio/stories/trinity-biotech-faces-nasdaq-delisting-risk-updates-diagnostics-eab3ec2026-09-28monthly0.7 https://app.readthrough.bio/stories/septerna-names-rajiv-patni-m-d-as-chief-medical-officer-f094632026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-ziihera-based-regimens-for-first-line-her2-f1392f2026-09-26monthly0.7 https://app.readthrough.bio/stories/molecular-partners-moves-mp0712-to-higher-dose-in-phase-1-2a-study-f304642026-09-26monthly0.7 https://app.readthrough.bio/stories/prenetics-ceo-and-cfo-buy-1-million-in-shares-after-q2-results-f46fc22026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-sun-pharma-s-vobrig-a-leuprolide-acetate-injection-f754e12026-09-28monthly0.7 https://app.readthrough.bio/stories/serina-therapeutics-signs-25-million-equity-purchase-deal-with-roth-f96f832026-09-27monthly0.7 https://app.readthrough.bio/stories/precision-biosciences-doses-first-patient-in-dmd-gene-editing-trial-040f062026-09-26monthly0.7 https://app.readthrough.bio/stories/medicinova-signs-new-employment-agreements-with-ceo-iwaki-and-cmo-05460c2026-09-28monthly0.7 https://app.readthrough.bio/stories/tempest-therapeutics-names-nicholas-rossettos-as-new-cfo-058d952026-09-28monthly0.7 https://app.readthrough.bio/stories/apimeds-acquires-korean-apitox-rights-from-freet-in-august-2026-0bf6a42026-09-27monthly0.7 https://app.readthrough.bio/stories/change-agents-amends-equity-line-terms-issues-oid-notes-to-repay-debt-11b9202026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-pushes-back-capricor-s-deramiocel-pdufa-date-to-november-22-2026-19d83a2026-09-27monthly0.7 https://app.readthrough.bio/stories/os-therapies-sets-up-75-million-at-the-market-stock-offering-with-1cc9f82026-09-27monthly0.7 https://app.readthrough.bio/stories/volitionrx-issues-shares-to-lind-under-existing-note-conversions-1d9c652026-09-28monthly0.7 https://app.readthrough.bio/stories/cdt-equity-s-sarborg-unit-reports-all-revenue-from-cdt-under-related-27a0502026-09-27monthly0.7 https://app.readthrough.bio/stories/jaguar-health-reports-q2-2026-results-targets-mvid-nda-submission-in-q2-280c3e2026-09-28monthly0.7 https://app.readthrough.bio/stories/amylyx-prices-14-09-million-share-offering-at-35-50-after-lucidity-281d692026-09-27monthly0.7 https://app.readthrough.bio/stories/silo-pharma-buys-software-assets-from-parkview-consulting-in-stock-deal-283f7f2026-09-27monthly0.7 https://app.readthrough.bio/stories/aer-therapeutics-discloses-3-million-securities-offering-in-sec-form-d-292c4a2026-09-28monthly0.7 https://app.readthrough.bio/stories/neonc-technologies-amends-filing-to-add-shomali-s-audit-committee-role-2af0422026-09-28monthly0.7 https://app.readthrough.bio/stories/nasus-pharma-cfo-eyal-rubin-to-resign-interim-successor-named-2d1a982026-09-28monthly0.7 https://app.readthrough.bio/stories/serina-therapeutics-registers-12-5-million-shares-for-roth-principal-2ed99f2026-09-28monthly0.7 https://app.readthrough.bio/stories/revelation-biosciences-grants-restricted-stock-to-ceo-and-cfo-tied-to-35a6c22026-09-28monthly0.7 https://app.readthrough.bio/stories/fibrobiologics-adds-sports-agent-leigh-steinberg-to-board-of-directors-370f5f2026-09-28monthly0.7 https://app.readthrough.bio/stories/jupiter-neurosciences-prices-2-0-million-registered-direct-offering-at-392dbe2026-09-28monthly0.7 https://app.readthrough.bio/stories/biocardia-says-fda-finalized-minutes-on-helix-catheter-pre-submission-458e702026-09-25monthly0.7 https://app.readthrough.bio/stories/bicara-therapeutics-signs-sublease-for-new-boston-headquarters-45c9ad2026-09-27monthly0.7 https://app.readthrough.bio/stories/tempest-therapeutics-registers-8-9-million-shares-for-lincoln-park-4cbd332026-09-27monthly0.7 https://app.readthrough.bio/stories/japan-approves-gsk-s-hibsago-as-first-functional-cure-for-chronic-51930a2026-09-26monthly0.7 https://app.readthrough.bio/stories/cybin-files-two-form-d-notices-for-equity-awards-to-executives-and-54bb382026-09-28monthly0.7 https://app.readthrough.bio/stories/werewolf-therapeutics-sells-preclinical-platforms-to-emd-serono-for-28m-54c0e62026-09-27monthly0.7 https://app.readthrough.bio/stories/longeveron-names-nirav-jhaveri-as-chief-financial-officer-55e1172026-09-25monthly0.7 https://app.readthrough.bio/stories/crescel-llc-files-form-d-for-2-million-securities-offering-5a336b2026-09-28monthly0.7 https://app.readthrough.bio/stories/quoin-pharmaceuticals-shareholders-vote-on-five-proposals-at-2026-62aabe2026-09-28monthly0.7 https://app.readthrough.bio/stories/oruka-therapeutics-names-todd-edwards-as-chief-commercial-officer-62daa72026-09-27monthly0.7 https://app.readthrough.bio/stories/lifeward-overhauls-board-as-q2-revenue-rises-16-cfo-to-depart-68a8332026-09-28monthly0.7 https://app.readthrough.bio/stories/sol-gel-reports-q2-2026-results-sgt-610-phase-3-readout-on-track-for-6ed8752026-09-26monthly0.7 https://app.readthrough.bio/stories/ensysce-biosciences-discloses-77-2-million-private-securities-offering-75ed932026-09-28monthly0.7 https://app.readthrough.bio/stories/parabilis-medicines-adds-oncology-veteran-craig-tendler-to-board-7645712026-09-27monthly0.7 https://app.readthrough.bio/stories/vicore-completes-aspire-enrollment-adds-us-listing-and-new-cso-in-q2-7bc5902026-09-27monthly0.7 https://app.readthrough.bio/stories/moleculin-biotech-increases-atm-stock-offering-size-to-19-7-million-8359a62026-09-28monthly0.7 https://app.readthrough.bio/stories/newcelx-ltd-files-form-d-for-private-placement-raising-2-94-million-8ee9392026-09-28monthly0.7 https://app.readthrough.bio/stories/senti-biosciences-unit-issues-4-0-million-in-convertible-notes-to-974b122026-09-27monthly0.7 https://app.readthrough.bio/stories/werewolf-therapeutics-and-ambros-therapeutics-agree-to-merge-plan-150m-994a2e2026-09-26monthly0.7 https://app.readthrough.bio/stories/novabridge-reports-h1-2026-results-targets-year-end-phase-3-start-for-9dd3fc2026-09-28monthly0.7 https://app.readthrough.bio/stories/arbutus-plans-up-to-230-million-dutch-auction-tender-offer-for-common-a933642026-09-26monthly0.7 https://app.readthrough.bio/stories/tiziana-presents-banyan-trial-poster-on-intranasal-foralumab-in-als-at-aa39f42026-09-26monthly0.7 https://app.readthrough.bio/stories/elutia-closes-simpliderm-sale-to-cellution-biologics-redirects-focus-to-aeda652026-09-26monthly0.7 https://app.readthrough.bio/stories/gossamer-bio-secures-up-to-250-million-private-placement-tied-to-b639762026-09-26monthly0.7 https://app.readthrough.bio/stories/os-therapies-files-75-million-at-the-market-equity-offering-with-b816fe2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-places-clinical-hold-on-regenxbio-s-rgx-121-for-hunter-syndrome-b9b66c2026-09-26monthly0.7 https://app.readthrough.bio/stories/skye-bioscience-finalizes-up-to-22-million-equity-line-with-redmile-b9cb062026-09-27monthly0.7 https://app.readthrough.bio/stories/scienture-launches-rezenopy-cites-patent-wins-and-payer-gains-in-q2-bafe1a2026-09-28monthly0.7 https://app.readthrough.bio/stories/amylyx-prices-public-offering-of-14-09-million-shares-at-35-50-bc58bf2026-09-27monthly0.7 https://app.readthrough.bio/stories/prenetics-signs-lily-collins-as-im8-ambassador-raises-revenue-guidance-bc7fef2026-09-27monthly0.7 https://app.readthrough.bio/stories/organigram-fixes-sanity-group-earnout-moves-to-unified-global-operating-bfda052026-09-28monthly0.7 https://app.readthrough.bio/stories/ac-immune-reports-positive-early-phase-1-data-for-nlrp3-inhibitor-aci-c2ec012026-09-26monthly0.7 https://app.readthrough.bio/stories/tuhura-draws-two-more-tranches-on-50-million-parkview-credit-line-c410bd2026-09-28monthly0.7 https://app.readthrough.bio/stories/calcimedica-stockholders-back-plan-increase-reverse-split-and-warrant-c592202026-09-28monthly0.7 https://app.readthrough.bio/stories/kiora-licenses-south-korean-rights-to-kio-301-to-chong-kun-dang-c82d4f2026-09-27monthly0.7 https://app.readthrough.bio/stories/ani-pharmaceuticals-adds-henry-gosebruch-to-board-shanmugam-resigns-ce6b242026-09-27monthly0.7 https://app.readthrough.bio/stories/lipocine-amends-filing-to-detail-grissinger-s-compensation-committee-d130592026-09-28monthly0.7 https://app.readthrough.bio/stories/scisparc-subsidiary-neurothera-advances-mdma-pea-patent-with-clearmind-d6e3c02026-09-27monthly0.7 https://app.readthrough.bio/stories/bicycle-therapeutics-director-charles-swanton-steps-down-from-board-d6ea522026-09-28monthly0.7 https://app.readthrough.bio/stories/alzamend-neuro-files-s-1-for-resale-of-up-to-98-4-million-shares-tied-dcda8a2026-09-28monthly0.7 https://app.readthrough.bio/stories/anavex-reports-fiscal-q3-2026-results-updates-progress-on-alzheimer-s-e82df92026-09-28monthly0.7 https://app.readthrough.bio/stories/alvotech-signs-licensing-deal-with-lotus-pharmaceutical-for-two-e9e9f72026-09-27monthly0.7 https://app.readthrough.bio/stories/hcw-biologics-files-s-1-to-resell-1-2-million-shares-from-july-2026-pipe-f310d32026-09-27monthly0.7 https://app.readthrough.bio/stories/pds-biotechnology-cfo-lars-boesgaard-to-resign-interim-replacements-f37f442026-09-28monthly0.7 https://app.readthrough.bio/stories/edesa-biotech-prices-25-million-public-offering-of-shares-and-warrants-f62a3a2026-09-28monthly0.7 https://app.readthrough.bio/stories/malarvx-files-form-d-for-2-5-million-convertible-note-offering-fafd112026-09-28monthly0.7 https://app.readthrough.bio/stories/telix-reports-22-h1-2026-revenue-growth-guides-to-upper-end-of-fy-fd754b2026-09-26monthly0.7 https://app.readthrough.bio/stories/ema-validates-maa-for-pfizer-and-valneva-s-lyme-disease-vaccine-000efe2026-09-26monthly0.7 https://app.readthrough.bio/stories/lantern-pharma-spins-out-open-medicine-ai-reports-deepening-lp-300-015efa2026-09-28monthly0.7 https://app.readthrough.bio/stories/ispecimen-settles-westpark-dispute-signs-2m-ir-consulting-deal-0a653e2026-09-27monthly0.7 https://app.readthrough.bio/stories/amylyx-reports-positive-phase-3-results-for-avexitide-in-post-bariatric-1832cc2026-09-26monthly0.7 https://app.readthrough.bio/stories/tvardi-reports-healthy-volunteer-data-for-tti-109-picks-ulcerative-19c6e62026-09-28monthly0.7 https://app.readthrough.bio/stories/coherus-oncology-refinances-debt-with-new-55-million-term-loan-1bc6e62026-09-27monthly0.7 https://app.readthrough.bio/stories/quoin-reports-q2-2026-results-fda-clearance-for-peeling-skin-syndrome-228baf2026-09-28monthly0.7 https://app.readthrough.bio/stories/helus-pharma-names-intra-cellular-veterans-to-leadership-and-advisory-296e422026-09-27monthly0.7 https://app.readthrough.bio/stories/outlook-therapeutics-prices-55-million-stock-and-warrant-offering-2b1d652026-09-28monthly0.7 https://app.readthrough.bio/stories/apollomics-closes-10-million-private-placement-insiders-take-part-313bef2026-09-28monthly0.7 https://app.readthrough.bio/stories/newamsterdam-pharma-names-new-accounting-officer-details-coo-exit-terms-31e4b62026-09-27monthly0.7 https://app.readthrough.bio/stories/citius-pharmaceuticals-reports-fiscal-q3-2026-results-as-lymphir-launch-348de72026-09-28monthly0.7 https://app.readthrough.bio/stories/trinity-biotech-s-trinovium-unit-partners-with-echelon-on-ai-data-35c21f2026-09-27monthly0.7 https://app.readthrough.bio/stories/hutchmed-and-astrazeneca-report-positive-phase-iii-saffron-data-in-egfr-3980ed2026-09-26monthly0.7 https://app.readthrough.bio/stories/bridgebio-secondary-offering-by-kkr-genetic-disorder-l-p-priced-at-78-39af222026-09-28monthly0.7 https://app.readthrough.bio/stories/entera-bio-names-riccardo-camisasca-as-chief-medical-officer-3bf11f2026-09-27monthly0.7 https://app.readthrough.bio/stories/liminatus-pharma-sets-1-for-50-reverse-stock-split-to-regain-nasdaq-3fef0e2026-09-28monthly0.7 https://app.readthrough.bio/stories/immuron-outlines-pipeline-partnering-push-at-emerging-growth-conference-46635f2026-09-27monthly0.7 https://app.readthrough.bio/stories/tonix-pharmaceuticals-names-ceo-seth-lederman-as-interim-chief-medical-4820d72026-09-28monthly0.7 https://app.readthrough.bio/stories/pmv-pharma-completes-pynnacle-enrollment-targets-q1-2027-nda-for-48bfc82026-09-28monthly0.7 https://app.readthrough.bio/stories/turn-therapeutics-discloses-gem-s-cashless-warrant-exercise-for-579-664-49d7282026-09-28monthly0.7 https://app.readthrough.bio/stories/prenetics-names-caroline-levy-independent-director-as-im8-parent-55c4aa2026-09-28monthly0.7 https://app.readthrough.bio/stories/agenus-subsidiary-amends-ocean-1181-loan-extends-maturity-to-2029-5687a22026-09-27monthly0.7 https://app.readthrough.bio/stories/galectin-says-fda-aligned-on-phase-3-design-for-belapectin-in-mash-57f4132026-09-28monthly0.7 https://app.readthrough.bio/stories/dyadic-raises-2-9-million-through-stock-offering-and-concurrent-warrant-5831e02026-09-28monthly0.7 https://app.readthrough.bio/stories/scisparc-subsidiary-neurothera-raises-c-5-4-million-in-private-586c4e2026-09-28monthly0.7 https://app.readthrough.bio/stories/traws-pharma-preps-revised-toxicology-data-for-mhra-resubmission-by-q3-5bb4c72026-09-26monthly0.7 https://app.readthrough.bio/stories/clene-reports-q2-2026-results-plans-als-drug-filing-for-early-q4-5ca18d2026-09-28monthly0.7 https://app.readthrough.bio/stories/abvc-biopharma-flags-going-concern-doubt-in-10-q-delays-biokey-cayman-5e61302026-09-27monthly0.7 https://app.readthrough.bio/stories/replimune-s-tudriqev-wins-fda-accelerated-approval-launch-set-within-60-5ef8662026-09-27monthly0.7 https://app.readthrough.bio/stories/intercure-files-form-d-covering-equity-issued-for-botanico-acquisition-5f9f172026-09-28monthly0.7 https://app.readthrough.bio/stories/valion-bio-expects-1-5-million-preferred-stock-closing-with-3i-lp-on-5fd5892026-09-28monthly0.7 https://app.readthrough.bio/stories/beyondspring-updates-plinabulin-data-names-new-ceo-reports-q2-2026-6621a62026-09-28monthly0.7 https://app.readthrough.bio/stories/prestige-consumer-healthcare-svp-of-operations-jeffrey-zerillo-to-retire-66c1b62026-09-28monthly0.7 https://app.readthrough.bio/stories/cue-biopharma-reports-q2-2026-results-ind-filing-for-cue-221-50m-pipe-6749ce2026-09-28monthly0.7 https://app.readthrough.bio/stories/leonabio-reports-q2-2026-results-enrollment-nears-completion-for-elaine-68b8f02026-09-26monthly0.7 https://app.readthrough.bio/stories/oncolytics-gets-fda-feedback-on-pivotal-path-for-pelareorep-in-6909da2026-09-26monthly0.7 https://app.readthrough.bio/stories/halozyme-adds-dannielle-appelhans-to-board-of-directors-6a75362026-09-28monthly0.7 https://app.readthrough.bio/stories/neumora-reports-q2-2026-results-names-joshua-pinto-ceo-as-berns-moves-6b4b6b2026-09-28monthly0.7 https://app.readthrough.bio/stories/legend-biotech-seeks-shareholder-approval-to-add-19-1-million-shares-to-70487c2026-09-28monthly0.7 https://app.readthrough.bio/stories/hcw-biologics-reports-q2-2026-results-alopecia-data-and-going-concern-70e4f62026-09-28monthly0.7 https://app.readthrough.bio/stories/argenx-reports-positive-phase-3-alkivia-results-for-efgartigimod-in-71202b2026-09-26monthly0.7 https://app.readthrough.bio/stories/opko-health-amends-note-agreement-issues-125-million-in-additional-75f1ad2026-09-27monthly0.7 https://app.readthrough.bio/stories/amgen-terminates-crohn-s-disease-collaboration-with-tscan-therapeutics-7995232026-09-27monthly0.7 https://app.readthrough.bio/stories/mesoblast-finishes-dosing-in-phase-3-trial-of-rexlemestrocel-l-for-79b6fe2026-09-26monthly0.7 https://app.readthrough.bio/stories/fulcrum-therapeutics-to-merge-with-slate-medicines-in-reverse-merger-7d21f02026-09-26monthly0.7 https://app.readthrough.bio/stories/cocrystal-pharma-adds-carol-brosgart-md-to-board-of-directors-82d3032026-09-27monthly0.7 https://app.readthrough.bio/stories/moleculin-reports-positive-interim-miracle-data-keeps-trial-timeline-on-858c1d2026-09-28monthly0.7 https://app.readthrough.bio/stories/bioaffinity-technologies-closes-4-million-private-placement-of-pre-862d282026-09-28monthly0.7 https://app.readthrough.bio/stories/can-fite-reports-preclinical-data-on-namodenoson-gemcitabine-87b9bd2026-09-26monthly0.7 https://app.readthrough.bio/stories/innate-pharma-to-hold-conference-call-august-14-2026-8929872026-09-27monthly0.7 https://app.readthrough.bio/stories/quince-therapeutics-reports-q2-2026-results-after-closing-orphai-9123682026-09-28monthly0.7 https://app.readthrough.bio/stories/heron-therapeutics-extends-tax-benefit-preservation-plan-to-2029-9385dd2026-09-27monthly0.7 https://app.readthrough.bio/stories/tuhura-reports-q2-2026-results-outlines-second-half-milestones-for-aml-9899142026-09-28monthly0.7 https://app.readthrough.bio/stories/enveric-reports-q2-2026-results-advances-eb-003-toward-ind-filing-9fe6512026-09-28monthly0.7 https://app.readthrough.bio/stories/dermata-therapeutics-announces-3-4-million-private-placement-a4e1732026-09-28monthly0.7 https://app.readthrough.bio/stories/astrazeneca-halts-evolve-lung02-trial-of-volrustomig-in-lung-cancer-a9ba9e2026-09-25monthly0.7 https://app.readthrough.bio/stories/hutchmed-discloses-insolvency-of-company-linked-to-its-chairman-aa80f42026-09-27monthly0.7 https://app.readthrough.bio/stories/nrx-reports-q2-2026-results-advances-ketamine-anda-and-darpa-backed-nrx-aee8692026-09-28monthly0.7 https://app.readthrough.bio/stories/skye-bioscience-and-redx-pharma-to-merge-form-fibrx-therapeutics-with-afb6c02026-09-27monthly0.7 https://app.readthrough.bio/stories/biomarin-to-acquire-alesta-therapeutics-for-its-oral-hpp-drug-candidate-b099f52026-09-26monthly0.7 https://app.readthrough.bio/stories/trinity-biotech-gets-7-0-million-from-perceptive-regains-nasdaq-bid-b61f772026-09-28monthly0.7 https://app.readthrough.bio/stories/allarity-completes-stenoparib-manufacturing-campaign-gets-key-us-patent-b939592026-09-28monthly0.7 https://app.readthrough.bio/stories/quantum-biopharma-gets-fda-nod-to-start-lucid-ms-phase-2-trial-in-bd7cda2026-09-26monthly0.7 https://app.readthrough.bio/stories/jasper-therapeutics-reports-q2-2026-results-after-closing-kira-c214002026-09-28monthly0.7 https://app.readthrough.bio/stories/cypherpunk-technologies-acquires-zcash-mining-fleet-from-winklevoss-c34b252026-09-27monthly0.7 https://app.readthrough.bio/stories/maze-therapeutics-adds-paula-johnson-and-sophie-kornowski-to-board-ced9912026-09-27monthly0.7 https://app.readthrough.bio/stories/adial-pharmaceuticals-reports-q2-2026-results-advances-at177-after-d0340e2026-09-28monthly0.7 https://app.readthrough.bio/stories/achieve-life-sciences-files-150-million-at-the-market-equity-offering-d113082026-09-28monthly0.7 https://app.readthrough.bio/stories/inflarx-registers-up-to-65-million-in-ordinary-shares-for-at-the-market-d43c722026-09-28monthly0.7 https://app.readthrough.bio/stories/prenetics-reports-im8-revenue-up-288-in-q2-2026-raises-full-year-dded862026-09-28monthly0.7 https://app.readthrough.bio/stories/silexion-advances-sil204-into-phase-2-3-trial-reports-q2-2026-results-de32832026-09-28monthly0.7 https://app.readthrough.bio/stories/assembly-bio-reports-q2-2026-results-expands-abi-6250-into-cholestatic-e002942026-09-27monthly0.7 https://app.readthrough.bio/stories/outlook-therapeutics-reports-q3-fy2026-results-details-lytenava-us-e35b832026-09-27monthly0.7 https://app.readthrough.bio/stories/gulf-sterilization-discloses-1m-private-offering-367-000-sold-so-far-e5a7882026-09-28monthly0.7 https://app.readthrough.bio/stories/zentalis-prices-80-5-million-stock-offering-at-3-50-a-share-ef827a2026-09-28monthly0.7 https://app.readthrough.bio/stories/vistagen-plans-fda-meeting-on-fasedienol-path-after-mixed-palisade-4-efb4402026-09-28monthly0.7 https://app.readthrough.bio/stories/citius-oncology-reports-lymphir-order-growth-in-fiscal-q3-2026-expands-f3e9d12026-09-28monthly0.7 https://app.readthrough.bio/stories/shuttle-pharmaceuticals-walks-back-merger-accounting-for-united-f83ccc2026-09-26monthly0.7 https://app.readthrough.bio/stories/aptevo-reports-frontline-aml-data-for-mipletamig-targets-phase-2-talks-fcd4062026-09-28monthly0.7 https://app.readthrough.bio/stories/abcellera-prices-200-million-stock-offering-to-fund-abcl635-program-0206372026-09-27monthly0.7 https://app.readthrough.bio/stories/cellectar-reports-q2-2026-results-advances-phase-3-wm-trial-toward-mid-035bd52026-09-28monthly0.7 https://app.readthrough.bio/stories/instil-bio-reports-q2-2026-results-says-it-is-weighing-acquisitions-and-0975912026-09-28monthly0.7 https://app.readthrough.bio/stories/edesa-reports-fiscal-q3-2026-results-readies-eb06-vitiligo-trial-and-0be3632026-09-28monthly0.7 https://app.readthrough.bio/stories/equillium-reports-q2-2026-results-plans-australia-dossier-filing-for-0f5a8c2026-09-28monthly0.7 https://app.readthrough.bio/stories/olema-oncology-names-jason-o-byrne-as-chief-financial-officer-134fd12026-09-27monthly0.7 https://app.readthrough.bio/stories/aposture-surgical-corp-discloses-150-000-safe-offering-in-sec-form-d-15189e2026-09-28monthly0.7 https://app.readthrough.bio/stories/adc-therapeutics-reweighs-zynlonta-path-after-fda-raises-lotis-5-safety-1662092026-09-26monthly0.7 https://app.readthrough.bio/stories/pelthos-posts-second-quarter-2026-results-as-zelsuvmi-revenue-climbs-198e762026-09-28monthly0.7 https://app.readthrough.bio/stories/pds-biotech-refocuses-pipeline-on-pds0301-halts-pds0101-phase-3-trial-1ab2392026-09-28monthly0.7 https://app.readthrough.bio/stories/omeros-adds-joseph-schocken-to-board-of-directors-1dbf3d2026-09-27monthly0.7 https://app.readthrough.bio/stories/adial-pharmaceuticals-plans-ceo-and-cfo-transition-tied-to-2026-annual-255fa02026-09-28monthly0.7 https://app.readthrough.bio/stories/aptevo-raises-4-5-million-via-warrant-inducement-and-pipe-financing-29c1b42026-09-27monthly0.7 https://app.readthrough.bio/stories/dare-bioscience-reports-q2-2026-results-as-first-direct-product-launches-2a67ea2026-09-28monthly0.7 https://app.readthrough.bio/stories/annovis-completes-enrollment-in-phase-3-alzheimer-s-trial-of-buntanetap-33c84a2026-09-28monthly0.7 https://app.readthrough.bio/stories/cabaletta-reports-q2-2026-results-reaffirms-mid-2027-myositis-data-and-38d3b72026-09-28monthly0.7 https://app.readthrough.bio/stories/atrium-therapeutics-gets-ind-clearance-for-atr-1072-starts-corventis-395a142026-09-27monthly0.7 https://app.readthrough.bio/stories/elutia-lines-up-new-financing-for-nxt-41x-backs-fda-timelines-3bf5a82026-09-28monthly0.7 https://app.readthrough.bio/stories/eupraxia-reports-new-odynophagia-data-from-phase-1b-2a-resolve-trial-in-3def882026-09-26monthly0.7 https://app.readthrough.bio/stories/yarrow-bioscience-files-amended-8-k-with-pre-merger-yarrow-financials-416da12026-09-28monthly0.7 https://app.readthrough.bio/stories/curis-prices-5-6-million-offering-of-stock-pre-funded-and-common-5320d02026-09-28monthly0.7 https://app.readthrough.bio/stories/pyxis-oncology-reports-q2-2026-results-keeps-micvo-data-timelines-on-533a732026-09-27monthly0.7 https://app.readthrough.bio/stories/cingulate-reports-q2-2026-results-updates-ctx-1301-cmc-and-nda-54c1992026-09-28monthly0.7 https://app.readthrough.bio/stories/silexion-prices-2-5-million-public-offering-closes-it-days-later-57b8ce2026-09-27monthly0.7 https://app.readthrough.bio/stories/abcuro-discloses-form-d-for-equity-offering-worth-up-to-176-5-million-589b012026-09-28monthly0.7 https://app.readthrough.bio/stories/ensysce-completes-cy-biopharma-acquisition-adds-crps-candidate-cy200-5b65282026-09-28monthly0.7 https://app.readthrough.bio/stories/akari-therapeutics-reports-q2-2026-results-keeps-aktx-101-phase-1-on-5b8d062026-09-28monthly0.7 https://app.readthrough.bio/stories/serina-completes-cohort-1-dosing-in-ser-252-parkinson-s-trial-ahead-of-60fc0b2026-09-27monthly0.7 https://app.readthrough.bio/stories/rockwell-medical-reports-second-quarter-2026-results-and-reiterates-63386d2026-09-28monthly0.7 https://app.readthrough.bio/stories/eton-pharmaceuticals-posts-99-revenue-growth-raises-2026-guidance-to-63d76b2026-09-28monthly0.7 https://app.readthrough.bio/stories/meiragtx-reports-q2-2026-results-advances-bota-vec-and-aav2-haqp1-66f3ed2026-09-27monthly0.7 https://app.readthrough.bio/stories/maplight-enters-150m-private-placement-agreement-reports-q2-2026-results-6b2a072026-09-26monthly0.7 https://app.readthrough.bio/stories/neonc-reports-phase-2a-neo100-01-met-primary-endpoint-in-recurrent-idh1-6c62352026-09-28monthly0.7 https://app.readthrough.bio/stories/auron-therapeutics-files-form-d-for-12-million-debt-offering-6c74d92026-09-28monthly0.7 https://app.readthrough.bio/stories/capricor-gives-update-on-deramiocel-bla-after-adcomm-setback-reports-q2-73a3a52026-09-28monthly0.7 https://app.readthrough.bio/stories/neurosense-ceo-updates-shareholders-on-paragon-financing-canada-filing-75dd512026-09-28monthly0.7 https://app.readthrough.bio/stories/archean-sciences-files-form-d-for-safe-offering-of-indefinite-size-76af082026-09-28monthly0.7 https://app.readthrough.bio/stories/candel-targets-q4-2026-bla-for-prostate-cancer-therapy-opens-nsclc-77011a2026-09-27monthly0.7 https://app.readthrough.bio/stories/grace-therapeutics-details-gtx-104-resubmission-plan-after-crl-sets-7d3b8b2026-09-28monthly0.7 https://app.readthrough.bio/stories/pulmatrix-reports-q2-2026-results-cites-progress-on-eos-senolytix-merger-81accd2026-09-28monthly0.7 https://app.readthrough.bio/stories/proqr-reports-q2-2026-results-cites-first-axiomer-clinical-validation-83c7de2026-09-26monthly0.7 https://app.readthrough.bio/stories/volitionrx-reports-q2-2026-results-cites-licensing-talks-and-sysmex-88f9ee2026-09-28monthly0.7 https://app.readthrough.bio/stories/nektar-reports-q2-2026-results-details-phase-3-rezpegaldesleukin-891a552026-09-28monthly0.7 https://app.readthrough.bio/stories/ascentage-pharma-corrects-timing-for-august-19-interim-results-release-8d4dc42026-09-26monthly0.7 https://app.readthrough.bio/stories/mink-reports-early-phase-2-data-for-agent-797-in-acute-lung-injury-q2-9331db2026-09-28monthly0.7 https://app.readthrough.bio/stories/aktis-oncology-reports-q2-2026-results-three-phase-1b-trials-now-94ba7f2026-09-27monthly0.7 https://app.readthrough.bio/stories/aethlon-medical-dosed-first-patient-in-final-cohort-of-australia-95f4272026-09-28monthly0.7 https://app.readthrough.bio/stories/fate-therapeutics-doses-first-lupus-nephritis-patient-in-phase-2-ft819-9611262026-09-28monthly0.7 https://app.readthrough.bio/stories/karyopharm-says-myelofibrosis-snda-submission-remains-on-track-for-97c05a2026-09-27monthly0.7 https://app.readthrough.bio/stories/tempest-therapeutics-signs-up-to-50-million-stock-purchase-deal-with-97fc352026-09-27monthly0.7 https://app.readthrough.bio/stories/rani-therapeutics-reports-q2-2026-results-advances-rt-114-oral-glp-1-9fa5342026-09-28monthly0.7 https://app.readthrough.bio/stories/macrogenics-posts-q2-results-outsources-manufacturing-updates-adc-a6c3192026-09-27monthly0.7 https://app.readthrough.bio/stories/caribou-reports-q2-2026-results-updates-vispa-cel-and-cb-011-data-ae398b2026-09-28monthly0.7 https://app.readthrough.bio/stories/immucell-reports-q2-2026-results-presses-ahead-with-capacity-expansion-afe6432026-09-28monthly0.7 https://app.readthrough.bio/stories/zenas-biopharma-reports-q2-2026-results-obexelimab-bla-now-accepted-by-b1094e2026-09-27monthly0.7 https://app.readthrough.bio/stories/renovorx-completes-phase-iii-enrollment-raises-2026-revenue-guidance-b2be102026-09-28monthly0.7 https://app.readthrough.bio/stories/harton-files-form-d-for-18-1-million-private-offering-b587892026-09-28monthly0.7 https://app.readthrough.bio/stories/tempest-reports-q2-2026-results-in-vivo-car-t-collaboration-with-bdd97a2026-09-28monthly0.7 https://app.readthrough.bio/stories/eledon-reports-q2-2026-results-confirms-phase-3-kidney-transplant-trial-c09d022026-09-27monthly0.7 https://app.readthrough.bio/stories/4dmt-reports-q2-2026-results-completes-enrollment-for-second-wet-amd-c214a72026-09-28monthly0.7 https://app.readthrough.bio/stories/abeona-reports-second-quarter-zevaskyn-growth-expanded-treatment-center-c29aa92026-09-28monthly0.7 https://app.readthrough.bio/stories/indaptus-halts-decoy20-enrollment-pivots-to-strategic-review-after-q2-c4b4272026-09-28monthly0.7 https://app.readthrough.bio/stories/calidi-gets-fda-pre-ind-feedback-on-cld-401-still-targets-q1-2027-first-c5c33a2026-09-27monthly0.7 https://app.readthrough.bio/stories/kyntra-bio-reports-q2-2026-results-reaffirms-fourth-quarter-trial-c8b9712026-09-27monthly0.7 https://app.readthrough.bio/stories/dogwood-reports-q2-2026-results-as-halneuron-phase-2b-nears-fall-readout-c9df022026-09-28monthly0.7 https://app.readthrough.bio/stories/cadrenal-reports-q2-2026-results-launches-partnering-process-for-ce93cf2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-tauklarify-new-molecular-entity-from-cerveau-lantheus-ceb8432026-09-28monthly0.7 https://app.readthrough.bio/stories/ars-pharma-narrows-commercial-focus-for-neffy-sees-csu-data-in-q1-2027-db5fc82026-09-28monthly0.7 https://app.readthrough.bio/stories/parabilis-reports-q2-2026-results-1-1b-cash-regeneron-pact-de825b2026-09-26monthly0.7 https://app.readthrough.bio/stories/eikon-therapeutics-reports-q2-2026-results-with-seven-esmo-abstracts-e1def62026-09-28monthly0.7 https://app.readthrough.bio/stories/promis-reports-interim-precise-ad-data-showing-no-aria-e-ends-q2-with-e208d42026-09-28monthly0.7 https://app.readthrough.bio/stories/ascendis-pharma-posts-q2-2026-revenue-of-315-million-up-105-year-over-e20c982026-09-27monthly0.7 https://app.readthrough.bio/stories/invivyd-completes-enrollment-in-two-vyd2311-pivotal-trials-reports-q2-e290c02026-09-28monthly0.7 https://app.readthrough.bio/stories/camp4-clears-regulatory-hurdles-in-australia-argentina-for-syngap1-trial-e2d6cd2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-bristol-myers-squibb-s-zenbexus-a-new-molecular-entity-e2d85b2026-09-25monthly0.7 https://app.readthrough.bio/stories/cormedix-reports-q2-2026-results-flags-rezzayo-filing-and-defencath-e3718b2026-09-28monthly0.7 https://app.readthrough.bio/stories/ptc-therapeutics-wins-bankruptcy-auction-for-sangamo-s-fabry-gene-e69ff22026-09-26monthly0.7 https://app.readthrough.bio/stories/gossamer-reports-q2-2026-results-reacquires-seralutinib-rights-from-eaf9932026-09-28monthly0.7 https://app.readthrough.bio/stories/inhibrx-reports-q2-2026-results-sets-q3-pfs-readout-for-inbrx-106-ef67992026-09-28monthly0.7 https://app.readthrough.bio/stories/biofrontera-reports-q2-2026-results-cites-pending-sbcc-decision-and-f3a7f02026-09-28monthly0.7 https://app.readthrough.bio/stories/elicio-reports-q2-2026-results-plans-new-phase-1-combination-trial-f728872026-09-28monthly0.7 https://app.readthrough.bio/stories/kodiak-reports-q2-2026-results-confirms-three-phase-3-readouts-by-year-f82e7a2026-09-28monthly0.7 https://app.readthrough.bio/stories/assembly-bio-reports-q2-2026-results-expands-abi-6250-into-cholestatic-fae3c12026-09-26monthly0.7 https://app.readthrough.bio/stories/fortress-biotech-reports-q2-2026-results-as-partnered-pipeline-advances-faede22026-09-27monthly0.7 https://app.readthrough.bio/stories/alumis-reports-long-term-onward3-data-keeps-nda-and-lumus-timelines-on-fcb7062026-09-28monthly0.7 https://app.readthrough.bio/stories/connect-biopharma-finishes-enrollment-in-phase-2-asthma-copd-0223cd2026-09-28monthly0.7 https://app.readthrough.bio/stories/humacyte-reports-atev-outperformed-av-fistula-in-phase-3-dialysis-trial-02882d2026-09-27monthly0.7 https://app.readthrough.bio/stories/biostem-technologies-posts-q2-2026-revenue-growth-completes-nasdaq-02ab142026-09-28monthly0.7 https://app.readthrough.bio/stories/unicycive-says-fda-has-assigned-facility-inspection-for-olc-02ff032026-09-28monthly0.7 https://app.readthrough.bio/stories/eloxx-reports-q2-2026-results-after-66-million-raise-and-nasdaq-04a7fa2026-09-27monthly0.7 https://app.readthrough.bio/stories/scilex-extends-20-million-credit-line-to-related-company-vivasor-0cf0552026-09-27monthly0.7 https://app.readthrough.bio/stories/madrigal-adds-j-j-r-d-executive-john-c-reed-to-board-of-directors-0f872d2026-09-25monthly0.7 https://app.readthrough.bio/stories/cypherpunk-s-leap-therapeutics-subsidiary-aligns-with-fda-on-phase-3-0fe5732026-09-28monthly0.7 https://app.readthrough.bio/stories/inovio-s-ino-3107-bla-review-advances-toward-october-30-pdufa-date-11b7172026-09-28monthly0.7 https://app.readthrough.bio/stories/dermata-sets-august-25-launch-for-tome-skincare-product-reports-q2-2026-149b582026-09-28monthly0.7 https://app.readthrough.bio/stories/adagene-reports-mid-2026-results-muzastotug-data-across-crc-and-hcc-1865c22026-09-26monthly0.7 https://app.readthrough.bio/stories/alkermes-amends-credit-facility-cuts-interest-rate-spreads-190de52026-09-27monthly0.7 https://app.readthrough.bio/stories/xilio-gets-fda-clearance-for-xtx501-ind-reports-q2-2026-results-1d53482026-09-27monthly0.7 https://app.readthrough.bio/stories/armata-says-it-is-preparing-to-launch-phase-3-trial-of-phage-therapy-ap-1e60e52026-09-27monthly0.7 https://app.readthrough.bio/stories/bio-techne-posts-q4-fy2026-results-as-merck-kgaa-acquisition-proceeds-1f8f2d2026-09-27monthly0.7 https://app.readthrough.bio/stories/altimmune-reports-q2-2026-results-as-pemvidutide-advances-in-mash-aud-21cd1a2026-09-28monthly0.7 https://app.readthrough.bio/stories/minerva-neurosciences-names-anthony-aliquo-chief-accounting-officer-253bc32026-09-28monthly0.7 https://app.readthrough.bio/stories/alto-neuroscience-adds-third-phase-3-trial-for-alto-207-cites-nature-2ac8b92026-09-27monthly0.7 https://app.readthrough.bio/stories/pds-biotech-drops-pds0101-phase-3-trial-shifts-focus-to-pds0301-in-2cf51e2026-09-26monthly0.7 https://app.readthrough.bio/stories/liquidia-reports-yutrepia-sales-growth-begins-enrollment-in-l606-3549f32026-09-27monthly0.7 https://app.readthrough.bio/stories/kura-oncology-posts-9-1-million-in-komzifti-revenue-in-second-quarter-355dd32026-09-28monthly0.7 https://app.readthrough.bio/stories/agenus-grants-ceo-garo-armen-a-special-performance-stock-option-award-3798d82026-09-28monthly0.7 https://app.readthrough.bio/stories/mereo-biopharma-and-sentynl-sign-option-deal-for-alvelestat-in-lung-390dd52026-09-27monthly0.7 https://app.readthrough.bio/stories/milestone-activates-sites-for-phase-3-afib-rvr-trial-reports-170-6m-cash-399d052026-09-27monthly0.7 https://app.readthrough.bio/stories/belite-bio-posts-q2-2026-results-as-fda-reviews-tinlarebant-nda-under-3f2b282026-09-27monthly0.7 https://app.readthrough.bio/stories/entera-bio-reports-274-99-million-offering-completed-under-form-d-448bfb2026-09-28monthly0.7 https://app.readthrough.bio/stories/paterna-biosciences-holdco-discloses-form-d-equity-offering-of-11-2-46d40d2026-09-28monthly0.7 https://app.readthrough.bio/stories/biocardia-gets-positive-regulator-signals-in-japan-and-us-for-cardiamp-4746152026-09-27monthly0.7 https://app.readthrough.bio/stories/arrivent-reports-q2-2026-results-licenses-arr-002-to-allist-in-greater-4cbd852026-09-27monthly0.7 https://app.readthrough.bio/stories/sutro-biopharma-posts-early-stro-004-responses-updates-q2-2026-4cea8c2026-09-26monthly0.7 https://app.readthrough.bio/stories/pharvaris-reports-q2-2026-results-expects-chapter-3-data-in-third-4ead192026-09-27monthly0.7 https://app.readthrough.bio/stories/silence-therapeutics-prices-175-million-ads-offering-at-13-50-per-share-5205ae2026-09-28monthly0.7 https://app.readthrough.bio/stories/vogenx-prices-81-25-million-ipo-ahead-of-nasdaq-listing-under-vogx-58d75b2026-09-27monthly0.7 https://app.readthrough.bio/stories/dyadic-reports-q2-2026-results-cites-commercial-and-c1-platform-progress-608a9b2026-09-28monthly0.7 https://app.readthrough.bio/stories/onkure-reprices-underwater-stock-options-for-ceo-and-other-executives-6a45012026-09-28monthly0.7 https://app.readthrough.bio/stories/journey-medical-reports-q2-2026-results-as-emrosi-prescriptions-climb-7213fc2026-09-28monthly0.7 https://app.readthrough.bio/stories/first-tracks-reports-q2-2026-results-anb033-gets-fda-fast-track-in-7a04352026-09-28monthly0.7 https://app.readthrough.bio/stories/omeros-reports-q2-2026-results-as-yartemlea-sales-climb-and-chmp-issues-7bc8d32026-09-27monthly0.7 https://app.readthrough.bio/stories/trace-biosciences-files-form-d-covering-16-2-million-equity-offering-7f736d2026-09-28monthly0.7 https://app.readthrough.bio/stories/absci-reports-q2-2026-results-positive-abs-201-phase-1-data-100m-raise-85992d2026-09-26monthly0.7 https://app.readthrough.bio/stories/neonc-reports-positive-phase-2a-data-for-neo100-in-recurrent-idh1-8615fc2026-09-26monthly0.7 https://app.readthrough.bio/stories/aeon-biopharma-reports-q2-2026-results-cites-new-financing-and-fda-86cc172026-09-28monthly0.7 https://app.readthrough.bio/stories/lexeo-starts-pivotal-lx2006-trial-wins-rmat-for-lx2020-87b7622026-09-25monthly0.7 https://app.readthrough.bio/stories/acrivon-reports-q2-2026-results-flags-acr-368-interim-data-for-second-88b8c32026-09-28monthly0.7 https://app.readthrough.bio/stories/os-therapies-details-leonite-settlement-and-10-million-august-note-89264d2026-09-27monthly0.7 https://app.readthrough.bio/stories/theriva-doses-first-patients-in-virage2-trial-of-vcn-01-in-pancreatic-8ac8c22026-09-28monthly0.7 https://app.readthrough.bio/stories/citius-oncology-adds-jonathan-peri-to-board-expanding-to-nine-members-8bd48f2026-09-28monthly0.7 https://app.readthrough.bio/stories/pliant-reports-q2-2026-results-cites-strong-fortify-enrollment-for-pln-8e69fa2026-09-27monthly0.7 https://app.readthrough.bio/stories/maze-therapeutics-reports-q2-2026-results-cites-progress-on-kidney-8e7baa2026-09-27monthly0.7 https://app.readthrough.bio/stories/atara-reports-fda-meeting-progress-on-tabelecleucel-bla-resubmission-91908a2026-09-28monthly0.7 https://app.readthrough.bio/stories/acumen-reports-q2-2026-results-reaffirms-altitude-ad-readout-for-late-927cd72026-09-26monthly0.7 https://app.readthrough.bio/stories/tango-therapeutics-files-new-400-million-at-the-market-equity-offering-939b6e2026-09-27monthly0.7 https://app.readthrough.bio/stories/polypid-reports-q2-2026-results-fda-priority-review-for-d-plex100-9776fe2026-09-28monthly0.7 https://app.readthrough.bio/stories/maxcyte-posts-q2-2026-revenue-reiterates-full-year-guidance-9ab0b42026-09-27monthly0.7 https://app.readthrough.bio/stories/arbutus-reaches-fda-alignment-on-imdusiran-phase-2b-design-advances-9e18f02026-09-27monthly0.7 https://app.readthrough.bio/stories/monopar-starts-rolling-nda-for-wilson-disease-drug-alxn1840-reports-q2-9f44712026-09-28monthly0.7 https://app.readthrough.bio/stories/zipalertinib-combo-hits-pfs-endpoint-in-phase-3-lung-cancer-trial-a38ca22026-09-26monthly0.7 https://app.readthrough.bio/stories/annexon-reports-q2-2026-results-sets-tanruprubart-bla-for-fourth-quarter-a897e72026-09-28monthly0.7 https://app.readthrough.bio/stories/imunon-reports-q2-2026-results-cites-ovation-3-enrollment-pace-and-new-a944902026-09-28monthly0.7 https://app.readthrough.bio/stories/spruce-biosciences-targets-q4-2026-bla-filing-for-ta-ert-in-mps-iiib-ae22532026-09-28monthly0.7 https://app.readthrough.bio/stories/kardigan-advances-three-late-stage-cardiovascular-trials-reports-660-7m-b664c02026-09-27monthly0.7 https://app.readthrough.bio/stories/onconetix-files-s-1-to-register-100-million-shares-tied-to-series-f-b6ad292026-09-28monthly0.7 https://app.readthrough.bio/stories/talphera-reports-nephro-crrt-trial-75-enrolled-kdigo-2026-draft-b89d0d2026-09-27monthly0.7 https://app.readthrough.bio/stories/longeveron-reports-q2-2026-results-keeps-september-readout-for-hlhs-b8cf322026-09-27monthly0.7 https://app.readthrough.bio/stories/aura-biosciences-completes-phase-3-compass-enrollment-cuts-staff-20-to-bc06f92026-09-26monthly0.7 https://app.readthrough.bio/stories/allogene-reports-q2-2026-results-cites-alpha3-futility-data-and-fda-bf69a62026-09-28monthly0.7 https://app.readthrough.bio/stories/aprea-reports-q2-2026-results-faster-enrollment-in-apr-1051-trial-bfbe402026-09-26monthly0.7 https://app.readthrough.bio/stories/atea-reports-q2-2026-results-cites-c-beyond-phase-3-win-in-hepatitis-c-c023242026-09-28monthly0.7 https://app.readthrough.bio/stories/lakefront-reports-h1-2026-results-after-closing-ouro-medicines-deal-c0446a2026-09-26monthly0.7 https://app.readthrough.bio/stories/avalyn-completes-enrollment-in-phase-2b-pulmonary-fibrosis-trial-of-ap01-c1a4fd2026-09-28monthly0.7 https://app.readthrough.bio/stories/mineralys-reports-q2-2026-results-names-new-cmo-ahead-of-lorundrostat-c274532026-09-25monthly0.7 https://app.readthrough.bio/stories/can-fite-recaps-fda-ema-regulatory-status-for-two-phase-iii-drugs-c9e6a42026-09-27monthly0.7 https://app.readthrough.bio/stories/prelude-reports-q2-2026-results-plans-phase-1-start-for-kat6a-degrader-ca25312026-09-27monthly0.7 https://app.readthrough.bio/stories/tscan-doses-first-patient-in-phase-3-heme-trial-cites-cohort-c-cd5ac02026-09-27monthly0.7 https://app.readthrough.bio/stories/spero-reports-q2-2026-results-highlights-utebzi-approval-and-innovent-cde10f2026-09-28monthly0.7 https://app.readthrough.bio/stories/kailera-reports-q2-2026-results-oral-ind-active-phase-2b-fully-enrolled-ce66072026-09-27monthly0.7 https://app.readthrough.bio/stories/century-therapeutics-reports-q2-2026-results-fda-pre-ind-meeting-for-d3cd812026-09-26monthly0.7 https://app.readthrough.bio/stories/protalix-reports-q2-2026-results-reaffirms-prx-115-gout-trial-timeline-daafc72026-09-27monthly0.7 https://app.readthrough.bio/stories/immunome-reports-q2-2026-results-varegacestat-nda-under-fda-review-db69ca2026-09-28monthly0.7 https://app.readthrough.bio/stories/turn-therapeutics-expands-phase-2-atopic-dermatitis-trial-after-interim-f316bd2026-09-28monthly0.7 https://app.readthrough.bio/stories/azitra-reports-q2-2026-results-pauses-netherton-syndrome-enrollment-fc3a4f2026-09-28monthly0.7 https://app.readthrough.bio/stories/sellas-reports-q2-2026-results-nears-key-regal-trial-milestone-ffb3e72026-09-28monthly0.7 https://app.readthrough.bio/stories/innate-pharma-partners-with-sobi-to-license-lacutamab-in-t-cell-lymphoma-000ccf2026-09-26monthly0.7 https://app.readthrough.bio/stories/olema-completes-opera-01-enrollment-pushes-top-line-data-to-q1-2027-031aee2026-09-28monthly0.7 https://app.readthrough.bio/stories/tango-reports-phase-1-2-pancreatic-cancer-data-eyes-phase-3-as-it-posts-0444a12026-09-27monthly0.7 https://app.readthrough.bio/stories/upstream-bio-reports-q2-2026-results-copd-enrollment-complete-phase-3-059d502026-09-28monthly0.7 https://app.readthrough.bio/stories/glucotrack-amends-stock-purchase-agreement-with-white-lion-capital-07bfa02026-09-28monthly0.7 https://app.readthrough.bio/stories/nkarta-reports-q2-2026-results-continued-enrollment-in-autoimmune-nk-0c358f2026-09-28monthly0.7 https://app.readthrough.bio/stories/bicara-names-successor-ceo-reports-pivotal-trial-on-track-for-2027-0f86392026-09-28monthly0.7 https://app.readthrough.bio/stories/veraxa-biotech-completes-spac-merger-registers-resale-of-over-145-1350d62026-09-27monthly0.7 https://app.readthrough.bio/stories/aardvark-to-review-unblinded-ard-101-data-in-q3-2026-amid-fda-clinical-19b4c62026-09-28monthly0.7 https://app.readthrough.bio/stories/autolus-posts-45-7-million-in-aucatzyl-revenue-raises-2026-guidance-1ebdce2026-09-28monthly0.7 https://app.readthrough.bio/stories/kalaris-reports-q2-2026-results-dosing-continues-in-th103-mid-stage-1f598f2026-09-28monthly0.7 https://app.readthrough.bio/stories/bridgebio-reports-q2-2026-results-as-all-three-pipeline-ndas-reach-fda-20129f2026-09-28monthly0.7 https://app.readthrough.bio/stories/anteris-reports-q2-2026-progress-on-paradigm-trial-adds-two-board-213ed12026-09-28monthly0.7 https://app.readthrough.bio/stories/an2-therapeutics-reports-q2-2026-results-updates-timelines-on-three-22b7222026-09-28monthly0.7 https://app.readthrough.bio/stories/imunon-lets-three-top-executives-take-part-of-salary-in-stock-through-28b4162026-09-28monthly0.7 https://app.readthrough.bio/stories/sana-reports-q2-2026-progress-on-sc451-sg293-as-mayo-clinic-invests-25m-2df0032026-09-27monthly0.7 https://app.readthrough.bio/stories/achieve-life-sciences-details-cytisinicline-crl-response-and-2f084b2026-09-28monthly0.7 https://app.readthrough.bio/stories/veradermics-reports-q2-2026-results-completes-enrollment-in-female-2fd72e2026-09-28monthly0.7 https://app.readthrough.bio/stories/vera-therapeutics-reports-q2-2026-results-after-trutakna-accelerated-36504a2026-09-27monthly0.7 https://app.readthrough.bio/stories/imdx-says-fda-sought-more-data-on-graftassuredx-gives-itself-180-days-3f3fff2026-09-26monthly0.7 https://app.readthrough.bio/stories/intensity-moves-to-resume-invincible-3-sites-restarts-tnbc-treatment-42a9a72026-09-28monthly0.7 https://app.readthrough.bio/stories/aspire-biopharma-closes-30-million-acquisition-of-dura-driver-control-486fb92026-09-27monthly0.7 https://app.readthrough.bio/stories/helus-pharma-names-michael-halstead-ceo-ahead-of-hlp003-phase-3-readout-48767a2026-09-27monthly0.7 https://app.readthrough.bio/stories/arc-medical-inc-files-form-d-for-equity-offering-of-about-117-668-4a3f962026-09-28monthly0.7 https://app.readthrough.bio/stories/moonlake-reports-positive-phase-3-izar-1-results-in-psoriatic-arthritis-4e95f12026-09-26monthly0.7 https://app.readthrough.bio/stories/rocket-reports-danon-safety-clearance-and-180m-prv-sale-in-q2-2026-50edc32026-09-27monthly0.7 https://app.readthrough.bio/stories/sionna-s-sion-719-misses-key-endpoint-in-phase-2a-cystic-fibrosis-trial-51703f2026-09-26monthly0.7 https://app.readthrough.bio/stories/harrow-reports-q2-2026-results-reiterates-full-year-guidance-cites-54f4132026-09-28monthly0.7 https://app.readthrough.bio/stories/hemab-reports-q2-2026-results-as-fda-clears-sutacimig-path-to-phase-3-57b8f02026-09-28monthly0.7 https://app.readthrough.bio/stories/silence-therapeutics-reports-q2-2026-results-and-divesiran-trial-58bf5e2026-09-27monthly0.7 https://app.readthrough.bio/stories/neonc-confirms-august-12-topline-readout-for-phase-2a-neo100-glioma-59e1112026-09-26monthly0.7 https://app.readthrough.bio/stories/therapeuticsmd-reports-second-quarter-2026-results-continues-strategic-5aa4a82026-09-28monthly0.7 https://app.readthrough.bio/stories/shattuck-labs-reports-phase-1-data-for-sl-325-sets-phase-2b-start-for-5c07142026-09-28monthly0.7 https://app.readthrough.bio/stories/ac-immune-wins-fda-fast-track-and-ind-clearance-for-parkinson-s-5d39ed2026-09-27monthly0.7 https://app.readthrough.bio/stories/nrc-health-cfo-shane-harrison-resigns-effective-august-28-2026-6417772026-09-28monthly0.7 https://app.readthrough.bio/stories/metagenomi-reports-q2-2026-results-stays-on-track-for-mgx-001-6861552026-09-28monthly0.7 https://app.readthrough.bio/stories/gain-therapeutics-gets-fda-ind-clearance-for-rexaceract-targets-phase-2-6b5a622026-09-28monthly0.7 https://app.readthrough.bio/stories/cardiff-oncology-reports-q2-2026-results-plans-phase-3-mcrc-trial-for-6ce79f2026-09-28monthly0.7 https://app.readthrough.bio/stories/heron-withdraws-2026-guidance-weighs-strategic-alternatives-after-6d748b2026-09-28monthly0.7 https://app.readthrough.bio/stories/amneal-closes-acquisition-of-kashiv-biosciences-to-build-biosimilars-7231ab2026-09-25monthly0.7 https://app.readthrough.bio/stories/prokidney-finishes-enrollment-for-accelerated-approval-analysis-in-7f40f22026-09-27monthly0.7 https://app.readthrough.bio/stories/aquestive-reports-positive-human-factors-and-pk-data-for-anaphylm-ahead-7fadb02026-09-26monthly0.7 https://app.readthrough.bio/stories/aim-immunotech-reports-q2-2026-results-cites-pancreatic-cancer-trial-82aaa72026-09-27monthly0.7 https://app.readthrough.bio/stories/bridgebio-oncology-reports-q2-2026-results-starts-two-kras-inhibitor-84fd2c2026-09-28monthly0.7 https://app.readthrough.bio/stories/enanta-reports-fiscal-q3-2026-results-dosing-underway-in-pediatric-rsv-8806d42026-09-27monthly0.7 https://app.readthrough.bio/stories/protara-reports-q2-2026-results-redesigns-advanced-3-trial-for-tara-002-8849742026-09-28monthly0.7 https://app.readthrough.bio/stories/inhibikase-reports-q2-2026-results-as-phase-3-pah-trial-expands-across-8c198f2026-09-27monthly0.7 https://app.readthrough.bio/stories/aquestive-completes-anaphylm-studies-keeps-q3-2026-nda-resubmission-8cd8cf2026-09-28monthly0.7 https://app.readthrough.bio/stories/fulcrum-therapeutics-names-new-principal-accounting-officer-as-98b41e2026-09-28monthly0.7 https://app.readthrough.bio/stories/immunic-adds-elena-ridloff-to-board-ahead-of-phase-3-ms-readout-a4e15b2026-09-28monthly0.7 https://app.readthrough.bio/stories/aim-immunotech-ceo-ties-ampligen-antiviral-research-to-military-a68f362026-09-28monthly0.7 https://app.readthrough.bio/stories/septerna-reports-q2-2026-results-sees-sep-479-pharmacokinetics-support-a88ca72026-09-28monthly0.7 https://app.readthrough.bio/stories/prana-therapies-files-form-d-for-40-2-million-equity-offering-ab81cf2026-09-28monthly0.7 https://app.readthrough.bio/stories/grace-therapeutics-raises-10-million-in-private-placement-for-gtx-104-ada7662026-09-28monthly0.7 https://app.readthrough.bio/stories/lb-pharmaceuticals-moves-up-nova-2-schizophrenia-readout-to-first-half-ae91c22026-09-28monthly0.7 https://app.readthrough.bio/stories/neurogene-reports-long-term-rett-syndrome-gene-therapy-data-extends-b09c8d2026-09-28monthly0.7 https://app.readthrough.bio/stories/theravance-biopharma-reports-q2-2026-results-confirms-zymeworks-deal-on-b3535f2026-09-28monthly0.7 https://app.readthrough.bio/stories/quantum-biopharma-gets-fda-clearance-to-start-lucid-ms-phase-2-in-b640bd2026-09-26monthly0.7 https://app.readthrough.bio/stories/merlin-biotech-reports-50-000-debt-offering-to-sec-b8d0a72026-09-28monthly0.7 https://app.readthrough.bio/stories/zura-bio-reports-q2-2026-results-completes-enrollment-in-two-ba69e32026-09-26monthly0.7 https://app.readthrough.bio/stories/cogent-biosciences-files-400-million-stock-offering-under-existing-at-bafc2b2026-09-28monthly0.7 https://app.readthrough.bio/stories/abcellera-reports-positive-phase-2-results-for-menopause-drug-abcl635-bbc0762026-09-26monthly0.7 https://app.readthrough.bio/stories/silence-therapeutics-reports-positive-phase-2-topline-data-for-c01a492026-09-26monthly0.7 https://app.readthrough.bio/stories/diamedica-reports-q2-2026-results-highlights-preeclampsia-data-and-fgr-c2f90c2026-09-27monthly0.7 https://app.readthrough.bio/stories/taysha-completes-dosing-in-pivotal-rett-syndrome-trials-raises-230-c4ac422026-09-28monthly0.7 https://app.readthrough.bio/stories/bolt-biotherapeutics-reports-q2-2026-results-initial-bdc-4182-data-c8d9682026-09-28monthly0.7 https://app.readthrough.bio/stories/erasca-names-charles-fuchs-as-president-of-research-development-c8e04f2026-09-27monthly0.7 https://app.readthrough.bio/stories/biohaven-advances-degrader-and-epilepsy-pipelines-reports-q2-2026-cbf66a2026-09-28monthly0.7 https://app.readthrough.bio/stories/annexon-adds-retinal-surgeon-mark-blumenkranz-to-board-as-muneer-satter-ccd9862026-09-28monthly0.7 https://app.readthrough.bio/stories/calcimedica-reports-q2-2026-results-advances-pulmonary-hypertension-and-cd15772026-09-28monthly0.7 https://app.readthrough.bio/stories/jade-biosciences-reports-positive-phase-1-data-for-jade101-advances-cf04512026-09-27monthly0.7 https://app.readthrough.bio/stories/perspective-therapeutics-reports-2q-2026-results-advances-toward-vmt-d09a232026-09-26monthly0.7 https://app.readthrough.bio/stories/c4-therapeutics-reports-q2-2026-results-cemsidomide-trials-on-track-for-d18fb72026-09-27monthly0.7 https://app.readthrough.bio/stories/jazz-pharmaceuticals-to-acquire-actio-biosciences-for-up-to-1-32-billion-d817842026-09-27monthly0.7 https://app.readthrough.bio/stories/agomab-proposes-marino-garcia-and-dr-naimish-patel-for-board-seats-d9582a2026-09-27monthly0.7 https://app.readthrough.bio/stories/tenax-s-tnx-103-misses-primary-endpoint-in-phase-3-level-trial-for-ph-d964042026-09-25monthly0.7 https://app.readthrough.bio/stories/lenz-reports-q2-2026-results-as-vizz-adds-telehealth-access-and-global-ddbca12026-09-28monthly0.7 https://app.readthrough.bio/stories/kyverna-reports-q2-2026-results-and-rmat-nod-for-miv-cel-in-progressive-e171bd2026-09-28monthly0.7 https://app.readthrough.bio/stories/veru-s-phase-2b-plateau-trial-fully-enrolled-with-239-obesity-patients-e242e12026-09-27monthly0.7 https://app.readthrough.bio/stories/coya-therapeutics-reports-q2-2026-results-updates-alstars-trial-and-ftd-e35bdc2026-09-28monthly0.7 https://app.readthrough.bio/stories/jazz-pharmaceuticals-to-acquire-actio-biosciences-for-820-million-ec2aba2026-09-26monthly0.7 https://app.readthrough.bio/stories/tonix-reports-q2-2026-results-tonmya-sales-rise-197-horizon-trial-begins-f2e2da2026-09-28monthly0.7 https://app.readthrough.bio/stories/erasca-updates-eras-0015-data-plans-registration-enabling-trials-f7895f2026-09-27monthly0.7 https://app.readthrough.bio/stories/replimune-prices-150-million-stock-offering-following-tudriqev-approval-fa6d8d2026-09-27monthly0.7 https://app.readthrough.bio/stories/sagimet-reports-q2-2026-results-cash-to-fund-operations-through-2028-fb6a9b2026-09-26monthly0.7 https://app.readthrough.bio/stories/mereo-biopharma-reports-q2-2026-results-alvelestat-licensing-deal-with-fe899a2026-09-28monthly0.7 https://app.readthrough.bio/stories/biohaven-adds-john-yetimoglu-to-board-of-directors-008f392026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-grants-accelerated-approval-to-replimune-s-tudriqev-plus-nivolumab-03964f2026-09-26monthly0.7 https://app.readthrough.bio/stories/alector-advances-al137-toward-ind-reports-q2-2026-results-04386f2026-09-28monthly0.7 https://app.readthrough.bio/stories/veradermics-files-s-1-to-register-16-8-million-resale-shares-from-pipe-04f69d2026-09-28monthly0.7 https://app.readthrough.bio/stories/opus-genetics-reports-q2-2026-results-cites-september-best1-data-and-0818612026-09-28monthly0.7 https://app.readthrough.bio/stories/mbx-biosciences-reports-q2-2026-results-canvuparatide-phase-3-recruiting-09c3552026-09-26monthly0.7 https://app.readthrough.bio/stories/pepgen-dsmb-recommends-advancing-pgn-edodm1-to-highest-freedom2-dm1-0a66122026-09-26monthly0.7 https://app.readthrough.bio/stories/latigo-biotherapeutics-prices-ipo-at-18-per-share-on-nasdaq-0e7fa22026-09-27monthly0.7 https://app.readthrough.bio/stories/celularity-ends-rick-gonzalez-s-role-as-chief-commercial-officer-107e5a2026-09-28monthly0.7 https://app.readthrough.bio/stories/biomarin-raises-2026-revenue-and-voxzogo-guidance-discontinues-bmn-401-1711f12026-09-27monthly0.7 https://app.readthrough.bio/stories/ani-pharmaceuticals-posts-record-q2-2026-trims-cortrophin-gel-outlook-1b2fb02026-09-28monthly0.7 https://app.readthrough.bio/stories/coya-therapeutics-adds-board-member-mark-pavao-to-audit-committee-1bb19c2026-09-28monthly0.7 https://app.readthrough.bio/stories/prestige-consumer-healthcare-raises-fiscal-2027-outlook-after-two-2498972026-09-28monthly0.7 https://app.readthrough.bio/stories/optimi-health-ceo-buys-3-800-shares-via-affiliated-company-28abed2026-09-28monthly0.7 https://app.readthrough.bio/stories/relay-therapeutics-files-to-sell-up-to-213-million-more-shares-via-td-28f9fd2026-09-27monthly0.7 https://app.readthrough.bio/stories/xenon-reports-q2-2026-results-confirms-azetukalner-nda-submission-on-2a1dff2026-09-26monthly0.7 https://app.readthrough.bio/stories/cogent-biosciences-reports-q2-2026-results-two-bezuclastinib-pdufa-2a2eb22026-09-28monthly0.7 https://app.readthrough.bio/stories/prenetics-discloses-terms-of-1-billion-im8-financing-with-general-2f60ff2026-09-28monthly0.7 https://app.readthrough.bio/stories/ensysce-completes-cy-biopharma-acquisition-lines-up-up-to-77-million-2ffb2f2026-09-27monthly0.7 https://app.readthrough.bio/stories/blossomhill-therapeutics-prices-ipo-at-16-00-per-share-raising-150-342d352026-09-27monthly0.7 https://app.readthrough.bio/stories/corbus-pharmaceuticals-files-127-5-million-at-the-market-stock-offering-348f6d2026-09-28monthly0.7 https://app.readthrough.bio/stories/braveheart-bio-prices-ipo-at-18-per-share-raising-382-5-million-3988e72026-09-25monthly0.7 https://app.readthrough.bio/stories/clearmind-s-dsmb-clears-phase-i-ii-aud-trial-to-advance-to-next-stages-3aeae12026-09-26monthly0.7 https://app.readthrough.bio/stories/harrow-to-acquire-global-rights-to-tyrvaya-nasal-spray-from-viatris-3e31b72026-09-26monthly0.7 https://app.readthrough.bio/stories/iovance-posts-record-q2-2026-revenue-gains-fda-fast-track-for-3ff1482026-09-27monthly0.7 https://app.readthrough.bio/stories/metavia-reports-q2-2026-results-all-patients-reach-top-da-1726-doses-4485af2026-09-26monthly0.7 https://app.readthrough.bio/stories/ispecimen-closes-5-million-public-offering-of-stock-and-pre-funded-44dfd52026-09-28monthly0.7 https://app.readthrough.bio/stories/annexon-reports-early-data-from-first-10-gbs-forward-study-patients-454dfe2026-09-26monthly0.7 https://app.readthrough.bio/stories/voyager-reports-q2-2026-results-sets-q4-milestones-for-two-alzheimer-s-48a12b2026-09-27monthly0.7 https://app.readthrough.bio/stories/nuvation-bio-posts-q2-2026-results-expands-safusidenib-program-reports-50da972026-09-27monthly0.7 https://app.readthrough.bio/stories/zentalis-reports-q2-2026-results-as-denali-part-2-nears-full-enrollment-52d37b2026-09-26monthly0.7 https://app.readthrough.bio/stories/nextcure-reports-q2-2026-results-moves-toward-avere-therapeutics-merger-5635a42026-09-28monthly0.7 https://app.readthrough.bio/stories/generate-biomedicines-reports-q2-2026-results-advances-asthma-and-5ae7db2026-09-27monthly0.7 https://app.readthrough.bio/stories/verrica-reports-ycanth-demand-growth-sets-mid-2027-wart-data-secures-5e440e2026-09-28monthly0.7 https://app.readthrough.bio/stories/alx-oncology-reports-q2-2026-results-aspen-09-breast-readout-on-track-627a832026-09-27monthly0.7 https://app.readthrough.bio/stories/foghorn-reports-q2-2026-results-fhd-909-trial-on-track-with-lilly-6702592026-09-26monthly0.7 https://app.readthrough.bio/stories/gyre-reports-q2-2026-results-advances-f351-nda-and-cullgen-pipeline-6703032026-09-28monthly0.7 https://app.readthrough.bio/stories/sanuwave-withdraws-fy2026-guidance-after-cms-reimbursement-proposal-6c74f42026-09-28monthly0.7 https://app.readthrough.bio/stories/surrozen-reports-q2-2026-results-plans-szn-8141-ind-filing-by-q3-end-712c532026-09-27monthly0.7 https://app.readthrough.bio/stories/collegium-cuts-2026-revenue-guidance-on-weaker-nucynta-generic-pricing-73436a2026-09-26monthly0.7 https://app.readthrough.bio/stories/tectonic-completes-apex-enrollment-for-tx45-in-ph-hfpef-idmc-backs-7574132026-09-27monthly0.7 https://app.readthrough.bio/stories/aim-immunotech-signs-manufacturing-deal-ends-atm-stock-sale-program-79ca2b2026-09-27monthly0.7 https://app.readthrough.bio/stories/vivosim-regains-nasdaq-equity-compliance-discloses-post-10-k-cash-7c99552026-09-27monthly0.7 https://app.readthrough.bio/stories/tango-therapeutics-executive-chair-barbara-weber-departs-separation-7cdafb2026-09-28monthly0.7 https://app.readthrough.bio/stories/intellia-reports-positive-phase-3-haelo-data-for-lonvo-z-resumes-nex-z-7d2cac2026-09-27monthly0.7 https://app.readthrough.bio/stories/thierry-bernard-steps-down-from-neogen-board-83a8ed2026-09-28monthly0.7 https://app.readthrough.bio/stories/cdt-equity-amends-note-twice-raising-debt-to-2-536-650-and-interest-to-83bd392026-09-27monthly0.7 https://app.readthrough.bio/stories/halozyme-posts-record-q2-2026-raises-full-year-guidance-on-royalty-8981bc2026-09-27monthly0.7 https://app.readthrough.bio/stories/lexicon-completes-sonata-hcm-enrollment-keeps-q1-2027-data-timeline-8a9b162026-09-28monthly0.7 https://app.readthrough.bio/stories/shiverbright-technologies-files-form-d-for-safe-offering-first-sale-9036b92026-09-28monthly0.7 https://app.readthrough.bio/stories/sanofi-wins-eu-approval-for-menquadfi-in-infants-from-six-weeks-old-960aae2026-09-25monthly0.7 https://app.readthrough.bio/stories/novavax-reports-q2-2026-results-raises-revenue-outlook-cites-sanofi-and-a909862026-09-27monthly0.7 https://app.readthrough.bio/stories/vistagen-reports-phase-2-repeat-dose-results-for-fasedienol-in-social-abe8192026-09-26monthly0.7 https://app.readthrough.bio/stories/entera-bio-reports-q2-2026-results-cites-fda-alignment-on-eb613-phase-3-ac31c02026-09-26monthly0.7 https://app.readthrough.bio/stories/cg-oncology-reports-q2-2026-results-flags-near-term-pivot-006-data-ade4092026-09-26monthly0.7 https://app.readthrough.bio/stories/ocugen-reports-q2-2026-update-with-fda-clearance-for-ocu410-phase-3-and-af009e2026-09-27monthly0.7 https://app.readthrough.bio/stories/zai-lab-reports-q2-2026-results-advances-zoci-and-zl-1503-toward-key-af4f822026-09-27monthly0.7 https://app.readthrough.bio/stories/palisade-bio-advances-pali-2108-toward-phase-2-trials-in-ulcerative-b07c762026-09-28monthly0.7 https://app.readthrough.bio/stories/minerva-reports-q2-2026-results-confirms-c19-trial-timeline-for-b0db572026-09-28monthly0.7 https://app.readthrough.bio/stories/evommune-reports-q2-2026-results-sets-evo756-ad-data-for-september-b7970e2026-09-28monthly0.7 https://app.readthrough.bio/stories/kiora-reports-q2-2026-results-advances-kio-301-and-kio-104-trials-bd3aa62026-09-28monthly0.7 https://app.readthrough.bio/stories/aclaris-amends-at-the-market-stock-sale-agreement-with-leerink-cantor-c5f3c52026-09-27monthly0.7 https://app.readthrough.bio/stories/atyr-pharma-cuts-workforce-60-to-focus-on-efzofitimod-in-lung-disease-ccfb532026-09-28monthly0.7 https://app.readthrough.bio/stories/sionna-keeps-two-cf-trial-readouts-on-track-for-summer-2026-cd39a52026-09-28monthly0.7 https://app.readthrough.bio/stories/corbus-reports-q2-2026-results-clears-fda-hurdle-for-crb-701-trial-cea30a2026-09-26monthly0.7 https://app.readthrough.bio/stories/insmed-raises-brinsupri-guidance-and-combined-peak-sales-estimate-to-d28f282026-09-27monthly0.7 https://app.readthrough.bio/stories/scholar-rock-refiles-at-the-market-offering-for-up-to-200-million-d35a072026-09-27monthly0.7 https://app.readthrough.bio/stories/verastem-amends-oberland-note-agreement-adds-new-revenue-linked-notes-d3e0762026-09-26monthly0.7 https://app.readthrough.bio/stories/cellectis-reports-q2-2026-results-as-lasme-cel-gains-fda-rmat-status-d58a492026-09-26monthly0.7 https://app.readthrough.bio/stories/cryoport-supports-779-clinical-trials-and-22-approved-cell-and-gene-dc4c5e2026-09-28monthly0.7 https://app.readthrough.bio/stories/bioaffinity-reports-q2-2026-cypath-lung-test-volume-up-216-year-over-e2a0612026-09-28monthly0.7 https://app.readthrough.bio/stories/organogenesis-enters-at-the-market-equity-sales-agreement-worth-up-to-e6742c2026-09-27monthly0.7 https://app.readthrough.bio/stories/atossa-reports-q2-2026-results-completes-enrollment-in-evangeline-trial-e9541e2026-09-28monthly0.7 https://app.readthrough.bio/stories/xenetic-reports-q2-2026-results-highlights-dnase-collaboration-progress-ea36fa2026-09-28monthly0.7 https://app.readthrough.bio/stories/amylyx-completes-lucidity-dosing-period-sets-late-august-early-ea57062026-09-27monthly0.7 https://app.readthrough.bio/stories/biovie-reports-topline-phase-2-sunrise-pd-results-for-bezisterim-in-eeadca2026-09-26monthly0.7 https://app.readthrough.bio/stories/oruka-reports-q2-2026-results-advances-orka-001-and-orka-002-programs-f054a72026-09-28monthly0.7 https://app.readthrough.bio/stories/volitionrx-issues-shares-to-lind-to-satisfy-note-payment-and-conversion-f4bd302026-09-28monthly0.7 https://app.readthrough.bio/stories/axsome-reports-2q-2026-results-alzheimer-s-agitation-launch-axs-12-nda-f5389a2026-09-28monthly0.7 https://app.readthrough.bio/stories/change-agents-corporation-files-s-1-for-resale-of-up-to-35-6-million-fb20332026-09-28monthly0.7 https://app.readthrough.bio/stories/cervomed-reports-q2-2026-results-seeks-partner-for-neflamapimod-phase-3-fcc13f2026-09-28monthly0.7 https://app.readthrough.bio/stories/theriva-doses-first-patient-in-virage2-trial-testing-repeat-vcn-01-fd15412026-09-26monthly0.7 https://app.readthrough.bio/stories/agomab-reports-first-half-2026-results-confirms-fda-alignment-on-crohn-fdcff32026-09-26monthly0.7 https://app.readthrough.bio/stories/korro-bio-posts-q2-2026-results-highlights-krro-121-and-new-candidate-fe8fcc2026-09-27monthly0.7 https://app.readthrough.bio/stories/relmada-targets-year-end-ind-filings-for-ndv-01-and-sepranolone-reports-0734ff2026-09-28monthly0.7 https://app.readthrough.bio/stories/amphastar-posts-q2-2026-revenue-growth-as-new-launches-offset-pricing-0ba75c2026-09-27monthly0.7 https://app.readthrough.bio/stories/prothena-reports-q2-2026-results-updates-year-end-cash-guidance-to-259-0eac452026-09-27monthly0.7 https://app.readthrough.bio/stories/newamsterdam-reports-positive-chmp-opinion-for-obicetrapib-sets-prevail-0f61042026-09-27monthly0.7 https://app.readthrough.bio/stories/vir-reports-week-96-solstice-data-eclipse-program-fully-enrolled-vir-0fd0162026-09-27monthly0.7 https://app.readthrough.bio/stories/aclaris-reports-q2-2026-results-ati-052-phase-1a-data-and-reaffirmed-1060862026-09-27monthly0.7 https://app.readthrough.bio/stories/cognition-therapeutics-targets-mid-2027-start-for-dlb-psychosis-phase-3-12a7c32026-09-28monthly0.7 https://app.readthrough.bio/stories/zoetis-names-jay-saccaro-evp-cfo-and-coo-effective-august-17-2026-1881ce2026-09-28monthly0.7 https://app.readthrough.bio/stories/imagenebio-reports-q2-2026-results-as-olevaprubart-pipeline-advances-on-1944d52026-09-27monthly0.7 https://app.readthrough.bio/stories/revelation-biosciences-reports-q2-2026-results-advances-aki-trial-prep-1d747a2026-09-28monthly0.7 https://app.readthrough.bio/stories/hcw-biologics-reports-1-6-million-private-securities-sale-in-sec-filing-2093542026-09-28monthly0.7 https://app.readthrough.bio/stories/scisparc-s-neurothera-launches-tourette-syndrome-trial-site-at-yale-23a2b52026-09-26monthly0.7 https://app.readthrough.bio/stories/verastem-starts-dosing-in-all-three-vs-7375-registration-trials-secures-24c8a62026-09-27monthly0.7 https://app.readthrough.bio/stories/phio-reports-q2-2026-results-sets-q3-fda-meeting-on-ph-762-path-25eb992026-09-28monthly0.7 https://app.readthrough.bio/stories/cartesian-reports-q2-2026-results-four-clinical-readouts-expected-264d0a2026-09-28monthly0.7 https://app.readthrough.bio/stories/puma-biotechnology-raises-2026-guidance-on-nerlynx-demand-details-26d6b02026-09-28monthly0.7 https://app.readthrough.bio/stories/janux-reports-q2-2026-results-keeps-prostate-cancer-and-autoimmune-27edae2026-09-28monthly0.7 https://app.readthrough.bio/stories/elanco-raises-2026-revenue-and-profit-outlook-on-zenrelia-and-credelio-28bff02026-09-28monthly0.7 https://app.readthrough.bio/stories/abbvie-prices-10-billion-notes-offering-to-help-fund-apogee-deal-299f642026-09-25monthly0.7 https://app.readthrough.bio/stories/viatris-raises-2026-guidance-reports-fda-approvals-and-tyrvaya-sale-in-2f79b42026-09-28monthly0.7 https://app.readthrough.bio/stories/cullinan-reports-q2-2026-results-outlines-t-cell-engager-trial-timelines-32c9502026-09-28monthly0.7 https://app.readthrough.bio/stories/cytomx-reports-q2-2026-results-advances-varseta-m-toward-first-33b0232026-09-27monthly0.7 https://app.readthrough.bio/stories/vanda-reports-q2-2026-results-reaffirms-guidance-and-three-phase-iii-3436272026-09-28monthly0.7 https://app.readthrough.bio/stories/omniab-raises-2026-revenue-and-cash-guidance-on-partner-pipeline-3e57762026-09-27monthly0.7 https://app.readthrough.bio/stories/ligand-raises-eps-guidance-floor-closes-xoma-royalty-deal-reports-3e62772026-09-27monthly0.7 https://app.readthrough.bio/stories/ardelyx-revises-ibsrela-guidance-pulls-xphozah-long-term-outlook-amid-3fa7cb2026-09-28monthly0.7 https://app.readthrough.bio/stories/siga-reports-37-million-in-tpoxx-sales-for-second-quarter-of-2026-402e312026-09-28monthly0.7 https://app.readthrough.bio/stories/celldex-reports-q2-2026-results-as-barzolvolimab-phase-3-enrollment-43c9dc2026-09-28monthly0.7 https://app.readthrough.bio/stories/nature-s-sunshine-posts-q2-net-sales-of-117-0-million-cuts-full-year-47d89d2026-09-28monthly0.7 https://app.readthrough.bio/stories/ginkgo-bioworks-reports-q2-2026-results-cites-new-autonomous-lab-work-4816a62026-09-28monthly0.7 https://app.readthrough.bio/stories/viridian-reports-q2-2026-results-as-lumvoa-launch-begins-in-the-u-s-48444d2026-09-28monthly0.7 https://app.readthrough.bio/stories/zymeworks-posts-q2-2026-results-flags-august-pdufa-date-and-theravance-4a34542026-09-27monthly0.7 https://app.readthrough.bio/stories/lantheus-posts-q2-2026-results-pulls-guidance-amid-pending-curium-merger-4c1ab32026-09-28monthly0.7 https://app.readthrough.bio/stories/organogenesis-files-to-sell-up-to-75-million-in-stock-through-at-the-4db77f2026-09-28monthly0.7 https://app.readthrough.bio/stories/precision-biosciences-reports-first-biopsy-evidence-of-cccdna-4feb982026-09-27monthly0.7 https://app.readthrough.bio/stories/agenus-advances-phase-3-robbin-trial-in-colon-cancer-backed-by-july-5216ee2026-09-28monthly0.7 https://app.readthrough.bio/stories/charles-river-raises-2026-guidance-after-stronger-dsa-demand-and-5449fe2026-09-27monthly0.7 https://app.readthrough.bio/stories/standard-biotools-reports-q2-2026-results-says-treeline-merger-on-track-55b8892026-09-28monthly0.7 https://app.readthrough.bio/stories/denali-reports-first-full-avlayah-quarter-advances-alzheimer-s-pipeline-567e122026-09-27monthly0.7 https://app.readthrough.bio/stories/vtv-therapeutics-reports-q2-2026-results-reaffirms-cadisegliatin-trial-57c12e2026-09-27monthly0.7 https://app.readthrough.bio/stories/cytokinetics-reports-q2-2026-results-acacia-hcm-hits-both-primary-5c8b7f2026-09-27monthly0.7 https://app.readthrough.bio/stories/os-therapies-registers-500-000-shares-for-leonite-as-part-of-debt-5d87142026-09-28monthly0.7 https://app.readthrough.bio/stories/roivant-reports-q1-fiscal-2027-results-pipeline-on-track-across-four-5f0d5c2026-09-27monthly0.7 https://app.readthrough.bio/stories/climb-bio-reports-q2-2026-results-sets-clym116-r-d-event-and-phase-2-6011d72026-09-28monthly0.7 https://app.readthrough.bio/stories/aurinia-starts-preserve-trial-combining-lupkynis-with-biologics-in-6b9a7c2026-09-28monthly0.7 https://app.readthrough.bio/stories/organogenesis-cuts-2026-revenue-outlook-after-steep-quarterly-sales-6f17662026-09-28monthly0.7 https://app.readthrough.bio/stories/immunocore-posts-q2-kimmtrak-sales-growth-as-key-melanoma-trial-nears-6fa5a22026-09-28monthly0.7 https://app.readthrough.bio/stories/avalo-reports-q2-2026-results-plans-phase-3-start-for-abdakibart-in-hs-6fac652026-09-28monthly0.7 https://app.readthrough.bio/stories/arcturus-reports-q2-2026-results-regains-kostaive-rights-from-csl-6ff71d2026-09-28monthly0.7 https://app.readthrough.bio/stories/tiziana-ceo-elrifi-buys-more-shares-on-two-dates-in-august-2026-70adf72026-09-28monthly0.7 https://app.readthrough.bio/stories/immuneering-reports-q2-2026-results-mapkeeper-301-dosing-underway-77b1c22026-09-27monthly0.7 https://app.readthrough.bio/stories/solid-biosciences-launches-200-million-at-the-market-stock-offering-7de1b92026-09-25monthly0.7 https://app.readthrough.bio/stories/structure-therapeutics-doses-first-patients-in-phase-3-obesity-program-832a0e2026-09-27monthly0.7 https://app.readthrough.bio/stories/adicet-bio-pushes-prula-cel-phase-1-update-to-q3-2026-cites-fda-talks-88ca8d2026-09-27monthly0.7 https://app.readthrough.bio/stories/aligos-reports-q2-2026-results-pevifoscorvir-sodium-enrollment-complete-8e6ba02026-09-28monthly0.7 https://app.readthrough.bio/stories/regenxbio-reports-q2-2026-results-cites-duchenne-trial-win-and-new-94cd172026-09-28monthly0.7 https://app.readthrough.bio/stories/in8bio-reports-q2-2026-results-gbm-survival-data-and-tce-platform-94fe322026-09-28monthly0.7 https://app.readthrough.bio/stories/cg-oncology-expands-stock-sale-program-to-1-05-billion-950c792026-09-28monthly0.7 https://app.readthrough.bio/stories/scholar-rock-updates-apitegromab-bla-progress-starts-fshd-phase-2-trial-95de012026-09-28monthly0.7 https://app.readthrough.bio/stories/prime-medicine-clears-path-for-two-liver-programs-gains-rmat-for-pm359-98ec242026-09-27monthly0.7 https://app.readthrough.bio/stories/lyell-reports-q2-2026-results-updated-ronde-cel-and-lyl273-data-9b6a2c2026-09-28monthly0.7 https://app.readthrough.bio/stories/whitehawk-reports-q2-2026-results-hwk-206-trial-on-track-for-q3-start-9e6ffe2026-09-28monthly0.7 https://app.readthrough.bio/stories/arcus-biosciences-advances-casdatifan-combinations-reports-775m-cash-at-a393e02026-09-27monthly0.7 https://app.readthrough.bio/stories/entrada-reports-q2-2026-results-with-dmd-data-due-by-year-end-vx-670-a3bff52026-09-28monthly0.7 https://app.readthrough.bio/stories/monte-rosa-reports-q2-2026-results-as-mgd-pipeline-advances-on-three-a7a4e32026-09-27monthly0.7 https://app.readthrough.bio/stories/lineage-reports-q2-2026-results-advances-cor1-corneal-program-and-b099812026-09-27monthly0.7 https://app.readthrough.bio/stories/biocryst-reports-q2-2026-results-completes-navenibart-pivotal-enrollment-b1eed92026-09-28monthly0.7 https://app.readthrough.bio/stories/corvus-reports-q2-2026-results-updates-soquelitinib-pipeline-progress-b40d9d2026-09-28monthly0.7 https://app.readthrough.bio/stories/tarsus-pharmaceuticals-prices-125-million-private-placement-financing-b7394c2026-09-28monthly0.7 https://app.readthrough.bio/stories/compass-therapeutics-awaits-fda-input-on-tovecimig-biliary-cancer-data-b9b8aa2026-09-28monthly0.7 https://app.readthrough.bio/stories/xeris-reports-second-quarter-2026-results-tightens-full-year-revenue-bc95c82026-09-28monthly0.7 https://app.readthrough.bio/stories/schrodinger-launches-bunsen-ai-co-scientist-raises-2026-drug-discovery-c061952026-09-27monthly0.7 https://app.readthrough.bio/stories/quidelortho-cuts-full-year-2026-guidance-on-china-pricing-pressure-c0a0612026-09-28monthly0.7 https://app.readthrough.bio/stories/lifecore-reaffirms-2026-guidance-cites-new-manufacturing-wins-in-fiscal-c58cf12026-09-28monthly0.7 https://app.readthrough.bio/stories/praxis-reports-q2-2026-results-mid-cycle-fda-meetings-clear-for-two-c5d06d2026-09-27monthly0.7 https://app.readthrough.bio/stories/lilly-raises-2026-revenue-guidance-to-85-87-billion-on-mounjaro-c797d32026-09-27monthly0.7 https://app.readthrough.bio/stories/zoetis-cuts-full-year-2026-guidance-as-companion-animal-demand-softens-cd61f72026-09-28monthly0.7 https://app.readthrough.bio/stories/immunovant-reports-q1-fiscal-2026-results-says-imvt-1402-timelines-on-cec1c12026-09-28monthly0.7 https://app.readthrough.bio/stories/tarsus-posts-record-xdemvy-sales-raises-guidance-moves-to-acquire-alkeus-cf57c22026-09-28monthly0.7 https://app.readthrough.bio/stories/biolife-solutions-posts-q2-2026-results-as-repligen-acquisition-heads-d6d28b2026-09-28monthly0.7 https://app.readthrough.bio/stories/valion-bio-hits-first-entolimod-milestone-pays-statera-in-preferred-dd72e32026-09-27monthly0.7 https://app.readthrough.bio/stories/eton-licenses-asn-001-topical-gel-to-expand-infantile-hemangioma-e1e0ec2026-09-26monthly0.7 https://app.readthrough.bio/stories/relay-therapeutics-expands-at-the-market-stock-offering-to-462-978-049-e483b72026-09-27monthly0.7 https://app.readthrough.bio/stories/ironwood-raises-2026-guidance-as-apraglutide-trial-begins-recruiting-e6c1952026-09-27monthly0.7 https://app.readthrough.bio/stories/edgewise-reports-q2-2026-results-positive-phase-2-hcm-data-and-closed-ea65bb2026-09-27monthly0.7 https://app.readthrough.bio/stories/emergent-biosolutions-posts-q2-revenue-surge-but-takes-191-million-ec9e962026-09-26monthly0.7 https://app.readthrough.bio/stories/sarepta-names-michael-severino-ceo-reports-q2-2026-results-and-pipeline-ecea192026-09-27monthly0.7 https://app.readthrough.bio/stories/kymera-moves-up-kt-621-atopic-dermatitis-data-after-fast-enrollment-ef67062026-09-27monthly0.7 https://app.readthrough.bio/stories/trevi-starts-phase-3-ocean-1-and-phase-2b-lake-trials-for-haduvio-f039102026-09-28monthly0.7 https://app.readthrough.bio/stories/mannkind-reports-q2-2026-results-with-pediatric-afrezza-and-furoscix-f1f8202026-09-27monthly0.7 https://app.readthrough.bio/stories/geron-reports-q2-2026-results-as-rytelo-revenue-climbs-to-57-5-million-f3f30d2026-09-28monthly0.7 https://app.readthrough.bio/stories/maravai-reports-q2-2026-revenue-up-8-5-raises-full-year-adjusted-ebitda-f59e152026-09-28monthly0.7 https://app.readthrough.bio/stories/artiva-reports-q2-2026-results-rmat-for-allonk-in-refractory-ra-phase-3-f775e52026-09-28monthly0.7 https://app.readthrough.bio/stories/summit-therapeutics-starts-phase-ii-iii-bladder-cancer-trial-for-f951cc2026-09-26monthly0.7 https://app.readthrough.bio/stories/biontech-names-guido-oelkers-ceo-trims-2026-revenue-guidance-in-q2-0914bd2026-09-27monthly0.7 https://app.readthrough.bio/stories/zevra-reports-q2-2026-results-as-miplyffa-revenue-grows-and-eu-review-094f942026-09-28monthly0.7 https://app.readthrough.bio/stories/arvinas-reports-q2-2026-results-after-first-ever-fda-approval-of-a-09dfdf2026-09-27monthly0.7 https://app.readthrough.bio/stories/syndax-posts-2q26-results-adds-egfr-and-menin-candidates-to-pipeline-1ba6a12026-09-27monthly0.7 https://app.readthrough.bio/stories/palvella-submits-first-nda-module-for-qtorin-rapamycin-in-lymphatic-1d8cd62026-09-27monthly0.7 https://app.readthrough.bio/stories/onkure-amends-atm-prospectus-drops-form-s-3-offering-cap-1dfc792026-09-28monthly0.7 https://app.readthrough.bio/stories/innoviva-posts-second-quarter-2026-results-adds-dr-reddy-s-licensing-213a162026-09-28monthly0.7 https://app.readthrough.bio/stories/black-diamond-reports-phase-2-silevertinib-data-plans-fda-meeting-on-24b8212026-09-28monthly0.7 https://app.readthrough.bio/stories/larimar-reports-q2-2026-update-on-nomlabofusp-bla-phase-3-timing-and-26ffc52026-09-28monthly0.7 https://app.readthrough.bio/stories/arrowhead-reports-fiscal-q3-2026-results-with-plozasiran-phase-3-data-2879b62026-09-27monthly0.7 https://app.readthrough.bio/stories/mirum-raises-2026-sales-guidance-volixibat-gets-fda-breakthrough-status-2d51332026-09-27monthly0.7 https://app.readthrough.bio/stories/jnj-s-taubert-to-retire-cavanaugh-named-evp-worldwide-chairman-31f56e2026-09-27monthly0.7 https://app.readthrough.bio/stories/protagonist-posts-q2-2026-profit-as-icotyde-launch-and-rusfertide-3c198a2026-09-27monthly0.7 https://app.readthrough.bio/stories/rani-therapeutics-adds-michelle-gilson-to-board-names-her-audit-chair-3dabaa2026-09-27monthly0.7 https://app.readthrough.bio/stories/harmony-biosciences-reports-record-wakix-revenue-posts-phase-1-data-for-401a372026-09-28monthly0.7 https://app.readthrough.bio/stories/tenaya-reports-q2-2026-results-with-new-tn-201-tn-401-data-and-alnylam-498b7a2026-09-27monthly0.7 https://app.readthrough.bio/stories/ideaya-reports-q2-2026-results-darovasertib-trial-hits-primary-endpoint-4b60d62026-09-27monthly0.7 https://app.readthrough.bio/stories/united-therapeutics-submits-ralinepag-and-nebulized-tyvaso-ndas-flags-4d76cd2026-09-27monthly0.7 https://app.readthrough.bio/stories/pfizer-raises-2026-revenue-outlook-reports-q2-loss-on-impairment-charges-4dd9ad2026-09-27monthly0.7 https://app.readthrough.bio/stories/arcutis-posts-q2-2026-profit-as-zoryve-sales-climb-raises-full-year-4ef0e92026-09-26monthly0.7 https://app.readthrough.bio/stories/seres-reports-ser-155-irec-trial-data-as-it-seeks-partners-and-cuts-4fb26c2026-09-28monthly0.7 https://app.readthrough.bio/stories/recursion-posts-q2-2026-results-genentech-advances-first-neuroscience-5203392026-09-26monthly0.7 https://app.readthrough.bio/stories/perrigo-reaffirms-2026-outlook-cites-softer-consumption-in-second-5aed4f2026-09-28monthly0.7 https://app.readthrough.bio/stories/travere-reports-q2-2026-results-as-fsgs-launch-begins-and-5b330f2026-09-27monthly0.7 https://app.readthrough.bio/stories/evolus-expands-symatese-pact-to-add-canada-australia-new-zealand-for-5dda8b2026-09-27monthly0.7 https://app.readthrough.bio/stories/akebia-reports-q2-2026-results-voice-interim-data-and-new-ebribafusp-6138ee2026-09-27monthly0.7 https://app.readthrough.bio/stories/60-degrees-pharmaceuticals-prices-1-0-million-private-placement-6467082026-09-28monthly0.7 https://app.readthrough.bio/stories/cumberland-shares-dmd-and-cancer-trial-data-closes-apotex-sale-in-q2-6806f32026-09-28monthly0.7 https://app.readthrough.bio/stories/xencor-advances-xmab819-to-esmo-oral-slot-reports-q2-2026-results-69a3192026-09-27monthly0.7 https://app.readthrough.bio/stories/evolus-raises-2026-revenue-guidance-adds-profhilo-to-u-s-pipeline-via-69e2bd2026-09-28monthly0.7 https://app.readthrough.bio/stories/theriva-stockholders-approve-stock-plan-increase-other-proposals-at-6f28332026-09-28monthly0.7 https://app.readthrough.bio/stories/ibio-names-endocrinologist-molly-carr-as-chief-medical-officer-6fae132026-09-27monthly0.7 https://app.readthrough.bio/stories/faeth-therapeutics-reports-second-quarter-2026-results-awaits-7436622026-09-28monthly0.7 https://app.readthrough.bio/stories/dianthus-reports-phase-3-cidp-interim-data-and-gmg-trial-start-1-2-75d9ee2026-09-28monthly0.7 https://app.readthrough.bio/stories/organigram-to-release-fiscal-q3-2026-results-on-august-11-775d1b2026-09-26monthly0.7 https://app.readthrough.bio/stories/amgen-reports-q2-2026-results-details-maritide-phase-3-program-and-7dc1ce2026-09-27monthly0.7 https://app.readthrough.bio/stories/bioage-doses-first-patient-in-phase-2-quell-cv-trial-of-bge-102-plans-7f62672026-09-27monthly0.7 https://app.readthrough.bio/stories/processa-pharmaceuticals-shareholders-approve-equity-plan-increase-at-80eefc2026-09-28monthly0.7 https://app.readthrough.bio/stories/attovia-therapeutics-prices-289-million-ipo-ahead-of-nasdaq-debut-8370c12026-09-26monthly0.7 https://app.readthrough.bio/stories/seres-therapeutics-issues-shares-to-former-landlord-to-settle-lease-84653b2026-09-28monthly0.7 https://app.readthrough.bio/stories/editas-reports-q2-2026-results-plans-australia-ctn-filing-for-edit-401-89016b2026-09-26monthly0.7 https://app.readthrough.bio/stories/q32-bio-posts-positive-bempikibart-phase-2a-data-plans-registration-8b82422026-09-28monthly0.7 https://app.readthrough.bio/stories/beam-doses-first-patient-in-pivotal-beam-302-cohort-updates-pku-and-91b7852026-09-28monthly0.7 https://app.readthrough.bio/stories/rhythm-reports-q2-2026-imcivree-revenue-of-71-3-million-strong-ho-9336032026-09-26monthly0.7 https://app.readthrough.bio/stories/compass-pathways-reports-q2-2026-results-cites-phase-3-data-as-nda-93bf182026-09-28monthly0.7 https://app.readthrough.bio/stories/onkure-reports-q2-2026-results-keeps-ind-filings-for-two-pi3k-drugs-on-9412bd2026-09-28monthly0.7 https://app.readthrough.bio/stories/rigel-adds-veppanu-to-portfolio-keeps-r289-timeline-raises-2026-revenue-975b8b2026-09-27monthly0.7 https://app.readthrough.bio/stories/galectin-s-chairman-converts-105-8-million-in-debt-into-equity-9a26442026-09-28monthly0.7 https://app.readthrough.bio/stories/pacira-reports-q2-2026-results-updates-guidance-after-iovera-sale-to-9f4d5b2026-09-28monthly0.7 https://app.readthrough.bio/stories/nuvectis-reports-q2-2026-results-as-ciprocopan-wins-first-china-approval-a119172026-09-28monthly0.7 https://app.readthrough.bio/stories/twist-bioscience-prices-upsized-300-million-stock-offering-closes-a220fb2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-takeda-s-orzeyful-for-new-molecular-entity-application-a4a4352026-09-27monthly0.7 https://app.readthrough.bio/stories/idexx-reports-second-quarter-revenue-growth-of-10-raises-full-year-b35b252026-09-28monthly0.7 https://app.readthrough.bio/stories/adma-biologics-reports-second-quarter-2026-results-as-asceniv-revenue-b477c92026-09-28monthly0.7 https://app.readthrough.bio/stories/merck-posts-q2-loss-on-terns-charge-raises-full-year-sales-outlook-b5c5342026-09-27monthly0.7 https://app.readthrough.bio/stories/bnb-plus-faces-nasdaq-delisting-determination-moves-to-otcqb-pending-ba492c2026-09-27monthly0.7 https://app.readthrough.bio/stories/lipocine-s-ppd-drug-misses-phase-3-goal-but-company-cites-site-data-bc89052026-09-28monthly0.7 https://app.readthrough.bio/stories/beone-medicines-reports-q2-2026-results-raises-full-year-revenue-c3357f2026-09-27monthly0.7 https://app.readthrough.bio/stories/royalty-pharma-raises-2026-guidance-after-14-royalty-receipts-growth-in-c5d7c72026-09-27monthly0.7 https://app.readthrough.bio/stories/ultragenyx-reports-q2-2026-results-cites-two-pdufa-dates-and-angelman-c8dfc72026-09-28monthly0.7 https://app.readthrough.bio/stories/immunitybio-posts-q2-2026-revenue-of-50-7-million-as-anktiva-pipeline-cc23752026-09-27monthly0.7 https://app.readthrough.bio/stories/precigen-posts-first-quarterly-profit-as-papzimeos-revenue-more-than-ceb1fb2026-09-28monthly0.7 https://app.readthrough.bio/stories/coherus-reports-q2-2026-results-flags-october-data-update-for-tagmokitug-d56acf2026-09-28monthly0.7 https://app.readthrough.bio/stories/glucotrack-closes-5-5-million-financing-tied-to-bridge-notes-and-pipe-d6b8b52026-09-28monthly0.7 https://app.readthrough.bio/stories/camp4-therapeutics-closes-second-tranche-of-private-placement-raising-d827102026-09-28monthly0.7 https://app.readthrough.bio/stories/urogen-posts-50-4-million-zusduri-revenue-cites-patent-allowance-and-d84e922026-09-28monthly0.7 https://app.readthrough.bio/stories/revolution-medicines-advances-daraxonrasib-nda-and-reports-new-lung-dd77fa2026-09-27monthly0.7 https://app.readthrough.bio/stories/cervomed-s-neflamapimod-gets-uk-innovation-passport-for-lewy-body-e0993a2026-09-27monthly0.7 https://app.readthrough.bio/stories/alpha-teknova-raises-2026-revenue-guidance-after-record-quarter-e42b5c2026-09-28monthly0.7 https://app.readthrough.bio/stories/jasper-therapeutics-discloses-132-million-private-securities-offering-e543a92026-09-28monthly0.7 https://app.readthrough.bio/stories/vaxcyte-reports-q2-2026-results-all-three-vax-31-adult-phase-3-trials-e755162026-09-27monthly0.7 https://app.readthrough.bio/stories/biocryst-updates-cost-estimate-for-closing-alabama-discovery-facility-e7c9102026-09-26monthly0.7 https://app.readthrough.bio/stories/tyra-reports-q2-2026-results-sets-september-readout-for-dabogratinib-e859e62026-09-27monthly0.7 https://app.readthrough.bio/stories/seres-therapeutics-ends-part-of-cambridge-lease-pays-landlord-in-cash-ead8442026-09-27monthly0.7 https://app.readthrough.bio/stories/tyra-biosciences-expands-at-the-market-stock-program-to-250-million-f0d7e12026-09-28monthly0.7 https://app.readthrough.bio/stories/exelixis-reports-q2-2026-results-as-zanzalintinib-fda-review-nears-f38db22026-09-27monthly0.7 https://app.readthrough.bio/stories/spyre-reports-phase-2-ibd-data-for-spy001-spy002-sets-q4-rheumatic-f54bbf2026-09-28monthly0.7 https://app.readthrough.bio/stories/gilead-reports-q2-2026-results-with-three-fda-approvals-three-positive-f7d53d2026-09-27monthly0.7 https://app.readthrough.bio/stories/acadia-raises-2026-revenue-guidance-on-daybue-and-nuplazid-growth-f7e0aa2026-09-28monthly0.7 https://app.readthrough.bio/stories/enliven-reports-phase-1-cml-data-for-elvn-001-aligns-with-fda-on-phase-f93d972026-09-28monthly0.7 https://app.readthrough.bio/stories/lisata-cuts-72-of-workforce-terminates-cmo-amid-kuva-labs-merger-dispute-faa4da2026-09-26monthly0.7 https://app.readthrough.bio/stories/rapport-therapeutics-advances-rap-219-phase-3-epilepsy-program-in-q2-fb0c062026-09-28monthly0.7 https://app.readthrough.bio/stories/odyssey-therapeutics-reports-q2-2026-results-plans-next-od-001-trials-fd168b2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-supplement-37-for-novartis-s-pluvicto-0153aa2026-09-25monthly0.7 https://app.readthrough.bio/stories/indivior-raises-2026-guidance-on-record-sublocade-revenue-01e3482026-09-28monthly0.7 https://app.readthrough.bio/stories/evommune-doses-first-patient-in-phase-2b-trial-of-evo756-for-migraine-04a01e2026-09-26monthly0.7 https://app.readthrough.bio/stories/lakefront-biotherapeutics-discloses-six-weeks-of-share-buybacks-through-04aefc2026-09-26monthly0.7 https://app.readthrough.bio/stories/lantheus-agrees-to-be-acquired-by-curium-us-holdings-in-deal-worth-up-0c8ce92026-09-27monthly0.7 https://app.readthrough.bio/stories/ocular-therapeutix-targets-q4-2026-axpaxli-nda-filing-for-wet-amd-after-0cc93f2026-09-28monthly0.7 https://app.readthrough.bio/stories/clearmind-medicine-signs-loi-to-acquire-51-stake-in-ev-wireless-1702482026-09-26monthly0.7 https://app.readthrough.bio/stories/krystal-biotech-posts-second-quarter-results-outlines-multiple-late-1aae312026-09-27monthly0.7 https://app.readthrough.bio/stories/rocket-one-expands-at-the-market-stock-sale-program-by-5-26-million-1c6e732026-09-28monthly0.7 https://app.readthrough.bio/stories/autolus-enters-250-million-notes-facility-with-perceptive-credit-206e172026-09-27monthly0.7 https://app.readthrough.bio/stories/autolus-reports-q2-aucatzyl-revenue-raises-2026-guidance-secures-250m-23acc72026-09-28monthly0.7 https://app.readthrough.bio/stories/can-fite-submits-phase-2-protocol-testing-piclidenoson-in-lowe-syndrome-25a0022026-09-26monthly0.7 https://app.readthrough.bio/stories/abbvie-to-acquire-apogee-therapeutics-updates-2026-eps-guidance-amid-q2-2670d12026-09-27monthly0.7 https://app.readthrough.bio/stories/radiopharm-reports-rad-101-phase-2b-hit-plans-phase-3-cash-falls-to-4-1m-2b31482026-09-26monthly0.7 https://app.readthrough.bio/stories/vertex-raises-2026-revenue-guidance-sets-povetacicept-pdufa-date-and-2b39572026-09-27monthly0.7 https://app.readthrough.bio/stories/seaport-therapeutics-reports-q2-2026-results-cites-glyphago-phase-1-win-305a4d2026-09-27monthly0.7 https://app.readthrough.bio/stories/tenax-reports-q2-2026-results-confirms-august-level-trial-data-and-esc-38da092026-09-27monthly0.7 https://app.readthrough.bio/stories/regeneron-reports-q2-2026-results-cemdisiran-filings-accepted-fianlimab-3bb41d2026-09-27monthly0.7 https://app.readthrough.bio/stories/alzamend-neuro-sells-7-5-million-in-preferred-stock-flags-board-401c872026-09-27monthly0.7 https://app.readthrough.bio/stories/atyr-and-kyorin-sign-termination-agreement-ending-japan-efzofitimod-deal-414c412026-09-27monthly0.7 https://app.readthrough.bio/stories/xortx-board-sees-departure-and-new-appointment-within-days-in-july-2026-4159152026-09-28monthly0.7 https://app.readthrough.bio/stories/aldeyra-therapeutics-signs-new-lease-for-concord-massachusetts-47ab5c2026-09-27monthly0.7 https://app.readthrough.bio/stories/moleculin-reports-37-blinded-crc-in-venetoclax-failed-aml-patients-from-49152e2026-09-26monthly0.7 https://app.readthrough.bio/stories/stoke-therapeutics-files-200-million-at-the-market-stock-offering-4b76872026-09-27monthly0.7 https://app.readthrough.bio/stories/keros-reports-second-quarter-2026-results-as-phase-2-rinvatercept-dmd-55306e2026-09-28monthly0.7 https://app.readthrough.bio/stories/datroway-wins-eu-approval-for-first-line-metastatic-tnbc-5c77d42026-09-25monthly0.7 https://app.readthrough.bio/stories/amneal-raises-2026-guidance-reprices-2-084b-term-loan-in-july-5dbcda2026-09-27monthly0.7 https://app.readthrough.bio/stories/compugen-reports-q2-2026-results-cash-runway-extended-into-2029-657d9d2026-09-26monthly0.7 https://app.readthrough.bio/stories/oro-muscles-files-form-d-for-2-million-equity-offering-6a09872026-09-28monthly0.7 https://app.readthrough.bio/stories/silexion-therapeutics-director-amnon-peled-resigns-from-board-6d5b8d2026-09-28monthly0.7 https://app.readthrough.bio/stories/moleculin-prices-9-3m-offering-of-stock-and-warrants-at-0-75-share-7111ca2026-09-28monthly0.7 https://app.readthrough.bio/stories/cue-biopharma-names-james-ahlers-as-chief-financial-officer-72117f2026-09-28monthly0.7 https://app.readthrough.bio/stories/cdt-equity-files-amended-8-k-on-sarborg-limited-investments-76a8762026-09-26monthly0.7 https://app.readthrough.bio/stories/twist-bioscience-posts-record-quarterly-revenue-raises-full-year-78c8e02026-09-28monthly0.7 https://app.readthrough.bio/stories/crescent-biopharma-reports-q2-2026-results-cites-progress-across-pd-1-x-7db6082026-09-28monthly0.7 https://app.readthrough.bio/stories/myriad-genetics-reports-q2-2026-revenue-decline-launches-efficiency-7f6f772026-09-28monthly0.7 https://app.readthrough.bio/stories/supernus-and-indivior-agree-to-all-stock-merger-of-equals-7fc5542026-09-27monthly0.7 https://app.readthrough.bio/stories/newcelx-prices-1-4-million-private-placement-at-20-premium-82a13d2026-09-27monthly0.7 https://app.readthrough.bio/stories/werewolf-reports-q2-2026-results-points-to-wtx-124-and-wtx-330-data-8422b12026-09-27monthly0.7 https://app.readthrough.bio/stories/supernus-and-indivior-agree-to-merge-as-supernus-reports-second-quarter-846a672026-09-27monthly0.7 https://app.readthrough.bio/stories/indivior-and-supernus-agree-to-merge-forming-supernus-inc-85286f2026-09-27monthly0.7 https://app.readthrough.bio/stories/tg-therapeutics-posts-q2-2026-results-raises-briumvi-revenue-guidance-9373df2026-09-28monthly0.7 https://app.readthrough.bio/stories/quince-ceo-thye-and-coo-hannah-file-conditional-resignations-ahead-of-94bfdb2026-09-27monthly0.7 https://app.readthrough.bio/stories/eikon-therapeutics-discloses-two-board-resignations-effective-july-31-99c48c2026-09-28monthly0.7 https://app.readthrough.bio/stories/crinetics-reports-q2-2026-results-alongside-pending-10-billion-vertex-99fa682026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-advisory-panel-votes-against-deramiocel-for-dmd-cardiomyopathy-9-to-9a99972026-09-27monthly0.7 https://app.readthrough.bio/stories/tonix-says-fda-aligns-on-phase-2-design-for-lyme-antibody-tnx-4800-9d455b2026-09-26monthly0.7 https://app.readthrough.bio/stories/inovio-prices-20-million-public-offering-of-stock-and-warrants-9f74682026-09-27monthly0.7 https://app.readthrough.bio/stories/biolife-shares-employee-video-from-repligen-ceo-on-pending-merger-a06cbe2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-advisory-committee-backs-rp1-efficacy-data-in-advanced-melanoma-10-3-a635082026-09-27monthly0.7 https://app.readthrough.bio/stories/lipocine-appoints-michael-grissinger-to-board-of-directors-a74daa2026-09-27monthly0.7 https://app.readthrough.bio/stories/obsidian-therapeutics-completes-merger-with-galera-closes-350-million-a86cad2026-09-27monthly0.7 https://app.readthrough.bio/stories/eton-pharmaceuticals-names-danka-radosavljevic-as-chief-operating-aa610d2026-09-28monthly0.7 https://app.readthrough.bio/stories/vistagen-adds-douglas-j-williamson-to-board-of-directors-ad60be2026-09-27monthly0.7 https://app.readthrough.bio/stories/oric-pharmaceuticals-starts-phase-3-himalayas-1-trial-adds-bayer-supply-b448182026-09-28monthly0.7 https://app.readthrough.bio/stories/alkermes-expands-blair-jackson-s-role-to-president-and-ceo-sets-pay-and-c172b82026-09-28monthly0.7 https://app.readthrough.bio/stories/amneal-repriced-term-loans-cutting-interest-rate-margin-by-50-basis-c3aa122026-09-25monthly0.7 https://app.readthrough.bio/stories/wave-life-sciences-reports-q2-2026-results-advances-obesity-and-aatd-c8940c2026-09-26monthly0.7 https://app.readthrough.bio/stories/ptc-therapeutics-reports-q2-2026-revenue-of-361-million-raises-full-cb184d2026-09-27monthly0.7 https://app.readthrough.bio/stories/opko-health-invests-5-million-more-in-cocrystal-pharma-via-private-cf9e8f2026-09-26monthly0.7 https://app.readthrough.bio/stories/apnimed-prices-ipo-at-16-per-share-ahead-of-nasdaq-debut-cfbf422026-09-27monthly0.7 https://app.readthrough.bio/stories/adlai-nortye-clears-australian-regulatory-steps-for-an4035-phase-i-trial-da4e452026-09-26monthly0.7 https://app.readthrough.bio/stories/ascentage-pharma-names-new-chief-business-officer-and-chief-commercial-db19e32026-09-27monthly0.7 https://app.readthrough.bio/stories/moleculin-biotech-closes-9-3-million-public-offering-with-roth-capital-dd14662026-09-27monthly0.7 https://app.readthrough.bio/stories/immunitybio-wins-uae-authorization-for-anktiva-in-bladder-cancer-and-de6c1e2026-09-26monthly0.7 https://app.readthrough.bio/stories/indivior-and-supernus-agree-to-merger-of-equals-e0bbdc2026-09-26monthly0.7 https://app.readthrough.bio/stories/stoke-reports-full-emperor-enrollment-sets-pre-nda-meeting-and-q1-2027-e628ca2026-09-27monthly0.7 https://app.readthrough.bio/stories/vivosim-labs-files-s-1-to-register-9-4-million-warrant-shares-for-resale-e6f7ae2026-09-27monthly0.7 https://app.readthrough.bio/stories/supernus-and-indivior-detail-merger-of-equals-in-august-3-investor-eb11432026-09-26monthly0.7 https://app.readthrough.bio/stories/lifevantage-board-approves-new-employee-incentive-plan-reserves-1-5-ef25a42026-09-28monthly0.7 https://app.readthrough.bio/stories/design-therapeutics-updates-restore-fa-trial-design-reports-q2-2026-ef5cb52026-09-28monthly0.7 https://app.readthrough.bio/stories/annexon-sets-up-200-million-loan-facility-with-oxford-finance-f9388e2026-09-28monthly0.7 https://app.readthrough.bio/stories/crispr-therapeutics-reports-q2-2026-results-expanded-casgevy-approval-f991432026-09-27monthly0.7 https://app.readthrough.bio/stories/moderna-s-norovirus-vaccine-misses-early-efficacy-bar-flu-shot-nears-f9fcbb2026-09-27monthly0.7 https://app.readthrough.bio/stories/jazz-pharmaceuticals-reports-2q26-results-raises-2026-revenue-guidance-fca0dc2026-09-27monthly0.7 https://app.readthrough.bio/stories/mesoblast-reports-36m-quarterly-ryoncil-revenue-115m-for-first-full-year-fefb002026-09-26monthly0.7 https://app.readthrough.bio/stories/hutchmed-posts-h1-2026-revenue-of-278-3m-as-china-sales-rebound-and-ff886f2026-09-26monthly0.7 https://app.readthrough.bio/stories/kiniksa-raises-2026-arcalyst-guidance-advances-kpl-387-into-phase-3-0087ae2026-09-27monthly0.7 https://app.readthrough.bio/stories/lb-pharmaceuticals-sets-150-million-private-placement-of-stock-and-07fb9c2026-09-27monthly0.7 https://app.readthrough.bio/stories/bnb-plus-corp-ends-cypress-agreements-chairman-to-resign-11d7ea2026-09-28monthly0.7 https://app.readthrough.bio/stories/abcellera-and-vertex-partner-on-t-cell-engagers-for-autoimmune-disease-13b46e2026-09-27monthly0.7 https://app.readthrough.bio/stories/dyne-reports-q2-2026-results-as-fda-accepts-bla-for-z-rostudirsen-14815d2026-09-28monthly0.7 https://app.readthrough.bio/stories/geovax-reports-q2-2026-results-keeps-geo-mva-study-on-track-for-q4-start-198bb82026-09-27monthly0.7 https://app.readthrough.bio/stories/teva-posts-q2-2026-gaap-loss-on-emalex-charge-raises-innovative-brand-1b88372026-09-27monthly0.7 https://app.readthrough.bio/stories/disc-medicine-reports-q2-2026-results-aligns-with-fda-on-bitopertin-1e61db2026-09-28monthly0.7 https://app.readthrough.bio/stories/agios-reports-q2-2026-results-sickle-cell-filing-gets-fda-priority-1f5daa2026-09-28monthly0.7 https://app.readthrough.bio/stories/adaptive-biotechnologies-posts-q2-2026-revenue-growth-plans-immune-1f6a952026-09-27monthly0.7 https://app.readthrough.bio/stories/tvardi-picks-ulcerative-colitis-as-lead-indication-for-tti-109-2598f72026-09-26monthly0.7 https://app.readthrough.bio/stories/neogen-posts-q4-fy26-core-growth-updates-on-petrifilm-shift-and-26ecea2026-09-28monthly0.7 https://app.readthrough.bio/stories/os-therapies-terminates-18-million-at-the-market-stock-sale-agreement-2aa53b2026-09-27monthly0.7 https://app.readthrough.bio/stories/alterity-says-fda-confirmed-registrational-path-for-ath434-in-msa-347bb52026-09-26monthly0.7 https://app.readthrough.bio/stories/anavex-updates-alzheimer-s-regulatory-strategy-reports-q2-fiscal-2026-3ca11b2026-09-28monthly0.7 https://app.readthrough.bio/stories/oric-pharmaceuticals-expands-inducement-equity-plan-by-1-1-million-3d46072026-09-28monthly0.7 https://app.readthrough.bio/stories/neumora-reports-favorable-nmra-215-toxicology-data-still-targets-q4-3edcce2026-09-26monthly0.7 https://app.readthrough.bio/stories/incyte-raises-2026-sales-guidance-adds-ten-data-readouts-closes-vega-3f67382026-09-27monthly0.7 https://app.readthrough.bio/stories/nextpoint-therapeutics-discloses-48-7-million-private-securities-527bb42026-09-28monthly0.7 https://app.readthrough.bio/stories/yarrow-bioscience-closes-vyne-merger-begins-dosing-in-phase-2a-2b-5674ca2026-09-26monthly0.7 https://app.readthrough.bio/stories/neurocrine-reports-q2-2026-results-raises-ingrezza-guidance-cites-2027-580cd82026-09-27monthly0.7 https://app.readthrough.bio/stories/repligen-raises-2026-guidance-after-13-organic-revenue-growth-in-q2-5b08842026-09-28monthly0.7 https://app.readthrough.bio/stories/processa-pharmaceuticals-acquires-vidya-therapeutics-lines-up-200-5c7a7a2026-09-26monthly0.7 https://app.readthrough.bio/stories/bausch-health-raises-2026-guidance-after-second-quarter-revenue-climbs-5e58782026-09-28monthly0.7 https://app.readthrough.bio/stories/biogen-posts-q2-2026-results-sets-five-late-stage-readouts-over-next-605ec42026-09-27monthly0.7 https://app.readthrough.bio/stories/argenx-to-acquire-forte-biosciences-for-77-per-share-in-cash-6458ea2026-09-26monthly0.7 https://app.readthrough.bio/stories/kyverna-and-elevatebio-sign-commercial-supply-deal-for-miv-cel-6a47aa2026-09-27monthly0.7 https://app.readthrough.bio/stories/camp4-gets-australian-clearance-to-start-cmp-002-trial-in-syngap1-6ae98f2026-09-28monthly0.7 https://app.readthrough.bio/stories/amarin-posts-q2-2026-results-as-international-partner-sales-grow-us-71afbf2026-09-28monthly0.7 https://app.readthrough.bio/stories/silexion-activates-first-site-for-sil204-pancreatic-cancer-trial-in-7354222026-09-26monthly0.7 https://app.readthrough.bio/stories/lite-strategy-buys-back-13-of-shares-since-december-boosting-litecoin-79d62b2026-09-28monthly0.7 https://app.readthrough.bio/stories/phathom-to-start-phase-3-as-needed-voquezna-trial-in-q4-2026-7b604d2026-09-28monthly0.7 https://app.readthrough.bio/stories/ionis-posts-q2-2026-results-flags-second-half-pipeline-milestones-7bb7b72026-09-27monthly0.7 https://app.readthrough.bio/stories/onconetix-arranges-30-25-million-pipe-financing-and-750-million-equity-7f8eac2026-09-27monthly0.7 https://app.readthrough.bio/stories/astrazeneca-s-ultomiris-misses-main-goal-in-adult-hsct-tma-trial-7f9bb82026-09-25monthly0.7 https://app.readthrough.bio/stories/contineum-reports-q2-2026-results-affirms-ipf-and-mdd-trial-timelines-7fb6be2026-09-27monthly0.7 https://app.readthrough.bio/stories/viking-reports-q2-2026-results-vanquish-trials-fully-enrolled-oral-84d0232026-09-28monthly0.7 https://app.readthrough.bio/stories/xencor-to-receive-105-million-from-alexion-to-settle-ultomiris-royalty-86977f2026-09-27monthly0.7 https://app.readthrough.bio/stories/kura-oncology-updates-severance-terms-for-ceo-and-two-other-executives-8928ef2026-09-28monthly0.7 https://app.readthrough.bio/stories/standard-biotools-agrees-to-sell-mass-cytometry-unit-gets-30m-illumina-8c6bac2026-09-26monthly0.7 https://app.readthrough.bio/stories/sellas-loses-arbitration-against-3d-medicines-over-gps-milestone-dispute-8e123c2026-09-28monthly0.7 https://app.readthrough.bio/stories/phibro-animal-health-declares-quarterly-dividend-of-0-12-per-share-9460622026-09-28monthly0.7 https://app.readthrough.bio/stories/corcept-raises-2026-revenue-guidance-to-1-1-1-2-billion-after-lifyorli-9951312026-09-27monthly0.7 https://app.readthrough.bio/stories/eton-pharmaceuticals-submits-fda-supplement-to-expand-khindivi-to-9a03f12026-09-26monthly0.7 https://app.readthrough.bio/stories/alnylam-cuts-2026-ttr-revenue-outlook-advances-alzheimer-s-and-rare-9b9c2b2026-09-27monthly0.7 https://app.readthrough.bio/stories/tuhura-biosciences-draws-1-5-million-more-under-parkview-credit-facility-9d9f6b2026-09-28monthly0.7 https://app.readthrough.bio/stories/opko-reports-q2-2026-results-with-multiple-pipeline-milestones-across-a029bb2026-09-27monthly0.7 https://app.readthrough.bio/stories/maplight-s-ml-007c-ma-hits-primary-endpoint-in-phase-2-schizophrenia-a2317a2026-09-26monthly0.7 https://app.readthrough.bio/stories/enlivex-to-hold-webinar-on-400-million-placement-rain-treasury-and-a2dd212026-09-28monthly0.7 https://app.readthrough.bio/stories/nasus-pharma-names-brendan-p-o-grady-ceo-succeeding-dan-teleman-a3ae772026-09-27monthly0.7 https://app.readthrough.bio/stories/bicara-therapeutics-adds-two-directors-sees-founding-board-member-retire-a3d4e42026-09-27monthly0.7 https://app.readthrough.bio/stories/iqvia-raises-2026-guidance-after-strong-second-quarter-bookings-and-a526b02026-09-28monthly0.7 https://app.readthrough.bio/stories/hansoh-s-ris-rez-hits-pfs-endpoint-in-second-phase-iii-osteosarcoma-a5b9f92026-09-26monthly0.7 https://app.readthrough.bio/stories/jupiter-neurosciences-sells-3-6m-in-stock-to-yorkville-under-equity-line-a70b162026-09-28monthly0.7 https://app.readthrough.bio/stories/sonavex-files-form-d-for-15-million-equity-offering-a79b972026-09-28monthly0.7 https://app.readthrough.bio/stories/polypid-s-d-plex100-nda-accepted-with-priority-review-pdufa-date-set-a907542026-09-28monthly0.7 https://app.readthrough.bio/stories/entera-bio-raises-275-million-in-private-placement-led-by-bvf-partners-a9e1f22026-09-28monthly0.7 https://app.readthrough.bio/stories/uniqure-reaffirms-q3-2026-bla-plans-for-amt-130-in-huntington-s-disease-ade82b2026-09-28monthly0.7 https://app.readthrough.bio/stories/lancet-publishes-capricor-s-hope-3-data-as-fda-review-continues-b53f962026-09-26monthly0.7 https://app.readthrough.bio/stories/bioharvest-sciences-to-present-at-canaccord-genuity-growth-conference-ba68e92026-09-28monthly0.7 https://app.readthrough.bio/stories/nrc-health-posts-11-trcv-growth-in-q2-2026-but-net-loss-on-stock-baff962026-09-28monthly0.7 https://app.readthrough.bio/stories/inovio-discloses-preliminary-cash-of-36-7-million-as-of-june-30-2026-bcde4b2026-09-28monthly0.7 https://app.readthrough.bio/stories/vericel-raises-2026-revenue-guidance-launches-200-million-buyback-beee3e2026-09-28monthly0.7 https://app.readthrough.bio/stories/change-agents-corporation-refinances-loan-adds-10m-equity-line-c1494c2026-09-28monthly0.7 https://app.readthrough.bio/stories/bicycle-therapeutics-reports-q2-2026-pipeline-progress-cash-into-2030-c1cc312026-09-28monthly0.7 https://app.readthrough.bio/stories/madrigal-advances-mgl-2086-into-phase-1-adds-resmetirom-patents-posts-ce7fb52026-09-27monthly0.7 https://app.readthrough.bio/stories/hcw-biologics-prices-1-6-million-private-placement-offering-d7fc1a2026-09-28monthly0.7 https://app.readthrough.bio/stories/precision-biosciences-promotes-cfo-to-coo-names-new-cfo-effective-dd9c742026-09-26monthly0.7 https://app.readthrough.bio/stories/cdt-equity-issues-32-110-shares-to-consultant-for-services-ddb1ea2026-09-28monthly0.7 https://app.readthrough.bio/stories/immuron-details-fy26-sales-growth-and-pipeline-partnering-plan-in-ddfa542026-09-26monthly0.7 https://app.readthrough.bio/stories/biostem-technologies-files-s-1-for-resale-of-up-to-3-57-million-shares-de1de82026-09-28monthly0.7 https://app.readthrough.bio/stories/relmada-names-bipin-dalmia-as-chief-business-officer-e55a642026-09-27monthly0.7 https://app.readthrough.bio/stories/filana-therapeutics-still-under-fda-clinical-hold-on-simufilam-trial-eb4bd82026-09-28monthly0.7 https://app.readthrough.bio/stories/nanoviricides-prices-3-85-million-registered-direct-offering-at-1-53-ec0e1e2026-09-26monthly0.7 https://app.readthrough.bio/stories/inhibikase-swaps-ra-capital-s-common-shares-for-pre-funded-warrant-f0b2642026-09-25monthly0.7 https://app.readthrough.bio/stories/j-j-closes-1-billion-acquisition-of-firefly-bio-f2f4db2026-09-26monthly0.7 https://app.readthrough.bio/stories/radiopharm-theranostics-prices-4-05-million-ads-offering-adds-atm-f4a2dd2026-09-28monthly0.7 https://app.readthrough.bio/stories/alkermes-names-blair-jackson-ceo-effective-august-1-as-pipeline-f5bec52026-09-27monthly0.7 https://app.readthrough.bio/stories/bristol-myers-squibb-raises-2026-guidance-after-second-quarter-revenue-fbc4442026-09-25monthly0.7 https://app.readthrough.bio/stories/glucotrack-amends-note-exchange-terms-changes-minimum-price-calculation-fda19d2026-09-28monthly0.7 https://app.readthrough.bio/stories/innate-pharma-completes-enrollment-in-phase-1-study-of-nectin-4-adc-07c4e32026-09-26monthly0.7 https://app.readthrough.bio/stories/apollomics-adds-new-director-after-two-board-members-resign-17b3af2026-09-26monthly0.7 https://app.readthrough.bio/stories/tybr-health-discloses-14-35-million-raised-in-ongoing-equity-offering-18165e2026-09-28monthly0.7 https://app.readthrough.bio/stories/digital-ether-computing-files-form-d-for-2-million-safe-offering-22d2282026-09-28monthly0.7 https://app.readthrough.bio/stories/incannex-begins-screening-patients-in-phase-2-sleep-apnea-trial-of-ihl-23121f2026-09-27monthly0.7 https://app.readthrough.bio/stories/cingulate-eliminates-chief-legal-officer-role-patel-to-depart-in-august-24045a2026-09-28monthly0.7 https://app.readthrough.bio/stories/dyne-therapeutics-prices-upsized-375-million-stock-offering-at-20-50-a-259b842026-09-28monthly0.7 https://app.readthrough.bio/stories/newamsterdam-and-menarini-get-positive-eu-chmp-opinion-for-obicetrapib-27c72a2026-09-27monthly0.7 https://app.readthrough.bio/stories/astrazeneca-s-etcamah-wins-eu-approval-for-1st-line-er-breast-cancer-318e4e2026-09-25monthly0.7 https://app.readthrough.bio/stories/radiopharm-reports-confirmed-partial-response-in-phase-1-trial-of-rad204-31e3602026-09-26monthly0.7 https://app.readthrough.bio/stories/summit-therapeutics-launches-380-million-at-the-market-stock-offering-339a7b2026-09-27monthly0.7 https://app.readthrough.bio/stories/china-pharma-holdings-prices-5-million-registered-direct-offering-at-2-3c13152026-09-28monthly0.7 https://app.readthrough.bio/stories/newamsterdam-pharma-s-coo-kling-to-resign-take-ceo-role-elsewhere-4bc30c2026-09-28monthly0.7 https://app.readthrough.bio/stories/helus-pharma-completes-enrollment-in-phase-3-approach-study-of-hlp003-4d92a52026-09-26monthly0.7 https://app.readthrough.bio/stories/pds-biotechnology-registers-shares-tied-to-ya-ii-pn-note-and-warrant-50f2212026-09-28monthly0.7 https://app.readthrough.bio/stories/champions-oncology-posts-record-59-4-million-fiscal-2026-revenue-5195382026-09-28monthly0.7 https://app.readthrough.bio/stories/okyo-pharma-executives-buy-shares-on-nasdaq-over-two-days-in-july-2026-52218f2026-09-28monthly0.7 https://app.readthrough.bio/stories/scribe-therapeutics-prices-128-7-million-ipo-at-15-per-share-57ad072026-09-27monthly0.7 https://app.readthrough.bio/stories/vyne-approves-1-for-50-reverse-split-sets-special-dividend-ahead-of-5b36ed2026-09-26monthly0.7 https://app.readthrough.bio/stories/scilex-agrees-to-sell-vivasor-preferred-stock-back-for-approximately-12-5b61ef2026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-accepts-bridgebio-s-nda-for-encaleret-in-adh1-5c5b7d2026-09-27monthly0.7 https://app.readthrough.bio/stories/bioaffinity-technologies-partners-with-pictor-on-asthma-and-copd-62202b2026-09-27monthly0.7 https://app.readthrough.bio/stories/imagenebio-names-yanina-grant-huerta-as-cfo-effective-july-20-2026-6355212026-09-27monthly0.7 https://app.readthrough.bio/stories/jupiter-neurosciences-signs-u-s-license-deal-with-pharmala-for-ala-002-66f77e2026-09-27monthly0.7 https://app.readthrough.bio/stories/matinas-biopharma-s-at-the-market-sales-pact-with-btig-terminated-69b7eb2026-09-27monthly0.7 https://app.readthrough.bio/stories/serina-names-trevi-executive-farrell-simon-to-board-days-after-amending-69dda42026-09-27monthly0.7 https://app.readthrough.bio/stories/trinity-biotech-to-implement-30-for-1-ads-ratio-change-6fe24f2026-09-28monthly0.7 https://app.readthrough.bio/stories/outlook-therapeutics-grants-options-and-bonuses-tied-to-ons-5010-bla-70dc9b2026-09-28monthly0.7 https://app.readthrough.bio/stories/gossamer-bio-reacquires-worldwide-seralutinib-rights-from-chiesi-7179f62026-09-28monthly0.7 https://app.readthrough.bio/stories/dr-reddy-s-records-rs-2-397-million-provision-for-out-of-spec-73f4582026-09-27monthly0.7 https://app.readthrough.bio/stories/repligen-to-acquire-biolife-solutions-for-about-1-5-billion-7692022026-09-28monthly0.7 https://app.readthrough.bio/stories/mannkind-raises-50-million-in-private-placement-tied-to-furoscix-7fbeec2026-09-28monthly0.7 https://app.readthrough.bio/stories/kala-bio-files-for-up-to-250-million-at-the-market-stock-offering-8407fd2026-09-28monthly0.7 https://app.readthrough.bio/stories/cue-biopharma-discloses-49-99-million-private-securities-offering-88f1e02026-09-28monthly0.7 https://app.readthrough.bio/stories/mentari-therapeutics-adds-200-million-private-placement-ahead-of-inmed-8a03a92026-09-28monthly0.7 https://app.readthrough.bio/stories/alterity-therapeutics-ceo-to-attend-btig-biotechnology-conference-2026-8c58af2026-09-28monthly0.7 https://app.readthrough.bio/stories/outlook-therapeutics-wins-fda-approval-for-lytenava-in-wet-amd-8cde432026-09-26monthly0.7 https://app.readthrough.bio/stories/fda-grants-orphan-drug-status-to-inhibikase-s-ikt-001-for-pah-8d82a02026-09-25monthly0.7 https://app.readthrough.bio/stories/corvus-pharmaceuticals-board-member-ian-t-clark-to-resign-effective-8fe4802026-09-28monthly0.7 https://app.readthrough.bio/stories/tonix-pharmaceuticals-cmo-gregory-sullivan-to-retire-in-august-2026-942e3c2026-09-28monthly0.7 https://app.readthrough.bio/stories/united-therapeutics-names-victor-dzau-to-board-of-directors-94de612026-09-25monthly0.7 https://app.readthrough.bio/stories/summit-therapeutics-sets-up-380-million-at-the-market-stock-sale-program-9aca202026-09-27monthly0.7 https://app.readthrough.bio/stories/lisata-terminates-kuva-labs-merger-after-failed-financing-for-tender-a544de2026-09-27monthly0.7 https://app.readthrough.bio/stories/phio-pharmaceuticals-adds-dermatologist-r-todd-plott-to-board-a5b6e32026-09-28monthly0.7 https://app.readthrough.bio/stories/medpace-reports-second-quarter-2026-revenue-of-707-3-million-raises-a6be372026-09-28monthly0.7 https://app.readthrough.bio/stories/china-sxt-pharmaceuticals-prices-9-million-registered-direct-offering-a82c012026-09-28monthly0.7 https://app.readthrough.bio/stories/polaryx-therapeutics-chief-medical-officer-resigns-effective-immediately-abd4c62026-09-28monthly0.7 https://app.readthrough.bio/stories/tempest-partners-with-senlang-on-cd7-targeted-in-vivo-car-t-for-ac9daa2026-09-27monthly0.7 https://app.readthrough.bio/stories/angelis-oncology-files-form-d-for-debt-offering-under-rule-506-b-ae2df12026-09-28monthly0.7 https://app.readthrough.bio/stories/trinity-biotech-and-latch-medical-partner-on-biosensor-guided-drug-ae94062026-09-27monthly0.7 https://app.readthrough.bio/stories/faeth-therapeutics-grants-performance-stock-options-to-three-executives-ba21712026-09-28monthly0.7 https://app.readthrough.bio/stories/supernus-sets-august-4-date-for-second-quarter-2026-results-ba4bf22026-09-28monthly0.7 https://app.readthrough.bio/stories/vir-biotechnology-cfo-jason-o-byrne-to-depart-interim-replacement-named-bb64042026-09-26monthly0.7 https://app.readthrough.bio/stories/repligen-agrees-to-acquire-biolife-solutions-in-deal-valued-around-1-5-bb7da02026-09-26monthly0.7 https://app.readthrough.bio/stories/gsk-wins-us-approval-for-jideytro-in-previously-treated-ros1-positive-be20be2026-09-26monthly0.7 https://app.readthrough.bio/stories/polypid-partners-with-azurity-to-commercialize-d-plex100-in-u-s-and-c3f0712026-09-28monthly0.7 https://app.readthrough.bio/stories/summit-reports-q2-2026-results-as-harmoni-os-data-hold-up-in-western-d087722026-09-26monthly0.7 https://app.readthrough.bio/stories/lb-pharmaceuticals-moves-up-nova-2-schizophrenia-trial-readout-to-first-da37532026-09-26monthly0.7 https://app.readthrough.bio/stories/scancell-to-merge-with-neuphoria-and-list-on-nasdaq-plans-up-to-89-db5f8c2026-09-27monthly0.7 https://app.readthrough.bio/stories/macrogenics-posts-phase-1-update-on-b7-h3-adc-mgc026-ahead-of-esmo-2026-e1e14b2026-09-26monthly0.7 https://app.readthrough.bio/stories/kairos-pharma-signs-research-agreement-with-bayer-to-test-env-105-with-e42c6f2026-09-26monthly0.7 https://app.readthrough.bio/stories/keros-therapeutics-cfo-keith-regnante-resigns-interim-replacement-named-ea5b7f2026-09-28monthly0.7 https://app.readthrough.bio/stories/innate-pharma-to-join-bladder-cancer-panel-at-btig-conference-f5db722026-09-27monthly0.7 https://app.readthrough.bio/stories/armata-pharmaceuticals-names-david-house-chief-financial-officer-01dc162026-09-28monthly0.7 https://app.readthrough.bio/stories/silence-therapeutics-discloses-separation-terms-for-craig-tooman-in-0892852026-09-28monthly0.7 https://app.readthrough.bio/stories/virax-biolabs-details-fiscal-2026-finances-fosun-supply-deal-nasdaq-09c96d2026-09-28monthly0.7 https://app.readthrough.bio/stories/blossomhill-therapeutics-files-s-1-for-ipo-on-nasdaq-under-blsm-09d7ad2026-09-27monthly0.7 https://app.readthrough.bio/stories/latigo-biotherapeutics-files-for-ipo-on-nasdaq-under-ticker-ltgo-0a21522026-09-27monthly0.7 https://app.readthrough.bio/stories/inhibrx-biosciences-expands-oxford-finance-credit-facility-to-500-0e98582026-09-27monthly0.7 https://app.readthrough.bio/stories/regenxbio-prices-100-million-stock-offering-at-9-00-per-share-1007b82026-09-27monthly0.7 https://app.readthrough.bio/stories/cardiff-oncology-prices-10-million-registered-direct-offering-116a2a2026-09-27monthly0.7 https://app.readthrough.bio/stories/veradermics-reports-positive-phase-2-data-for-oral-vdphl01-in-female-1979622026-09-26monthly0.7 https://app.readthrough.bio/stories/damora-therapeutics-completes-move-from-delaware-to-cayman-islands-1cdf392026-09-27monthly0.7 https://app.readthrough.bio/stories/can-fite-says-phase-2a-pancreatic-cancer-data-accepted-for-esmo-2ec0872026-09-26monthly0.7 https://app.readthrough.bio/stories/aditxt-amends-note-purchase-deal-with-ignite-proteomics-subsidiary-again-33b9ed2026-09-28monthly0.7 https://app.readthrough.bio/stories/vivosim-prices-4-0-million-private-placement-with-single-institutional-3ff22c2026-09-28monthly0.7 https://app.readthrough.bio/stories/karyopharm-sets-up-2026-cash-retention-program-for-top-executives-4308ab2026-09-27monthly0.7 https://app.readthrough.bio/stories/adlai-nortye-doses-first-patient-in-weekly-dosing-arm-of-an9025-phase-1-4403482026-09-26monthly0.7 https://app.readthrough.bio/stories/tvardi-therapeutics-files-for-up-to-9-7-million-more-in-at-the-market-4618812026-09-28monthly0.7 https://app.readthrough.bio/stories/kalaris-reports-expanded-phase-1a-data-for-th103-in-wet-amd-4ba16b2026-09-26monthly0.7 https://app.readthrough.bio/stories/insmed-reports-12-month-ole-data-for-tpip-in-pulmonary-arterial-4c1e8b2026-09-25monthly0.7 https://app.readthrough.bio/stories/jasper-therapeutics-completes-all-stock-merger-with-kira-4e76342026-09-27monthly0.7 https://app.readthrough.bio/stories/galmed-unveils-lnp-cardiac-targeted-aramchol-formulation-with-barcode-509a512026-09-27monthly0.7 https://app.readthrough.bio/stories/aeon-biopharma-closes-13-75-million-offering-with-attached-milestone-58a2262026-09-28monthly0.7 https://app.readthrough.bio/stories/sunshine-biopharma-files-4-million-at-the-market-stock-offering-with-5e650b2026-09-28monthly0.7 https://app.readthrough.bio/stories/cardiff-oncology-prices-10-05-million-gross-stock-and-warrant-offering-635eef2026-09-28monthly0.7 https://app.readthrough.bio/stories/nanoviricides-sets-up-at-the-market-stock-offering-with-d-boral-capital-6508392026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-accepts-axsome-s-nda-for-axs-12-in-narcolepsy-cataplexy-6771822026-09-27monthly0.7 https://app.readthrough.bio/stories/harmony-biosciences-preannounces-record-q2-2026-revenue-cfo-steps-down-69c1832026-09-28monthly0.7 https://app.readthrough.bio/stories/dbv-technologies-pushes-peanut-patch-bla-filing-to-third-quarter-of-2026-7005662026-09-28monthly0.7 https://app.readthrough.bio/stories/optimi-health-ceo-dane-stevens-buys-18-700-shares-in-mid-july-trades-70e68b2026-09-28monthly0.7 https://app.readthrough.bio/stories/mesoblast-ceo-itescu-exercises-options-boosting-stake-to-over-80-8-774a4e2026-09-28monthly0.7 https://app.readthrough.bio/stories/propanc-biopharma-files-s-1-to-register-2-5-million-resale-shares-for-78743d2026-09-27monthly0.7 https://app.readthrough.bio/stories/xeris-completes-exchange-of-2028-convertible-notes-eliminates-them-from-824afc2026-09-28monthly0.7 https://app.readthrough.bio/stories/gsk-completes-acquisition-of-nuvalent-for-10-6-billion-940d522026-09-26monthly0.7 https://app.readthrough.bio/stories/senti-biosciences-to-spin-off-senti-202-pipeline-to-celadon-affiliate-9628b12026-09-27monthly0.7 https://app.readthrough.bio/stories/arbutus-sues-pfizer-and-biontech-abroad-gets-178m-from-moderna-deal-96b2a42026-09-27monthly0.7 https://app.readthrough.bio/stories/valion-bio-files-s-1-for-offering-of-up-to-29-4-million-shares-and-99b6052026-09-28monthly0.7 https://app.readthrough.bio/stories/ars-pharmaceuticals-board-member-resigns-chief-medical-officer-departs-a189fe2026-09-28monthly0.7 https://app.readthrough.bio/stories/elutia-to-sell-simpliderm-business-to-cellution-biologics-for-up-to-11-a5e7212026-09-27monthly0.7 https://app.readthrough.bio/stories/novabridge-biosciences-adopts-2026-omnibus-share-incentive-plan-a7579a2026-09-28monthly0.7 https://app.readthrough.bio/stories/quantum-cyber-closes-purchase-of-bridgeport-manufacturing-facility-b215012026-09-26monthly0.7 https://app.readthrough.bio/stories/entera-bio-holds-annual-meeting-expands-share-pool-and-authorized-shares-b2d5672026-09-28monthly0.7 https://app.readthrough.bio/stories/evaxion-to-unveil-three-year-evx-01-melanoma-data-at-esmo-2026-b313772026-09-26monthly0.7 https://app.readthrough.bio/stories/q32-bio-prices-public-offering-expects-about-187-6-million-in-net-b332832026-09-27monthly0.7 https://app.readthrough.bio/stories/organigram-updates-on-sanity-group-s-initial-performance-and-canadian-b51ee82026-09-26monthly0.7 https://app.readthrough.bio/stories/oncolytics-wins-fda-fast-track-for-pelareorep-in-second-line-anal-cancer-b6ec552026-09-27monthly0.7 https://app.readthrough.bio/stories/arcutis-adds-mirum-ceo-chris-peetz-to-board-of-directors-c209842026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-new-efficacy-supplement-for-novartis-s-fabhalta-c2f1912026-09-25monthly0.7 https://app.readthrough.bio/stories/gsk-halts-camlipixant-development-in-refractory-chronic-cough-after-ca61152026-09-26monthly0.7 https://app.readthrough.bio/stories/cdt-equity-approves-1-for-10-reverse-stock-split-effective-july-17-d09d632026-09-26monthly0.7 https://app.readthrough.bio/stories/calidi-biotherapeutics-signs-new-san-diego-lease-ends-current-one-early-d130762026-09-27monthly0.7 https://app.readthrough.bio/stories/molecular-partners-reports-progress-in-phase-2-tactic-trial-of-mp0317-d699db2026-09-26monthly0.7 https://app.readthrough.bio/stories/biovie-files-s-1-for-stock-offering-discloses-phase-2b-parkinson-s-dfb9202026-09-27monthly0.7 https://app.readthrough.bio/stories/armata-reports-fda-submissions-complete-ahead-of-ap-sa02-phase-3-e051152026-09-26monthly0.7 https://app.readthrough.bio/stories/gyre-therapeutics-adds-three-directors-to-board-effective-august-1-2026-e361b42026-09-27monthly0.7 https://app.readthrough.bio/stories/abbott-raises-2026-eps-guidance-reports-pipeline-progress-across-device-e4dac12026-09-27monthly0.7 https://app.readthrough.bio/stories/kalaris-therapeutics-names-liisa-bayko-as-chief-financial-officer-e71f3d2026-09-28monthly0.7 https://app.readthrough.bio/stories/nanoviricides-files-4-million-at-the-market-stock-offering-with-d-boral-e9b2ca2026-09-28monthly0.7 https://app.readthrough.bio/stories/scisparc-s-neurothera-opens-german-phase-iib-site-for-tourette-drug-sci-ec48ab2026-09-26monthly0.7 https://app.readthrough.bio/stories/jasper-therapeutics-completes-all-stock-merger-with-kira-pharmaceuticals-f237012026-09-26monthly0.7 https://app.readthrough.bio/stories/prestige-brands-issues-400-million-in-senior-notes-due-2034-f8254e2026-09-27monthly0.7 https://app.readthrough.bio/stories/cadrenal-therapeutics-enters-separation-agreement-with-departing-cmo-f9326f2026-09-28monthly0.7 https://app.readthrough.bio/stories/sunshine-biopharma-sets-up-4-million-at-the-market-stock-sale-facility-ff6c7c2026-09-27monthly0.7 https://app.readthrough.bio/stories/propanc-biopharma-board-member-departs-accountant-carlo-campiciano-05183a2026-09-28monthly0.7 https://app.readthrough.bio/stories/traws-pharma-files-prospectus-supplement-for-up-to-5-58-million-at-the-051fbe2026-09-28monthly0.7 https://app.readthrough.bio/stories/sunshine-biopharma-settles-dispute-with-former-nora-pharma-president-06faf12026-09-27monthly0.7 https://app.readthrough.bio/stories/mesoblast-enrolls-300th-patient-in-phase-3-back-pain-trial-of-0a3ff12026-09-26monthly0.7 https://app.readthrough.bio/stories/os-therapies-files-form-d-for-debt-offering-worth-up-to-9-25-million-0da8d92026-09-28monthly0.7 https://app.readthrough.bio/stories/sanuwave-preliminary-q2-2026-revenue-tops-raised-guidance-range-13ae0b2026-09-28monthly0.7 https://app.readthrough.bio/stories/cellectar-shareholders-back-share-plan-increase-and-warrant-exercise-18545a2026-09-28monthly0.7 https://app.readthrough.bio/stories/q32-bio-reports-positive-phase-2a-bempikibart-results-in-alopecia-areata-1982b42026-09-26monthly0.7 https://app.readthrough.bio/stories/crescent-biopharma-prices-117-5-million-public-offering-of-shares-and-1b477b2026-09-27monthly0.7 https://app.readthrough.bio/stories/vera-therapeutics-names-new-chief-regulatory-officer-1fb37d2026-09-27monthly0.7 https://app.readthrough.bio/stories/revelation-biosciences-adopts-stockholder-rights-plan-21626d2026-09-28monthly0.7 https://app.readthrough.bio/stories/pliant-therapeutics-expands-board-adds-two-independent-directors-255f022026-09-28monthly0.7 https://app.readthrough.bio/stories/crescent-biopharma-reports-about-171-6-million-in-cash-as-of-june-30-26939a2026-09-28monthly0.7 https://app.readthrough.bio/stories/cardiol-s-phase-ii-pericarditis-data-published-in-jaha-as-phase-iii-32514b2026-09-25monthly0.7 https://app.readthrough.bio/stories/inmed-and-mentari-amend-merger-agreement-file-form-s-4-32e6052026-09-26monthly0.7 https://app.readthrough.bio/stories/ligand-closes-739-million-acquisition-of-xoma-royalty-34973b2026-09-26monthly0.7 https://app.readthrough.bio/stories/fda-approves-sarclisa-escena-a-new-dosage-form-from-sanofi-3788e12026-09-25monthly0.7 https://app.readthrough.bio/stories/cervomed-presents-new-neflamapimod-data-at-aaic-backs-50-mg-dose-for-3bd27d2026-09-26monthly0.7 https://app.readthrough.bio/stories/cullgen-discloses-2025-results-and-merger-deal-with-gyre-therapeutics-3c50ef2026-09-28monthly0.7 https://app.readthrough.bio/stories/silo-pharma-closes-4-million-private-placement-priced-at-the-market-3f49a02026-09-28monthly0.7 https://app.readthrough.bio/stories/alto-neuroscience-prices-93-9-million-stock-offering-to-fund-alto-207-41011b2026-09-27monthly0.7 https://app.readthrough.bio/stories/immutep-reports-30-9-month-median-survival-in-phase-i-nsclc-combination-5094422026-09-26monthly0.7 https://app.readthrough.bio/stories/jaguar-health-files-two-s-1s-to-register-up-to-46-3-million-resale-50fb7d2026-09-27monthly0.7 https://app.readthrough.bio/stories/astrazeneca-and-ionis-report-wainua-misses-primary-endpoint-in-cardio-5285aa2026-09-25monthly0.7 https://app.readthrough.bio/stories/amphastar-expands-board-adds-anthony-pierce-as-director-59388c2026-09-28monthly0.7 https://app.readthrough.bio/stories/edgewise-completes-sale-of-sevasemten-to-servier-refocuses-on-5b821c2026-09-25monthly0.7 https://app.readthrough.bio/stories/celldex-cfo-sam-martin-to-retire-in-march-2027-5ff0572026-09-28monthly0.7 https://app.readthrough.bio/stories/omniab-names-amechi-nwachuku-as-chief-operating-officer-6235e22026-09-27monthly0.7 https://app.readthrough.bio/stories/cue-biopharma-raises-50-million-in-private-placement-of-stock-and-62f36f2026-09-28monthly0.7 https://app.readthrough.bio/stories/alto-neuroscience-plans-added-phase-3-trial-for-depression-drug-alto-207-633de42026-09-28monthly0.7 https://app.readthrough.bio/stories/cadrenal-therapeutics-discloses-form-d-for-completed-private-placement-64bc282026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-subcutaneous-sarclisa-escena-with-on-body-injector-for-7053bb2026-09-25monthly0.7 https://app.readthrough.bio/stories/inventiva-completes-eib-warrant-restructuring-issues-new-warrants-to-72e4c82026-09-26monthly0.7 https://app.readthrough.bio/stories/lakefront-board-member-fontoura-resigns-after-sanofi-names-him-r-d-chief-7348652026-09-27monthly0.7 https://app.readthrough.bio/stories/nurix-strikes-2-3-billion-roche-pact-for-btk-degrader-bexobrutideg-7397d92026-09-27monthly0.7 https://app.readthrough.bio/stories/ionis-and-astrazeneca-s-eplontersen-misses-primary-endpoint-in-phase-3-7afa8f2026-09-25monthly0.7 https://app.readthrough.bio/stories/gossamer-bio-stockholders-approve-charter-amendment-incentive-plan-7ccdce2026-09-28monthly0.7 https://app.readthrough.bio/stories/pmgc-subsidiary-northstrive-defense-tech-secures-exclusive-license-tied-7d1c092026-09-27monthly0.7 https://app.readthrough.bio/stories/capricor-signs-lease-for-new-san-diego-headquarters-tied-to-fda-action-8197e02026-09-27monthly0.7 https://app.readthrough.bio/stories/cellular-logistics-files-form-d-for-100-000-convertible-note-offering-84055a2026-09-28monthly0.7 https://app.readthrough.bio/stories/glucotrack-completes-business-combination-with-l-kahi-therapeutics-8572b12026-09-27monthly0.7 https://app.readthrough.bio/stories/decoy-therapeutics-files-s-1-to-register-3-77-million-shares-from-8ec1ec2026-09-27monthly0.7 https://app.readthrough.bio/stories/j-j-raises-2026-sales-and-eps-guidance-after-strong-q2-results-8ffa9e2026-09-27monthly0.7 https://app.readthrough.bio/stories/apnimed-files-for-ipo-as-fda-reviews-oxnimbi-nda-for-sleep-apnea-93f4d62026-09-27monthly0.7 https://app.readthrough.bio/stories/nextcure-and-avere-therapeutics-agree-to-all-stock-merger-320-million-9560fd2026-09-28monthly0.7 https://app.readthrough.bio/stories/attovia-therapeutics-files-s-1-for-ipo-on-nasdaq-under-ticker-atto-9c3c022026-09-27monthly0.7 https://app.readthrough.bio/stories/tarsus-pharmaceuticals-chief-commercial-officer-to-depart-july-15-a17c3c2026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-supplement-7-for-eli-lilly-s-retevmo-selpercatinib-a20b0f2026-09-25monthly0.7 https://app.readthrough.bio/stories/cybin-discloses-two-form-d-filings-for-stock-options-and-rsus-b192712026-09-28monthly0.7 https://app.readthrough.bio/stories/erasca-prices-550-million-stock-offering-at-17-50-per-share-b69ff92026-09-28monthly0.7 https://app.readthrough.bio/stories/alto-neuroscience-prices-100-million-stock-offering-nets-93-9-million-b9d26e2026-09-27monthly0.7 https://app.readthrough.bio/stories/metavia-completes-dose-titration-in-phase-1-obesity-trial-of-da-1726-bda3612026-09-26monthly0.7 https://app.readthrough.bio/stories/cingulate-holds-annual-meeting-restructures-board-expands-equity-plan-bf11ab2026-09-28monthly0.7 https://app.readthrough.bio/stories/agenus-secures-up-to-340-million-to-fund-phase-3-robbin-trial-in-mss-c2a5382026-09-26monthly0.7 https://app.readthrough.bio/stories/q32-bio-prices-200-million-stock-offering-cites-signal-aa-part-b-data-c484f82026-09-27monthly0.7 https://app.readthrough.bio/stories/vaxcyte-board-sees-director-change-as-lukatch-retires-markels-joins-c640622026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-efficacy-related-supplement-for-eli-lilly-s-verzenio-c95d602026-09-25monthly0.7 https://app.readthrough.bio/stories/longeveron-names-marie-washburn-as-cfo-revises-ceo-pay-grants-executive-c998442026-09-25monthly0.7 https://app.readthrough.bio/stories/spero-licenses-anti-cd40l-antibody-sp001-from-innovent-in-deal-worth-up-cbce102026-09-27monthly0.7 https://app.readthrough.bio/stories/clearmind-reports-investigator-update-on-cmnd-100-trial-for-alcohol-use-ce508d2026-09-26monthly0.7 https://app.readthrough.bio/stories/jaguar-health-s-napo-signs-new-crofelemer-supply-deal-with-alivus-after-d4f40c2026-09-27monthly0.7 https://app.readthrough.bio/stories/ensysce-biosciences-chief-operating-officer-resigns-effective-july-10-d5aff42026-09-28monthly0.7 https://app.readthrough.bio/stories/vogenx-files-for-ipo-plans-nasdaq-listing-under-vogx-d635532026-09-27monthly0.7 https://app.readthrough.bio/stories/avalon-globocare-files-s-1-for-stock-and-warrant-offering-amid-nasdaq-e10c202026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-approves-efficacy-supplement-for-eli-lilly-s-retevmo-selpercatinib-e468b42026-09-25monthly0.7 https://app.readthrough.bio/stories/mbx-biosciences-names-steven-hoerter-ceo-as-kent-hawryluk-departs-e703f22026-09-28monthly0.7 https://app.readthrough.bio/stories/sl-science-seeks-fda-orphan-drug-status-for-gdt-cell-therapy-in-e8a01a2026-09-27monthly0.7 https://app.readthrough.bio/stories/igc-pharma-discloses-updated-calma-phase-2-data-in-investor-presentation-ebe4512026-09-26monthly0.7 https://app.readthrough.bio/stories/matinas-to-combine-with-gh-power-sell-drug-unit-mat2203-to-azurity-ec2c8e2026-09-27monthly0.7 https://app.readthrough.bio/stories/prenetics-im8-closes-1-billion-growth-financing-from-general-catalyst-s-ed4e742026-09-28monthly0.7 https://app.readthrough.bio/stories/crinetics-discloses-non-compete-deals-with-executives-tied-to-vertex-f49d562026-09-27monthly0.7 https://app.readthrough.bio/stories/proqr-therapeutics-files-prospectus-for-resale-of-up-to-3-030-303-shares-f595ab2026-09-28monthly0.7 https://app.readthrough.bio/stories/ocugen-signs-term-sheet-to-license-ocu400-for-mena-region-f62b232026-09-27monthly0.7 https://app.readthrough.bio/stories/braveheart-bio-files-for-ipo-plans-two-global-phase-3-trials-for-hcm-f9ccd32026-09-25monthly0.7 https://app.readthrough.bio/stories/vyne-declares-special-dividend-tied-to-pending-yarrow-bioscience-merger-fa76572026-09-26monthly0.7 https://app.readthrough.bio/stories/amicus-reports-fy2025-results-as-biomarin-merger-deal-proceeds-ffcb772026-09-27monthly0.7 https://app.readthrough.bio/stories/biohaven-announces-leadership-changes-as-car-retires-pirman-promoted-04dc892026-09-28monthly0.7 https://app.readthrough.bio/stories/moderna-adds-former-biogen-cfo-michael-mcdonnell-to-board-0cc5fb2026-09-27monthly0.7 https://app.readthrough.bio/stories/hutchmed-wins-nmpa-approval-for-orpathys-in-met-amplified-gastric-cancer-180fcd2026-09-26monthly0.7 https://app.readthrough.bio/stories/annovis-bio-completes-enrollment-in-phase-3-buntanetap-trial-for-early-18967c2026-09-26monthly0.7 https://app.readthrough.bio/stories/fda-approves-amneal-s-sodium-bicarbonate-injection-nda220790-1cfed72026-09-27monthly0.7 https://app.readthrough.bio/stories/nuvation-bio-s-underwriters-fully-exercise-greenshoe-on-convertible-1e87e72026-09-27monthly0.7 https://app.readthrough.bio/stories/bridgebio-secures-1-billion-preferred-equity-deal-led-by-sixth-street-1f20702026-09-27monthly0.7 https://app.readthrough.bio/stories/evolus-licenses-ibsa-s-profhilo-for-u-s-skin-quality-market-1f81b22026-09-27monthly0.7 https://app.readthrough.bio/stories/gsk-terminates-collaboration-agreement-with-alector-after-two-drug-25487c2026-09-27monthly0.7 https://app.readthrough.bio/stories/tarsus-acquires-irenix-medical-for-up-to-565-million-to-add-late-stage-25a16b2026-09-26monthly0.7 https://app.readthrough.bio/stories/aethlon-medical-prices-4-0-million-at-the-market-offering-closes-july-7-29f2132026-09-28monthly0.7 https://app.readthrough.bio/stories/pyxis-oncology-announces-up-to-114-million-private-placement-for-micvo-3777262026-09-26monthly0.7 https://app.readthrough.bio/stories/immuron-hires-pullan-consulting-to-find-imm-529-partner-for-c-diff-drug-39822c2026-09-26monthly0.7 https://app.readthrough.bio/stories/perrigo-revives-executive-severance-policy-amid-ceo-transition-3c05d72026-09-28monthly0.7 https://app.readthrough.bio/stories/abivax-prices-800-million-ads-offering-cites-phase-3-uc-maintenance-data-412a4f2026-09-28monthly0.7 https://app.readthrough.bio/stories/kyverna-amends-oxford-finance-loan-facility-pushes-back-term-a-deadline-4468e52026-09-27monthly0.7 https://app.readthrough.bio/stories/lifeward-amends-notes-with-oramed-closes-5-58-million-convertible-note-4505ed2026-09-28monthly0.7 https://app.readthrough.bio/stories/incyte-completes-acquisition-of-vega-therapeutics-from-star-therapeutics-459c182026-09-26monthly0.7 https://app.readthrough.bio/stories/tuhura-biosciences-draws-1-9-million-more-under-parkview-credit-line-45bff72026-09-28monthly0.7 https://app.readthrough.bio/stories/kalaris-therapeutics-board-director-resigns-new-director-elected-4e7e8f2026-09-28monthly0.7 https://app.readthrough.bio/stories/traws-pharma-stockholders-approve-share-increase-elect-directors-at-4fae392026-09-28monthly0.7 https://app.readthrough.bio/stories/tenaya-therapeutics-ends-lease-on-decommissioned-manufacturing-site-5293c12026-09-25monthly0.7 https://app.readthrough.bio/stories/immunic-board-adds-ceo-erik-lundgren-as-director-after-tamar-howson-s-5716492026-09-28monthly0.7 https://app.readthrough.bio/stories/fibrobiologics-adds-retired-nasa-astronaut-kate-rubins-to-board-of-57c8ac2026-09-28monthly0.7 https://app.readthrough.bio/stories/newcelx-names-diabetes-cure-researcher-dr-camillo-ricordi-to-scientific-59b45d2026-09-27monthly0.7 https://app.readthrough.bio/stories/meiragtx-secures-up-to-400-million-from-oberland-capital-for-gene-5b9c612026-09-26monthly0.7 https://app.readthrough.bio/stories/molecular-partners-updates-on-dll3-and-msln-radio-darpin-programs-5d40d12026-09-26monthly0.7 https://app.readthrough.bio/stories/quantum-cyber-names-peter-o-rourke-to-lead-drone-unit-adds-director-5e53302026-09-28monthly0.7 https://app.readthrough.bio/stories/abbvie-updates-2026-eps-guidance-for-q2-acquired-ipr-d-charge-6110002026-09-27monthly0.7 https://app.readthrough.bio/stories/lifeward-ltd-files-form-d-for-11-16-million-offering-under-rule-506-b-6251272026-09-28monthly0.7 https://app.readthrough.bio/stories/alterity-gets-fda-meeting-minutes-backing-phase-3-path-for-ath434-in-msa-65ad192026-09-26monthly0.7 https://app.readthrough.bio/stories/ars-pharmaceuticals-replaces-ceo-names-donn-casale-to-top-job-6816792026-09-28monthly0.7 https://app.readthrough.bio/stories/scilex-signs-term-sheet-for-100-million-investment-from-kazakhstan-s-68408c2026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-supplemental-application-for-glenmark-s-ryaltris-nasal-6c62272026-09-28monthly0.7 https://app.readthrough.bio/stories/regeneron-expects-127-million-ipr-d-charge-in-q2-2026-6daed02026-09-27monthly0.7 https://app.readthrough.bio/stories/igc-pharma-ceo-and-finance-chief-swap-unpaid-amounts-owed-to-them-for-72ffb12026-09-27monthly0.7 https://app.readthrough.bio/stories/vor-biopharma-board-sees-director-change-as-levin-resigns-zaccardelli-783a102026-09-27monthly0.7 https://app.readthrough.bio/stories/tvardi-s-tti-109-phase-1-study-confirms-prodrug-design-and-stat3-target-834a702026-09-26monthly0.7 https://app.readthrough.bio/stories/vertex-to-acquire-crinetics-for-85-a-share-in-10-billion-deal-89ba132026-09-27monthly0.7 https://app.readthrough.bio/stories/macrogenics-closes-sale-of-gmp-manufacturing-operations-to-bora-8be0812026-09-26monthly0.7 https://app.readthrough.bio/stories/can-fite-reports-two-updates-psoriasis-enrollment-milestone-and-8db8f72026-09-26monthly0.7 https://app.readthrough.bio/stories/creative-medical-technology-strikes-warrant-inducement-deal-pays-ceo-9963dd2026-09-27monthly0.7 https://app.readthrough.bio/stories/calcimedica-appoints-zaytsev-to-board-expands-to-eight-directors-a63a7d2026-09-28monthly0.7 https://app.readthrough.bio/stories/medicenna-therapeutics-discloses-form-d-for-private-securities-offering-aa84f12026-09-28monthly0.7 https://app.readthrough.bio/stories/okyo-pharma-gets-fda-type-d-feedback-moves-urcosimod-into-global-phase-ab2c042026-09-26monthly0.7 https://app.readthrough.bio/stories/compass-pathways-reports-26-week-comp006-data-for-psilocybin-depression-acdbb02026-09-26monthly0.7 https://app.readthrough.bio/stories/aura-biosciences-names-jeremy-bender-to-board-of-directors-ae98312026-09-27monthly0.7 https://app.readthrough.bio/stories/immucell-reports-11-5-q2-2026-sales-growth-driven-by-domestic-demand-b47ad62026-09-28monthly0.7 https://app.readthrough.bio/stories/seres-therapeutics-stockholders-approve-incentive-plan-increase-at-b8ce9d2026-09-28monthly0.7 https://app.readthrough.bio/stories/prestige-consumer-healthcare-launches-400-million-notes-offering-to-ba95c32026-09-27monthly0.7 https://app.readthrough.bio/stories/telix-and-fda-align-on-prostact-global-phase-3-protocol-ind-amendment-bccf4c2026-09-26monthly0.7 https://app.readthrough.bio/stories/travere-s-chief-accounting-officer-to-retire-controller-named-as-c0371c2026-09-27monthly0.7 https://app.readthrough.bio/stories/corbus-pharmaceuticals-names-leonardo-viana-nicacio-as-chief-medical-c18faf2026-09-27monthly0.7 https://app.readthrough.bio/stories/vertex-to-acquire-crinetics-pharmaceuticals-for-85-per-share-in-cash-c4f0f22026-09-26monthly0.7 https://app.readthrough.bio/stories/lixte-biotechnology-completes-merger-with-nomad-becomes-nomad-power-c93cfe2026-09-26monthly0.7 https://app.readthrough.bio/stories/oragenics-appoints-john-spencer-as-cfo-holds-annual-meeting-with-mixed-cea1092026-09-27monthly0.7 https://app.readthrough.bio/stories/bone-biologics-closes-3-million-private-placement-priced-at-the-market-d7b78b2026-09-28monthly0.7 https://app.readthrough.bio/stories/arcturus-and-thermo-fisher-form-cdmo-cro-pact-for-cystic-fibrosis-mrna-d831572026-09-27monthly0.7 https://app.readthrough.bio/stories/ovid-therapeutics-names-charles-carter-cfo-as-jeffrey-rona-departs-db4d902026-09-28monthly0.7 https://app.readthrough.bio/stories/macrogenics-board-member-karen-ferrante-to-resign-effective-september-1-db55b82026-09-28monthly0.7 https://app.readthrough.bio/stories/vicore-pharma-names-rob-slack-chief-scientific-officer-dfcc322026-09-28monthly0.7 https://app.readthrough.bio/stories/amlogenyx-discloses-10-million-raised-in-convertible-note-offering-dfe0e42026-09-28monthly0.7 https://app.readthrough.bio/stories/enanta-sets-up-75-million-at-the-market-stock-sale-program-with-e395422026-09-27monthly0.7 https://app.readthrough.bio/stories/abcellera-appoints-lynn-seely-to-board-of-directors-e91e852026-09-28monthly0.7 https://app.readthrough.bio/stories/veru-enters-at-the-market-equity-sales-agreement-with-oppenheimer-eb46262026-09-27monthly0.7 https://app.readthrough.bio/stories/agenus-extends-2015-notes-warrant-terms-adds-new-warrants-for-eb879b2026-09-27monthly0.7 https://app.readthrough.bio/stories/sanofi-s-nexviazyme-meets-all-endpoints-in-infantile-pompe-disease-trial-ee24a22026-09-25monthly0.7 https://app.readthrough.bio/stories/alkermes-and-amneal-terminate-vivitrol-authorized-generic-supply-deal-f050362026-09-27monthly0.7 https://app.readthrough.bio/stories/tenax-to-present-phase-3-level-trial-data-at-esc-congress-2026-expects-f20b332026-09-25monthly0.7 https://app.readthrough.bio/stories/theriva-gets-spanish-authorization-for-virage2-trial-of-vcn-01-in-f2dad52026-09-26monthly0.7 https://app.readthrough.bio/stories/cdt-equity-amends-loan-terms-delays-repayment-start-to-july-10-2026-f5658e2026-09-27monthly0.7 https://app.readthrough.bio/stories/chemomab-and-scipher-medicine-agree-to-merge-target-ra-precision-f8bb2d2026-09-26monthly0.7 https://app.readthrough.bio/stories/liminatus-pharma-closes-merger-with-innocsai-after-amending-deal-terms-fada3a2026-09-28monthly0.7 https://app.readthrough.bio/stories/bnb-plus-corp-amends-registration-rights-agreement-to-push-back-filing-0791ac2026-09-28monthly0.7 https://app.readthrough.bio/stories/avalyn-pharma-expands-boston-sublease-with-crispr-therapeutics-09b4992026-09-27monthly0.7 https://app.readthrough.bio/stories/exozymes-prices-offering-of-stock-and-warrant-units-for-18-each-0a81452026-09-28monthly0.7 https://app.readthrough.bio/stories/celularity-secures-1-million-loan-from-trust-tied-to-major-shareholder-0b01b92026-09-27monthly0.7 https://app.readthrough.bio/stories/inflarx-weighs-broader-eu-strategy-for-vasculitis-drugs-after-tavneos-18562c2026-09-26monthly0.7 https://app.readthrough.bio/stories/scribe-therapeutics-files-s-1-for-nasdaq-ipo-under-ticker-sctx-1d4f402026-09-27monthly0.7 https://app.readthrough.bio/stories/metavia-expands-at-the-market-stock-offering-to-4-million-21b1042026-09-28monthly0.7 https://app.readthrough.bio/stories/michael-goettler-resigns-from-bausch-health-board-effective-june-30-2026-2f2b792026-09-28monthly0.7 https://app.readthrough.bio/stories/rigel-pharmaceuticals-names-alison-hannah-as-new-chief-medical-officer-3433132026-09-28monthly0.7 https://app.readthrough.bio/stories/avalon-globocare-sells-400-000-of-series-f-preferred-stock-grants-348bdc2026-09-28monthly0.7 https://app.readthrough.bio/stories/os-therapies-adds-craig-eagle-to-board-signs-10-million-convertible-366bd22026-09-28monthly0.7 https://app.readthrough.bio/stories/ardelyx-draws-50-million-term-f-loan-under-existing-credit-agreement-36d6c92026-09-28monthly0.7 https://app.readthrough.bio/stories/aptevo-gets-1-5-million-grant-to-advance-solid-tumor-immunotherapy-37435c2026-09-27monthly0.7 https://app.readthrough.bio/stories/x4-pharmaceuticals-adds-camp4-therapeutics-cfo-kelly-gold-to-its-board-37e81b2026-09-28monthly0.7 https://app.readthrough.bio/stories/moleculin-reports-interim-miracle-data-showing-higher-remission-with-38ac3b2026-09-26monthly0.7 https://app.readthrough.bio/stories/nuvectis-pharma-prices-100-million-public-stock-offering-at-20-per-share-39b0c22026-09-28monthly0.7 https://app.readthrough.bio/stories/regenxbio-doses-first-patient-in-phase-iib-iii-diabetic-retinopathy-3b722e2026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-supplement-for-novartis-s-kisqali-femara-co-pack-3bf4c52026-09-25monthly0.7 https://app.readthrough.bio/stories/biogen-flags-q2-and-q3-2026-charges-tied-to-licensing-and-milestone-3c3d132026-09-27monthly0.7 https://app.readthrough.bio/stories/biodexa-prices-3-5-million-offering-with-warrant-inducement-3e699a2026-09-28monthly0.7 https://app.readthrough.bio/stories/trinity-biotech-says-cgm-data-can-flag-nocturnal-false-low-glucose-42ac562026-09-28monthly0.7 https://app.readthrough.bio/stories/jupiter-neurosciences-adds-health-economist-tomas-philipson-to-board-42fcfa2026-09-28monthly0.7 https://app.readthrough.bio/stories/adc-therapeutics-grants-retention-awards-to-ceo-cfo-cmo-44c8982026-09-28monthly0.7 https://app.readthrough.bio/stories/cognos-therapeutics-files-form-d-for-2-million-debt-offering-45d32c2026-09-28monthly0.7 https://app.readthrough.bio/stories/satellos-wins-fda-fast-track-for-sat-3247-in-duchenne-muscular-dystrophy-4ec5342026-09-27monthly0.7 https://app.readthrough.bio/stories/alx-oncology-names-scott-garland-chairman-hires-michael-listgarten-as-4ef40c2026-09-28monthly0.7 https://app.readthrough.bio/stories/palvella-therapeutics-adds-matthew-pauls-to-board-of-directors-5338332026-09-27monthly0.7 https://app.readthrough.bio/stories/inmune-bio-strikes-warrant-inducement-deal-extends-maturity-on-556f1a2026-09-27monthly0.7 https://app.readthrough.bio/stories/hutchmed-sets-july-30-2026-date-for-first-half-financial-results-5950f22026-09-26monthly0.7 https://app.readthrough.bio/stories/neurogene-prices-upsized-stock-offering-raises-134-8-million-net-5cff5f2026-09-27monthly0.7 https://app.readthrough.bio/stories/climb-bio-board-sees-director-resignation-adds-breanna-o-reilly-6002502026-09-28monthly0.7 https://app.readthrough.bio/stories/tonix-enrolls-first-patient-in-phase-2-depression-trial-of-tnx-102-sl-60db082026-09-26monthly0.7 https://app.readthrough.bio/stories/elicio-prices-15-million-registered-direct-stock-offering-623c632026-09-28monthly0.7 https://app.readthrough.bio/stories/addex-shareholders-back-all-board-proposals-at-2026-annual-meeting-643e972026-09-26monthly0.7 https://app.readthrough.bio/stories/halozyme-discloses-departure-of-coo-cortney-caudill-6a9b552026-09-28monthly0.7 https://app.readthrough.bio/stories/fda-clears-new-efficacy-supplement-for-novartis-s-kisqali-6d29502026-09-25monthly0.7 https://app.readthrough.bio/stories/neurogene-prices-125-million-public-offering-at-30-00-per-share-6eba832026-09-28monthly0.7 https://app.readthrough.bio/stories/akebia-and-usrc-halt-voice-trial-early-after-vafseo-beats-esa-on-safety-727ce92026-09-26monthly0.7 https://app.readthrough.bio/stories/rocket-pharmaceuticals-names-joseph-manhede-as-principal-accounting-75fe372026-09-27monthly0.7 https://app.readthrough.bio/stories/quantum-cyber-subsidiary-signs-deals-for-bridgeport-manufacturing-site-7f58692026-09-26monthly0.7 https://app.readthrough.bio/stories/stoke-therapeutics-completes-enrollment-of-162-patient-phase-3-emperor-8837a82026-09-26monthly0.7 https://app.readthrough.bio/stories/cybin-s-helus-pharma-reports-fy2026-results-phase-3-mdd-trial-past-88-927d392026-09-27monthly0.7 https://app.readthrough.bio/stories/onemednet-signs-25-million-standby-equity-purchase-deal-with-yorkville-986a272026-09-27monthly0.7 https://app.readthrough.bio/stories/bioaffinity-reports-cypath-lung-sales-growth-and-philips-veteran-9b500b2026-09-28monthly0.7 https://app.readthrough.bio/stories/enanta-files-to-sell-up-to-75-million-in-shares-through-jefferies-9c47cb2026-09-27monthly0.7 https://app.readthrough.bio/stories/cumberland-closes-100-million-asset-sale-to-apotex-keeps-rare-disease-9d7e9e2026-09-26monthly0.7 https://app.readthrough.bio/stories/vistagen-s-fasedienol-misses-primary-endpoint-in-palisade-4-trial-a3c5422026-09-26monthly0.7 https://app.readthrough.bio/stories/4d-molecular-therapeutics-secures-up-to-200-million-loan-facility-from-a855f52026-09-27monthly0.7 https://app.readthrough.bio/stories/viatris-amends-and-restates-yen-term-loan-facility-with-mizuho-as-agent-b1f5a02026-09-27monthly0.7 https://app.readthrough.bio/stories/exozymes-closes-639-990-follow-on-offering-with-mdb-capital-b810092026-09-27monthly0.7 https://app.readthrough.bio/stories/cadrenal-therapeutics-closes-3-million-private-placement-warrants-could-b923a62026-09-28monthly0.7 https://app.readthrough.bio/stories/jade-biosciences-licenses-undisclosed-target-antibody-program-from-b944f62026-09-27monthly0.7 https://app.readthrough.bio/stories/biocryst-to-close-birmingham-research-site-ends-internal-discovery-bb625f2026-09-26monthly0.7 https://app.readthrough.bio/stories/evommune-s-evo756-fails-primary-endpoint-in-phase-2b-urticaria-trial-bf85012026-09-26monthly0.7 https://app.readthrough.bio/stories/jaguar-health-files-two-form-d-notices-for-equity-offerings-totaling-42-c2e4c52026-09-28monthly0.7 https://app.readthrough.bio/stories/lenz-therapeutics-director-zach-scheiner-resigns-from-board-c60a992026-09-28monthly0.7 https://app.readthrough.bio/stories/pacira-to-divest-iovera-cryoneurolysis-business-to-zimmer-biomet-c8bca12026-09-27monthly0.7 https://app.readthrough.bio/stories/exicure-expands-board-adds-two-directors-forms-compensation-committee-cb939f2026-09-28monthly0.7 https://app.readthrough.bio/stories/pmgc-subsidiary-reports-positive-phase-iii-results-from-ai-drug-cf3ead2026-09-26monthly0.7 https://app.readthrough.bio/stories/ac-immune-reports-12-month-interim-data-from-abate-trial-of-aci-24-cfe7f12026-09-26monthly0.7 https://app.readthrough.bio/stories/emergent-biosolutions-gets-52-7-million-acam2000-contract-modification-d0dc802026-09-27monthly0.7 https://app.readthrough.bio/stories/tenax-and-orion-sign-supply-deal-and-sixth-amendment-for-oral-d104772026-09-25monthly0.7 https://app.readthrough.bio/stories/neonc-board-sees-resignation-of-director-election-of-ceo-s-niece-as-d158c92026-09-28monthly0.7 https://app.readthrough.bio/stories/abivax-reports-part-2-maintenance-data-for-obefazimod-in-ulcerative-d270492026-09-26monthly0.7 https://app.readthrough.bio/stories/disc-medicine-amends-hercules-capital-loan-agreement-to-extend-drawdown-d92cb32026-09-27monthly0.7 https://app.readthrough.bio/stories/onemednet-files-s-1-for-resale-of-up-to-11-68-million-shares-tied-to-ddec9a2026-09-28monthly0.7 https://app.readthrough.bio/stories/neurogene-reports-30-month-data-for-ngn-401-in-rett-syndrome-trial-de205f2026-09-26monthly0.7 https://app.readthrough.bio/stories/cingulate-added-to-russell-3000e-index-extends-cmo-s-employment-trial-deebd42026-09-28monthly0.7 https://app.readthrough.bio/stories/veru-launches-at-the-market-offering-of-up-to-21-8-million-in-common-df41282026-09-27monthly0.7 https://app.readthrough.bio/stories/alvotech-secures-75-million-additional-term-loan-facility-from-e46f7a2026-09-28monthly0.7 https://app.readthrough.bio/stories/xtl-biopharmaceuticals-completes-acquisition-of-psyga-bio-pivots-to-e84a2a2026-09-26monthly0.7 https://app.readthrough.bio/stories/xeris-ceo-john-shannon-named-board-chair-adds-new-director-kreher-e8cacc2026-09-28monthly0.7 https://app.readthrough.bio/stories/neurosense-says-phase-2b-als-trial-hit-primary-tdp-43-endpoint-ec0b312026-09-27monthly0.7 https://app.readthrough.bio/stories/larimar-submits-first-bla-module-for-nomlabofusp-in-friedreich-s-ataxia-eda0fc2026-09-27monthly0.7 https://app.readthrough.bio/stories/mesoblast-gets-bla-filing-number-for-rexlemestrocel-l-in-lvad-patients-f2e45c2026-09-27monthly0.7 https://app.readthrough.bio/stories/imunon-names-josh-blacher-interim-cfo-as-jeffrey-church-retires-f83dce2026-09-28monthly0.7 https://app.readthrough.bio/stories/eu-approves-enhertu-as-first-tumor-agnostic-her2-directed-adc-267e322026-09-25monthly0.7 https://app.readthrough.bio/stories/beyondspring-discloses-finalized-pay-package-for-new-ceo-min-qiu-30f2442026-09-28monthly0.7 https://app.readthrough.bio/stories/cadrenal-names-john-sharp-interim-cfo-board-reshuffles-after-director-3362812026-09-28monthly0.7 https://app.readthrough.bio/stories/tenaya-therapeutics-names-eric-hyllengren-as-new-cfo-effective-july-13-37c2e22026-09-25monthly0.7 https://app.readthrough.bio/stories/inhibikase-stockholders-back-director-elections-plan-amendments-at-2026-3ffd6c2026-09-25monthly0.7 https://app.readthrough.bio/stories/redhill-biopharma-expands-at-the-market-offering-capacity-by-2-128-4260b42026-09-28monthly0.7 https://app.readthrough.bio/stories/protara-therapeutics-chief-medical-officer-resigns-effective-june-26-42ea222026-09-28monthly0.7 https://app.readthrough.bio/stories/decoy-therapeutics-announces-private-placement-financing-of-up-to-21-4ed8a02026-09-27monthly0.7 https://app.readthrough.bio/stories/fibrobiologics-closes-3-0-million-private-placement-priced-at-the-market-5065fb2026-09-28monthly0.7 https://app.readthrough.bio/stories/chmp-backs-datroway-for-first-line-tnbc-treatment-in-eu-631cb62026-09-25monthly0.7 https://app.readthrough.bio/stories/tenax-therapeutics-amends-executive-pay-deals-adopts-new-severance-plans-676b532026-09-25monthly0.7 https://app.readthrough.bio/stories/united-therapeutics-shareholders-approve-2026-stock-incentive-plan-at-78b56f2026-09-25monthly0.7 https://app.readthrough.bio/stories/genmab-reports-positive-phase-3-results-for-epcoritamab-plus-9990702026-09-27monthly0.7 https://app.readthrough.bio/stories/rani-therapeutics-names-nicholas-maestas-as-new-chief-financial-officer-a06d252026-09-27monthly0.7 https://app.readthrough.bio/stories/fda-approves-viridian-s-lumvoa-for-thyroid-eye-disease-a4f5ba2026-09-27monthly0.7 https://app.readthrough.bio/stories/novabridge-biosciences-names-srishti-gupta-as-ceo-succeeding-sean-fu-c6dfee2026-09-28monthly0.7 https://app.readthrough.bio/stories/zymeworks-agrees-to-buy-theravance-biopharma-for-17-per-share-e4e0c22026-09-27monthly0.7 https://app.readthrough.bio/stories/zymeworks-to-acquire-theravance-biopharma-for-17-00-per-share-plus-cvr-f471af2026-09-27monthly0.7 https://app.readthrough.bio/stories/replimune-s-rp1-bla-resubmission-accepted-by-fda-adcomm-expected-late-ff414a2026-09-28monthly0.7